Focused libraries of genetic packages

ABSTRACT

Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.

This application claims the benefit under 35 USC §120 of U.S.provisional application 60/256,380, filed Dec. 18, 2001. The provisionalapplication and the Tables attached to it are specifically incorporatedby reference herein.

The present invention relates to focused libraries of genetic packagesthat each display, display and express, or comprise a member of adiverse family of peptides, polypeptides or proteins and collectivelydisplay, display and, express, or comprise at least a portion of thefocused diversity of the family. The focused diversity of the librariesof this invention comprises both sequence diversity and lengthdiversity. In a preferred embodiment, the focused diversity of thelibraries of this invention is biased toward the natural diversity ofthe selected family. In a more preferred embodiment, the libraries arebiased toward the natural diversity of human antibodies and arecharacterized by variegation in their heavy chain and light chaincomplementarity determining regions (“CDRs”)'.

The present invention further relates to vectors and genetic packages(e.g., cells, spores or viruses) for displaying, or displaying andexpressing a focused diverse family of peptides, polypeptides orproteins. In a preferred embodiment the genetic packages are filamentousphage or phagemids or yeast. Again, the focused diversity of the familycomprises diversity in sequence and diversity in length.

The present invention further relates to methods of screening thefocused libraries of the invention and to the peptides, polypeptides andproteins identified by such screening.

BACKGROUND OF THE INVENTION

It is now common practice in the art to prepare libraries of geneticpackages that individually display, display and express, or comprise amember of a diverse family of peptides, polypeptides or proteins andcollectively display, display and express, or comprise at least aportion of the amino acid diversity of the family. In many commonlibraries, the peptides, polypeptides or proteins are related toantibodies (e.g., single chain Fv (scFv), Fv, Fab, whole antibodies orminibodies (i.e., dimers that consist of V_(H) linked to V_(L))). Often,they comprise one or more of the CDRs and framework regions of the heavyand light chains of human antibodies.

Peptide, polypeptide or protein libraries have been produced in severalways in the prior art. See e.g., Knappik et al., J. Mol. Biol., 296, pp.57-86 (2000), which is incorporated herein by references. One method isto capture the diversity of native donors, either naive or immunized.Another way is to generate libraries having synthetic diversity. A thirdmethod is a combination of the first two. Typically, the diversityproduced by these methods is limited to sequence diversity, i.e., eachmember of the library differs from the other members of the family byhaving different amino acids or variegation at a given position in thepeptide, polypeptide or protein chain. Naturally diverse peptides,polypeptides or proteins, however, are not limited to diversity only intheir amino acid sequences. For example, human antibodies are notlimited to sequence diversity in their amino acids, they are alsodiverse in the lengths of their amino acid chains.

For antibodies, diversity in length occurs, for example, during variableregion rearrangements. See e.g., Corbett et al., J. Mol. Biol., 270, pp.587-97 (1997). The joining of V genes to J genes, for example, resultsin the inclusion of a recognizable D segment in CDR3 in about half ofthe heavy chain antibody sequences, thus creating regions encodingvarying lengths of amino acids. The following also may occur duringjoining of antibody gene segments: (i) the end of the V gene may havezero to several bases deleted or changed; (ii) the end of the D segmentmay have zero to many bases removed or changed; (iii) a number of randombases may be inserted between V and D or between D and J; and (iv) the5′ end of J may be edited to remove or to change several bases. Theserearrangements result in antibodies that are diverse both in amino acidsequence and in length.

Libraries that contain only amino acid sequence diversity are, thus,disadvantaged in that they do not reflect the natural diversity of thepeptide, polypeptide or protein that the library is intended to mimic.Further, diversity in length may be important to the ultimatefunctioning of the protein, peptide or polypeptide. For example, withregard to a library comprising antibody regions, many of the peptides,polypeptides, proteins displayed, displayed and expressed, or comprisedby the genetic packages of the library may not fold properly or theirbinding to an antigen may be disadvantaged, if diversity both insequence and length are not represented in the library.

An additional disadvantage of prior art libraries of genetic packagesthat display, display and express, or comprise peptides, polypeptidesand proteins is that they are not focused on those members that arebased on natural occurring diversity and thus on members that are mostlikely to be functional. Rather, the prior art libraries, typically,attempt to include as much diversity or variegation at every amino acidresidue as possible. This makes library construction time-consuming andless efficient than possible. The large number of members that areproduced by trying to capture complete diversity also makes screeningmore cumbersome than it needs to be. This is particularly true giventhat many members of the library will not be functional.

SUMMARY OF THE INVENTION

One objective of this invention is focused libraries of vectors orgenetic packages that encode members of a diverse family of peptides,polypeptides or proteins wherein the libraries encode populations thatare diverse in both length and sequence. The diverse length comprisingcomponents that contain motifs that are likely to fold and function inthe context of the parental peptide, polypeptide or protein.

Another object of this invention is focused libraries of geneticpackages that display, display and express, or comprise a member of adiverse family of peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least portion of thefocused diversity of the family. These libraries are diverse not only intheir amino acid sequences, but also in their lengths. And, theirdiversity is focused so as to more closely mimic or take into accountthe naturally-occurring diversity of the specific family that thelibrary represents.

Another object of this invention is diverse, but focused, populations ofDNA sequences encoding peptides, polypeptides or proteins suitable fordisplay or display and expression using genetic packages such as phageor phagemids) or other regimens that allow selection of specific bindingcomponents of a library.

A further object of this invention is focused libraries comprising theCDRs of human antibodies that are diverse in both their amino acidsequence and in their length (examples of such libraries includelibraries of single chain Fv (scFv), Fv, Fab, whole antibodies orminibodies (i.e., dimers that consist of V_(H) linked to V_(L))). Suchregions may be from the heavy or light chains or both and may includeone or more of the CDRs of those chains. More preferably, the diversityor variegation occurs in all of the heavy chain and light chain CDRs.

It is another object of this invention to provide methods of making andscreening the above libraries and the peptides, polypeptides andproteins obtained in such screening.

Among the preferred embodiments of this invention are the following:

1. A focused library of vectors or genetic packages that display,display and express, or comprise a member of a diverse family of humanantibody related peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least a portion of thediversity of the antibody family, the vectors or genetic packages beingcharacterized by variegated DNA sequences that encode a heavy chain CDR1selected from the group consisting of:

-   -   (1)<1>₁Y₂<1>₃M₄<1>₅, wherein <1> is an equimolar mixture of each        of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R,        S, and Y;    -   (2) (S/T)₁(S/G/X)₂(S/G/X)₃Y₄Y₅W₆(S/G/X)₇. wherein (SIT) is a 1:1        mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S,        0.2025 G and 0.035 of each of amino acid residues A, D, E, F, H,        I, K, L, M, N, P, Q, R, T, V, W, and Y;    -   (3) V₁S₂G₃G₄S₅I₆S₇<1>₈<1>₉<1>₁₀Y₁₁Y₁₂W₁₃<1>¹⁴, wherein <1> is an        equimolar mixture of each of amino acid residues A, D, E, F, G,        H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and    -   (4) mixtures of vectors or genetic packages characterized by any        of the above DNA sequences, preferably in the ratio: HC CDR1s        (1):(2):(3)::0.80:0.17:0.02.

2. A focused library of vectors or genetic packages that display,display and express, or comprise a member of a diverse family of humanantibody related peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least a portion of thediversity of the antibody facility, the vectors or genetic packagesbeing characterized by variegated DNA sequences that encode a heavychain CDR2 selected from the group consisting of:

-   -   (1)<2>I<2><3>SGG<1>T<1>YADSVKG, wherein <1> is an equimolar        mixture of each of amino acid residues A, D, E, F, G, H, I, K,        L, M, N, P, O, R, S, T, V, W, and Y; <2> is an equimolar mixture        of each of amino acid residues Y, R, W, V, G, and S; and <3> is        an equimolar mixture of each of amino acid residues P, S, and G        or an equimolar mixture of P and S;    -   (2)<1>I<4><1><1><G><5><1><1><1>YADSVKG, wherein <1> is an        equimolar mixture of each of amino acid residues A, D, E, F, G,        H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <4> is an        equimolar mixture of residues D, I, N, S, W, Y; and <5> is an        equimolar mixture of residues S, G, D and N;    -   (3). <1>I<4><1><1>G<5><1><1>YNPSLKG, wherein <1> is an equimolar        mixture of each of amino acid residues A, D, E, F, G, H, I, K,        L, M, N, P, Q, R, S, T, V, W and Y; and <4> and <5> are as        defined above;    -   (4)<1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar        mixture of each amino acid residues A, D, E, F, G, H, I, K, L,        M, N, P, Q, R, S, T, V, W and Y; <8> is 0.27 R and 0.027 of each        of ADEFGHIKLMNPQSTVWY; and    -   (5) mixtures of vectors or genetic packages characterized by any        of the above DNA sequences, preferably in the ratio: HC CDR2s:        (1)/(2) (equimolar): (3):(4)::0.54:0.43:0.03.

3. A focused library of vectors or genetic packages that display,display and express, or comprise a member of a diverse family of humanantibody related peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least a portion of thediversity of the antibody family, the vectors or genetic packages beingcharacterized by variegated DNA sequences that encode a heavy chain CDR3selected from the group consisting of:

-   -   (1) YYCA21111YFDYWG, wherein 1 is an equimolar mixture of each        amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S,        T, V; W and Y; and 2 is an equimolar mixture of K and R;    -   (2) YYCA2111111YFDYWG, wherein 1 is an equimolar mixture of each        amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S,        T, V, W and Y; and 2 is an equimolar mixture of K and R;    -   (3) YYCA211111111YFDAYTG, wherein 1 is an equimolar mixture of        each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q,        R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;    -   (4) YYCAR111S2S3111YFDYWG, wherein 1 is an equimolar mixture of        each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q,        R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G;        and 3 is an equimolar mixture of Y and W;    -   (5) YYCA2111CSG11CY1YFDYWG, wherein 1 is an equimolar mixture of        each amino acid residues*A, D, E, F, G, H, I, K, L, M, N, P, Q,        R, 5, T, V, W and Y; and 2 is an equimolar mixture of K and R;    -   (6) YYCA211S1TIFG11111YFDYWG, wherein 1 is an equimolar mixture        of each amino acid residues A; D, E, F, G, H, I, K, L, M, N, P,        Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and        R;    -   (7) YYCAR111YY2S3344111YFDYWG, wherein 1 is an equimolar mixture        of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P,        Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and S;        and 3 is an equimolar mixture of S and G;    -   (8) YYCAR1111YC2231CY111YFDYWG, wherein 1 is an equimolar        mixture of each amino acid residues A, D, E, F, G, H, I, K, L,        M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S        and G; and 3 is an equimolar mixture of T, D and G; and    -   (9) mixtures of vectors or genetic packages characterized by any        of the above DNA sequences, preferably the HC CDR3s (1)        through (8) are in the following proportions in the mixture:    -   (1) 0.10    -   (2) 0.14    -   (3) 0.25    -   (4) 0.13.    -   (5) 0.13    -   (6) 0.11    -   (7) 0.04 and    -   (8) 0.10; and more preferably the HC CDR3s (1) through (8) are        in the following proportions in the mixture:    -   (1) 0.02    -   (2) 0.14    -   (3) 0.25    -   (4) 0.14    -   (5) 0.14    -   (6) 0.12    -   (7) 0.08 and    -   (8) 0.11.

Preferably, 1 in one or all of HC CDR3s (1) through (8) is 0.095 of eachof G and Y and 0.048 of each of A, D, E, F, H, I, K, L, M, N, P, Q, R,S, T, V, and W.

4. A focused library of vectors or genetic packages that display,display and express, or comprise a member of a diverse family of humanantibody related peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least a portion of thediversity of the antibody family, the vectors or genetic packages beingcharacterized by variegated DNA sequences that encodes a kappa lightchain CDR1 selected from the group consisting of:

-   -   (1) RASQ<1>V<2><2><3>LA    -   (2) RASQ<1>V<2><2><2><3>LA;        wherein <1> is an equimolar mixture of amino acid residues        ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of        ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of        ADEFGHIKLMNPQRTVW and Y; and    -   (3) mixtures of vectors or genetic packages characterized by any        of the above DNA sequences, preferably in the ratio CDR1s        (1):(2)::0.68:0.32.

5. A focused library of vectors or genetic packages that display,display and express, or comprise a member of a diverse family of humanantibody related peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least a portion of thediversity of the antibody family, the vectors or genetic packages beingcharacterized by variegated DNA sequences that encode a kappa lightchain CDR2 having the sequence:

-   -   <1>AS<2>R<4><1>,        wherein <1> is an equimolar mixture of amino acid residues        ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of        ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and) 0.044 each of        DEFGHIKLMNPQRSTVWY.

6. A focused library of vectors or genetic packages that display,display and express, or comprise a member of a diverse family of humanantibody related peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least a portion of thediversity of the antibody family, the vectors or genetic packages beingcharacterized by variegated DNA sequences that encode a kappa lightchain CDR3 selected from the groups consisting of:

-   -   (1) QQ<3><1><1><1>P<1>T,        wherein <1> is an equimolar mixture of amino acid residues        ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of        ADEFGHIKLMNPQRTVW;    -   (2) QQ33111P, wherein 0.1 and 3 are as defined in (1) above;    -   (3) QQ3211PP1T, wherein 1 and 3 are as defined in (1) above and        2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and    -   (4) mixtures of vectors or genetic packages characterized by any        of the above DNA sequences, preferably in the ratio CDR3s        (1):(2):(3)::0.65:0.1:0.25.

7. A focused library of vectors or genetic packages that display,display and express, or comprise a member of a diverse family of humanantibody related peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least a portion of thediversity of the antibody family, the vectors or genetic packages beingcharacterized by variegated DNA sequences that encode a lambda lightchain CDR1 selected from the group consisting of:

-   -   (1) TG<1>SS<2>VG<1><3><2><3>VS, wherein <1> is 0.27 T, 0.27 G        and 0.027 each of ADEFHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and        0.027 each of AEFGHIKLMPQRSTVWY, and <3> is 0.36 Y and 0.036        each of ADEFGHIKLMNPQRSTVW;    -   (2) G<2><4>L<4><4><4><3><4><4>, wherein <2> is as defined in (1)        above and <4> is an equimolar mixture of amino acid residues        ADEFGHIKLMNPQRSTVWY; and    -   (3) mixtures of vectors or genetic packages characterized by any        of the above DNA sequences, preferably in the ratio CDR1s        (1):(2)::0.67:0.33.

8. A focused library of vectors or genetic packages that display,display and express, or comprise a member of a diverse family of humanantibody related peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least a portion of thediversity of the antibody family, the vectors or genetic packages beingcharacterized by variegated DNA sequences that encode a lambda lightchain CDR2 has the sequence:

-   -   <4><4><4><2>RPS,        wherein <2> is 0.27 D, 0.27 N, and 0.027 each of        AEFGHIKLMPQRSTVWY and <4> is an equimolar mixture of amino acid        residues ADEFGHIKLMNPQRSTVW.

9. A focused library of vectors or genetic packages that display,display and express, or comprise a member of a diverse family of humanantibody related peptides, polypeptides and proteins and collectivelydisplay, display and express, or comprise at least a portion of thediversity of the antibody family, the vectors or genetic packages beingcharacterized by variegated DNA sequences that encode a lambda lightchain CDR3 selected from the group consisting of:

-   -   (1)<4><5><4><2><4>S<4><4><4><4>V, wherein <2> is 0.27 D, 0.27 N,        and 0.027 each of AEFGHIKLMPQRSTVWY; <4> is an equimolar mixture        of amino acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and        0.0355 each of ADEFGHIKLMNPQRTVWY;    -   (2)<5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture        of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined in (1)        above; and    -   (3) mixtures of vectors or genetic packages characterized by any        of the above DNA sequences, preferably in the ratio CDR3s        (1):(2)::1:1.

10. A focused library comprising variegated DNA sequences that encode aheavy chain CDR selected from the group consisting of:

-   -   (1) one or more of the heavy chain CDR1s of paragraph 1 above;    -   (2) one or more of the heavy chain CDR2s of paragraph 2 above;    -   (3) one or more of the heavy chain CDR3s of paragraph 3 above;        and    -   (4) mixtures of vectors or genetic packages characterized by        (1), (2) and (3).

11. The focused library comprising one or more of the variegated DNAsequences that encodes a heavy chain CDR of paragraphs 1, 2 and 3 andfurther comprising variegated DNA sequences that encodes a light chainCDR selected from the group consisting of

-   -   (1) one or more the kappa light chain CDR1s of paragraph 4;    -   (2) the kappa light chain. CDR2 of paragraph 5;    -   (3) one or more of the kappa light chain CDR3s of paragraph 6;    -   (4) one or more of the kappa light chain CDR1s of paragraph 7;    -   (5) the lambda light chain CDR2 of paragraph 8;    -   (6) one or more of the lambda light chain CDR3s of paragraph 9;        and    -   (7) mixtures of vectors and genetic packages characterized by        one or more of (1) through (6).

12. A population of variegated DNA sequences as described in paragraphs1-11 above.

13. A population of vectors comprising the variegated DNA sequences asdescribed in paragraphs 1-11 above.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Antibodies (“Ab”) concentrate their diversity into those regions thatare involved in determining affinity and specificity of the Ab forparticular targets. These regions may be diverse in sequence or inlength. Generally, they are diverse in both ways. However, withinfamilies of human antibodies the diversities, both in sequence and inlength, are not truly random. Rather, some amino acid residues arepreferred at certain positions of the CDRs and some CDR lengths arepreferred. These preferred diversities account for the natural diversityof the antibody family.

According to this invention, and as more fully described below,libraries of vectors and genetic packages that more closely mirror thenatural diversity, both in sequence and in length; of antibody families,or portions thereof are prepared and used.

Human Antibody Heavy Chain Sequence and Length Diversity

(a) Framework

The heavy chain (“HC”) Germ-Line Gene (GLG) 3-23 (also known as VP-47)accounts for about 12% of all human Abs and is preferred as theframework in the preferred embodiment of the invention. It should,however, be understood that other well-known frameworks, such as 4-34,3-30, 3-30.3 and 4-30.1, may also be used without departing from theprinciples of the focused diversities of this invention.

In addition, JH4 (YFDYWGQGTLVTUSS) occurs more often than JH3 in nativeantibodies. Hence, it is preferred for the focused libraries of thisinvention. However, JH3 (AFDIWGQGTMVTVSS) could as well be used.

(b) Focused Length Diversity: CDR1, 2 and 3

(i) CDR1

For CDR1, GLGs provide CDR1s only of the lengths 5, and 7. Mutationsduring the maturation of the domain gene, however, can lead to CDR1shaving lengths as short as 2 and as long as 16. Nevertheless, length 5predominates. Accordingly, in the preferred embodiment of thisinvention, the preferred HC CDR1 is 5 amino acids, with less preferredCDR1s having lengths of 7 and 14. In the most preferred libraries ofthis invention, all three lengths are used in proportions similar tothose found in natural antibodies.

(ii) CDR2

GLGs provide CDR2s only of the lengths 15-19, but mutations duringmaturation may result in CDR2s of lengths from 16 to 28 amino acids. Thelengths 16 and 17 predominate in mature Ab genes. Accordingly, length 17is the preferred length for HC CDR2 of the present invention. Lesspreferred HC CDR2s of this invention have lengths 16 and 19. In the mostpreferred focused libraries of this invention, all three lengths areincluded in proportions similar to those found in natural antibodyfamilies.

(iii) CDR3

CDR3s vary in length. About half of human HCs consist of the components:V::nz::D::ny::JHn where V is a V gene, nz is a series of bases (mean 12)that are essentially random, D is a D segment, often with heavy editingat both ends, ny is a series of bases (mean 6) that are essentiallyrandom, and JH is one of the six JH segments, often with heavy editingat the 5′ end. The D segments appear to provide spacer segments thatallow folding of the IgG. The greatest diversity is at the junctions ofV with D and of D with JH.

In the preferred libraries of this invention both types of HC CDR3s areused. In HC CDR3s that have no identifiable D segment, the structure isV::nz::JHn where JH is usually edited at the 5′ end. In HC CDR3s thathave an identifiable D segment, the structure is V::nz::D::ny::JHn.

(c) Focused Sequence Diversity: CDR1, 2 and 3

(i) CDR1

In 5 amino acid length CDR1, examination of a 3D model of a humanized Abshowed that the side groups of residues 1, 3, and 5 were directed towardthe combining pocket. Consequently, in the focused libraries of thisinvention, each of these positions may be selected from any of thenative amino acid residues, except cysteine (“C”). Cysteine can formdisulfide bonds, which are an important component of the canonical Igfold. Having free thiol groups could, thus, interfere with properfolding of the HC and could lead to problems in production ormanipulation of selected Abs. Thus, in the focused libraries of thisinvention cysteine is excluded from positions 1, 3 and 5 of thepreferred 5 amino acid CDR1s. The other 19 natural amino acids residuesmay be used at positions 1, 3 and 5. Preferably, each is present inequimolar ratios in the variegated libraries of this invention.

3D modeling also suggests that the side groups of residue 2 in a 5 aminoacid CDR1 are directed away from the combining pocket. Although thisposition shows substantial diversity, both in GLG and mature genes, inthe focused libraries of this invention this residue is preferably Tyr(Y) because it occurs in 681/820 mature antibody genes. However, any ofthe other native amino acid residues, except Cys (C), could also be usedat this position.

For position 4, there is also some diversity in GLG and mature antibodygenes. However, almost all mature genes have uncharged hydrophobic aminoacid residues: A, G, L, P, F, M, W, I, V, at this position. Inspectionof a 3D model also shows that the side group of residue 4 is packed intothe innards of the HC. Thus, in the preferred embodiment of thisinvention which uses framework 3-23, residue 4 is preferably Met becauseit is likely to fit very well into the framework of 3-23. With otherframeworks, a similar fit consideration is used to assign residue 4.

Thus, the most preferred HC CDR1 of this invention consists of the aminoacid sequence <1>Y<1>M<1> where <1> can be any one of amino acidresidues: A, D, E, F, G, H, I, K, t, M, N, P, Q, R, S, T, V, W, Y (notC), preferably present at each position in an equimolar amount. Thisdiversity is shown in the context of a framework 3-23:JH4 in Table 1. Ithas a diversity of 6859-fold.

The two less preferred HC CDR1s of this invention have length 7 andlength 14. For length 7, a preferred variegation is(S/T)₁(S/G/<1>)₂(S/G/<1>)₃Y₄Y₅W₆(S/G/<1>)₇; where (S/T) indicates anequimolar mixture of Ser and Thr codons; (S/G/<1>) indicates a mixtureof 0.2025 S, 0.2025 G, and 0.035 for each of A, F, H, I, K, L, M, N, P,Q, R, T, V, W, Y. This design gives a predominance of Ser and Gly atpositions 2, 3, and 7, as occurs in mature HC genes. For length 14, apreferred variegation is VSGGSIS<1><1><1>YYW<1>, where <1> is anequimolar mixture of the 19 native amino acid residues, except Cys (C).

The DNA that encodes these preferred HC CDR1s is preferably synthesizedusing trinucleotide building blocks so that each amino acid residue ispresent in essentially equimolar or other described amounts. Thepreferred codons for the <1> amino acid residues are gct, gat, gag, ttt,ggt, cat, att, aag, ctt, atg, aat, cct, cag, cgt, tct, act, gtt, tgg,and tat. Of course, other codons for the chosen amino acid residue couldalso be used.

The diversity oligonucleotide (ON) is preferably synthesized from BspEIto BstXI (as shown in Table 1) and can, therefore, be incorporatedeither by PCR synthesis using overlapping ONs or introduced by ligationof BspEI/BstXI-cut fragments. Table 2 shows the oligonucleotides thatembody the specified variegations of the preferred length 5 HC CDR1s ofthis invention. PCR using ON-R1V1vg, ON-R1top, and ON-R1bot gives adsDNA product of 73 base pairs, cleavage with BspEI and BstXI trims 11and 13 bases from the ends and provides cohesive ends that can beligated to similarly cut vector having the 3-23 domain shown in Table 1.Replacement of ON-R1V1vg with either ONR1V2vg or ONR1V3vg (see Table 2)allows synthesis of the two alternative diversity patterns—the 7 residuelength and the 14 residue length HC CDR1.

The more preferred libraries of this invention comprise the 3 preferredHC CDR1 length diversities. Most preferably, the 3 lengths should beincorporated in approximately the ratios in which they are observed inantibodies selected without reference to the length of the CDRs. Forexample, one sample of 1095 HC genes have the three lengths present inthe ratio: L=5:L=7:L=14::820:175:23::0.80:0.17:0.02. This is thepreferred ratio in accordance with this invention.

(ii) CDR2

Diversity in HC CDR2 was designed with the same considerations as for HCCDR1: GLG sequences, mature sequences and 3D structure. A preferredlength for CDR2 is 17, as shown in Table 1. For this preferred 17 lengthCDR2, the preferred variegation in accordance with the invention is:<2>I<2><3>SGG<1>T<1>YADSVKG, where <2> indicates any amino acid residueselected from the group of Y, R, W, V, G and S (equimolar mixture), <3>is P, S and G or P and S only (equimolar mixture), and <1> is any nativeamino acid residue except C (equimolar mixture).

ON-R2V1vg shown in Table 3 embodies this diversity pattern. It ispreferably synthesized so that fragments of dsDNA containing the BstXIand XbaI site can be generated by PCR. PCR with ON-R2V1vg, ON-R2top, andONR2bot gives a dsDNA product of 122 base pairs. Cleavage with BstXI andXbaI removes about 10 bases from each end and produces cohesive endsthat can be ligated to similarly cut vector that contains the 3-23gene-shown in Table 1.

In an alternative embodiment for a 17 length HC CDR2, the followingvariegation may be used: <1>I<4><1><1>G<5><1><1><1>YADSVKG, where <1> isas described above for the more preferred alternative of HC CDR2; <4>indicates an equimolar mixture of DINSWY, and <5> indicates an equimolarmixture of SGDN. This diversity pattern is embodied in ON-R2V2vg shownin Table 3. Preferably, the two embodiments are used in equimolarmixtures in the libraries of this invention.

Other preferred HC CDR2s have lengths 16 and 19. Length 16:<1>I<4><1><1>G<5<1><1>YNPSLKG; Length 19:<1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture ofall native amino acid residues except C; <4> is a equimolar mixture ofDINSWY; <5> is an equimolar mixture of SGDN; and <8> is 0.27 R and 0.027of each of residues ADEFGHIKLMNPQSTVWY. Table 3 shows ON-R2V3vg whichembodies a preferred CDR2 variegation of length 16 and ON-R2V4vg whichembodies a preferred CDR2 variegation of length 19. To prepare thesevariegations ON-R2V3vg may be PCR amplified with ON-R2top and ON-R2bo3and ON-R2V4vg may be PCR amplified with ON-R2top and ON-R2-bo4. SeeTable 3. In the most preferred embodiment of this invention, all threeHC CDR2 lengths are used. Preferably, they are present in a ratio17:16:19::579:464:31::0.54:0.43:0.03.

(iii) CDR3

The preferred libraries of this invention comprise several HC CDR3components. Some of these will have only sequence diversity. Others willhave sequence diversity with embedded D segments to extend the length,while also incorporating sequences known to allow Igs to fold. The HCCDR3 components of the preferred libraries of this invention and theirdiversities are depicted in Table 4: Components 1-8.

This set of components was chosen after studying the sequences of 1383human HC sequences. The proposed components are meant to fulfill thefollowing goals:

1) approximately the same distribution of lengths as seen in native Abgenes;

2) high level of sequence diversity at places having high diversity innative Ab genes; and

3) incorporation of constant sequences often seen in native Ab genes.

Component 1 represents all the genes having lengths 0 to 8 (countingfrom the YYCAR motif at the end of FR3 to the WG dipeptide motif nearthe start of the J region, i.e., FR4). Component 2 corresponds the allthe genes having lengths 9 or 10. Component 3 corresponds to the geneshaving lengths 11 or 12 plus-half the genes having length 13. Component4 corresponds to those having length 14 plus half those having length13. Component 5 corresponds to the genes having length 15 and half ofthose having length 16. Component 6 corresponds to genes of length 17plus half of those with length 16. Component 7 corresponds to those withlength 18. Component 8 corresponds to those having length 19 andgreater. See Table 4.

For each HC CDR3 residue having the diversity <1>, equimolar ratios arepreferably not used. Rather, the following ratios are used 0.095 [G andY] and 0.048 [A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W].Thus, there is a double dose of G and Y with the other residues being inequimolar ratios. For the other diversities, e.g., KR or SG, theresidues are present in equimolar mixtures.

In the preferred libraries of this invention the eight components arepresent in the following fractions: 1 (0.10), 2 (0.14), 3 (0.25), 4(0.13), 5 (0.13), 6 (0.11), 7 (0.04) and 8 (0.10). See Table 4.

In the more preferred embodiment of this invention, the amounts of theeight components is adjusted because the first component is not complexenough to justify including it as 10% of the library. For example, ifthe final library were to have 1×10⁹ members, then 1×10⁸ sequences wouldcome from component 1, but it has only 2.6×10⁵ CDR3 sequences so thateach one would occur in ˜385 CDR1/2 contexts. Therefore, the morepreferred amounts of the eight components are 1(0.02), 2(0.14), 3(0.25),4(0.14), 5(0.14), 6(0.12), 7(0.08), 8(0.11). In accordance with the morepreferred embodiment component 1 occurs in ˜77 CDR1/2 contexts and theother, longer CDR3s occur more often.

Table 5 shows vgDNA that embodies each of the eight HC CDR3 componentsshown in Table 4. In Table 5, the oligonucleotides (ON) Ctop25, CtprmA,CBprmB, and CBot25 allow PCR amplification of each of the variegated ONs(vgDNA): C1t08, C2t10, C3t12, C4t14, C5t15, C6t17, C7t18, and C8t19.After amplification, the dsDNA can be cleaved with AflII and BstEII (orKpnI) and ligated to similarly cleaved vector that contains theremainder of the 3-23 domain. Preferably, this vector already containsdiversity in one, or both, of CDR1 and CDR2 as disclosed herein. Mostpreferably, it contains diversity in both the CDR1 and CDR2 regions. Itis, of course, to be understood that the various diversities can beincorporated into the vector in any order.

Preferably, the recipient vector originally contains a stuffer in placeof CDR1, CDR2 and CDR3 so that there will be no parental sequence thatwould then occur in the resulting library. Table 6 shows a version ofthe V3-23 gene segment with each CDR replaced by a short segment thatcontains both stop codons and restriction sites that will allow specificcleavage of any vector that does not have the stuffer removed. Thestuffer can either be short and contain a restriction enzyme site thatwill not occur in the finished library, allowing removal of vectors thatare not cleaved by both AflII and BstEII (or KpnI) and religated.Alternatively, the stuffer could be 200-400 bases long so that uncleavedor once-cleaved vector can be readily separated from doubly cleavedvector.

Human Antibody Light Chain: Sequence and Length Diversity

(i) Kappa Chain

(a) Framework

In the preferred embodiment of this invention, the kappa light chain isbuilt in an A27 framework with a JK1 region. These are the most common Vand J regions in the native genes. Other frameworks, such as O12, L2,and A11, and other J regions, such as JK4, however, may be used withoutdeparting from the scope of this invention.

(b) CDR1

In native human kappa chains, CDR's with lengths of 11, 12, 13, 16, and17 were observed with length 11 being predominant and length 12 beingwell represented. Thus, in the preferred embodiments of this inventionLC CDR1s of length 11 and 12 are used in an and mixture similar to thatobserved in native antibodies), length 11 being most preferred. Length11 has the following sequence: RASQ<1>V<2><2><3>LA and Length 12 has thefollowing sequence: RASQ<1>V<2><2><2><3>LA, wherein <1> is an equimolarmixture of all of the native amino acid residues, except C, <2> is 0.2 Sand 0.044 of each of A, ADEFGHIKLMNPQRTVWY, and <3> is 0.2 Y and 0.044each of A, D, E, F, G, H, I, K, L, M, N, Q, R, T, V, W and Y. In themost preferred embodiment of this invention, both CDR1 lengths are used.Preferably, they are present in a ratio of 11:12::154:73:0.68:0.32.

(c) CDR2

In native kappa; CDR2 exhibits only length 7.

This length is used in the preferred embodiments of this invention. Ithas the sequence <1>AS<2>R<4><1>, wherein <1> is an equimolar mixture ofamino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.004 of eachof ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and 0.044 of each ofDEFGHIKLMNPQRSTUWY.

CDR3

In native kappa, CDR3 exhibits lengths of 1, 4, 6, 7, 8, 9, 10, 11, 12,13, and 19. While any of these lengths and mixtures of them can beemployed in this invention, we prefer lengths 8, 9 and 10, length 9being more preferred. For the preferred Length 9, the sequence isQQ<3><1><1><1>P<1>T, wherein <1> is an equimolar mixture of amino acidresidues ADEFGHIKLMNPQRSTVWY and <3> is 0.2Y and 0.044 each ofADEFGHIKLMNPQRSVW. Length 8 is preferably QQ33111P and Length 10 ispreferably QQ3211PP1T, wherein 1 and 3 are as defined for Length 9 and 2is S (0.2) and 0.044 each of ADEFGHIKLMNPQRTVWY. A mixture of all 3lengths being most preferred (ratios as in native antibodies), i.e.,8:9:10::28:166:63::0.1:0.65:0.25.

Table 7 shows a kappa chain gene of this invention, including a PlacZpromoter, a ribosome-binding site, and signal sequence (M13 III signal).The DNA sequence encodes the GLG amino acid sequence, but does notcomprise the GLG DNA sequence. Restriction sites are designed to fallwithin each framework region so that diversity can be cloned into theCDRs. XmaI and EspI are in FR1, SexAI is in FR2, RsrII is in FR3, andKpnI (or Acc65I) are in FR4. Additional sites are provided in theconstant kappa chain to facilitate construction of the gene.

Table 7 also shows a suitable scheme of variegation for kappa. In CDR1,the most preferred length 11 is depicted. However, most preferably bothlengths 11 and 12 are used. Length 12 in CDR1 can be construed byintroducing codon 51 as <2> (i.e. a Ser-biased mixture). CDR2 of kappais always 7 codons. Table 7 shows a preferred variegation scheme forCDR2. Table 7 shows a variegation scheme for the most preferred CDR3(length 9). Similar variegations can be used for CDRs of length 8 and10. In the preferred embodiment of this invention, those three lengths(8, 9 and 10) are included in the libraries of this invention in thenative ratios, as described above.

Table 9 shows series of diversity oligonucleotides and primers that maybe used to construct the kappa chain diversities depicted in Table 7.

(ii) Lambda Chain

(a) Framework

The lambda chain is preferably built in a 2a2 framework with an L2Jregion. These are the most common V and J regions in the native genes.Other frameworks, such as 31, 4b, 1a and 6a, and other J regions, suchas L1J, L3J and L7J, however, may be used without departing from thescope of this invention.

(b) CDR1

In native human lambda chains, CDR1s with length 14 predominate, lengths11, 12 and 13 also occur. While any of these can be used in thisinvention, lengths 11 and 14 are preferred. For length 11 the sequenceis: TG<2><4>L<4><4><4><3><4><4> and for Length 14 the sequence: is:TG<1>SS<2>VG<1><3><2><3>VS, wherein <1> is 0.27 T, 0.27 G and 0.027 eachof ADEFHIKLMNPQRSVWY; <2> is 0.27 D, 0.27 N and 0.027 each ofAEFGHIKLMPQRSTVWY; <3> is 0.36 Y and 0.0355 each of ADEFGHIKLMNPQRSTVW;and <4> is an equimolar mixture of amino acid residuesADEFGHIKLMNPQRSTVWY. Most preferably, mixtures (similar to thoseoccurring in native antibodies) preferably, the ratio is11:14::23:46::0.33:0.67 of the three lengths are used.

(c) CDR2

In native human lambda chains, CDR2s with length 7 are by far the mostcommon. This length is preferred in this invention. The sequence of thisLength 7 CDR2 is <4><4><4><2>RPS, wherein <2> is 0.27 D, 0.27 N, and0.027 each of AEFGHIKLMPQRSTVWY and <4> is an equimolar mixture of aminoacid residues ADEFGHIKLMNPQRSTVW.

(d) CDR3

In native human lambda chains, CDR3s of length 10 and 11 predominate,while length 9 is also common. Any of these three lengths can be used inthe invention. Length 11 is preferred and mixtures of 10 and 11 morepreferred. The sequence of Length 11 is <4><5><4><2><4>S<4><4><4><4>V,where <2> and <4> are as defined for the lambda CDR1 and <5> is 0.36 Sand 0.0355 each of ADFFGHIKLMNPQRTVWY. The sequence of Length 10 is<5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture ofADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined for Length 11. Thepreferred mixtures of this invention comprise an equimolar mixture ofLength 10 and Length 11. Table 8 shows a preferred focused lambda lightchain-diversity in accordance with this invention.

Table 9 shows a series of diversity oligonucleotides and primers thatmay be used to construct the lambda chain diversities depicted in Table7:

Method of Construction of the Genetic Package

The diversities of heavy chain and the kappa and lambda light chains arebest constructed in separate vectors. First a synthetic gene is designedto embody each of the synthetic variable domains. The light chains arebounded by restriction sites for ApaLI (positioned at the very end ofthe signal sequence) and AscI (positioned afer the stop codon). Theheavy chain is bounded by SfiI (positioned within the PelB signalsequence) and NotI (positioned in the linker between CH1 and the anchorprotein). Signal sequences other than PelB may also need, e.g., a M13pIII signal sequence.

The initial genes are made with “stuffer” sequences in place of thedesired CDRs. A “Stuffer” is a sequence that is to be cut away andreplaced by diverse DNA but which does not allow expression of afunctional antibody gene. For example, the stuffer may contain severalstop codons and restriction sites that will not occur in the correctfinished library vector. For example, in Table 10, the stuffer for CDR1of kappa A27 contains a StuI site. The vgDNA for CDR1 is introduced as acassette from EspI, XmaI, or AflII to either SexAI or KasI. After theligation, the DNA is cleaved with StuI; there should be no StuI sites inthe desired vectors.

The sequences of the heavy chain gene with stuffers is depicted in Table6. The sequences of the kappa light chain gene with stuffers is depictedin Table 10. The sequence of the lambda light chain gene with stuffersis depicted in Table 11.

In another embodiment of the present intention the diversities of heavychain and the kappa or lambda light chains are constructed in a singlevector or genetic packages (e.g., for display or display and expression)having appropriate restriction sites that allow cloning of these chains.The processes to construct such vectors are well known and widely usedin the art. Preferably, a heavy chain and Kappa light chain library anda heavy chain and lambda, light chain library would be preparedseparately. The two libraries, most preferably, will then be mixed inequimolar amounts to attain maximum diversity.

Most preferably, the display is had on the 0.20 surface of a derivativeof M13 phage. The most preferred vector contains all the genes of M13,an antibiotic resistance gene, and the display cassette. The preferredvector is provided with restriction sites that allow introduction andexcision of members of the diverse family of genes, as cassettes. Thepreferred vector is stable against rearrangement under the growthconditions used to amplify phage.

In another embodiment of this invention, the diversity captured by themethods of the present invention may be displayed and/or expressed in aphagemid vector (e.g., pCES1) that displays and/or expresses thepeptide, polypeptide or protein. Such vectors may also be used to storethe diversity for subsequent display and/or expression using othervectors or phage.

In another embodiment of this invention, the diversity captured by themethods of the present invention may be displayed and/or expressed in ayeast vector.

TABLE 1 3-23: JH4 CDR1/2 diversity = 1.78 × 10⁸                                 FR1(VP47/V3-23)---------------          20   21  22            23  24  25  26  27  28  29  30           A   M   A              E   V   Q   L   L   E   S   Gctgtctgaac  cc atg gcc           gaa|gtt|caa|ttg|tta|gag|tct|ggt|Scab...... NcoI....                       MfeI     --------------FR1--------------------------------------------      31  32  33  34  35  36  37  38  39  40  41  42  43  44  45       G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A     |ggc|ggt|ctt|gtt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct|         Sites ofvariegation      <1>      <1> <1> <1>                 6859-folddiversity     ----FR1-------------------->|.....CDR1....................|---FR2------      46  47  48  49  50  51  52   53  54   55  56  57  58  59  60       A   S   G   F   T   F   S   -   Y   -   M   -   W   V   R     |gct|tcc|gga|ttc|act|ttc|tct| - |tac| - |atg| - |tgg|gtt|cgc|           BspEI                     BsiWI                        BstXI.                     Sites of variegation-><2>     <2> <3>     -------FR2-------------------------------->|...CDR2.........     61  62  63  64  65  66  67  68  69  70  71  72  73  74  75      Q   A   P   G   K   G   L   E   W   V   S   -   I   -   -     |caa|gct|cct|ggt|aaa|ggt|ttg|gag|tgg|gtt|tct| - |atc| - | - | ...BstXI                <1>     <1>  25992-fold diversity in CDR2 .....CDR2............................................|---FR3---   76  77  78  79  80  81  82  83  84  85  86  87  88  89  90    S   G   G   -   T   -   Y   A   D   S   V   K   G   R   F |tct|ggt|ggc| - |act| - |tat|gct|gac|tcc|gtt|aaa|ggt|cgc|ttc| --------FR3--------------------------------------------------   91  92  93  94  95  96  97  98  99 100 101 102 103 104 105    T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M |act|atc|tct|aga|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|            XbaI ---FR3----------------------------------------------------->|  106 107 108 109 110 111 112 113 114 115 116 117 118 119 120   N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   K |aac|agc|tta|agg|gct|gag|gac|acc|gct|gtc|tac|tac|tgc|gcc|aaa|         AflII  .......CDR3.................| Replaced by the variouscomponents!   121 122 123 124 125 126 127    D   Y   E   G   T   G   Y |gac|tat|gaa|ggt|act|ggt|tat|  |----- FR4---(JH4)-----------------------------------------    Y   F   D   Y   W   G   Q   G   T   L   V   T   V   S   S |tat|ttc|gat|tat|tgg|ggt|caa|ggt|acc|ctg|gtc|acc|gtc|tct|agt|...                               KpnI       BstEII <1> = Codons forADEFGHIKLMNPQRSTVWY (equimolar mixture) <2> = Codons for YRWVGS(equimolar mixture) <3> = Codons for PS or PS and G (equimolar mixture)

TABLE 2 Oligonucleotides used to variegate CDR1 of human HC CDR1 - 5residues (ON-R1V1vg):5′-ct|tcc|gga|ttc|act|ttc|tct|<1>|tac|<1>|atg|<1>|tgg|gtt|cgc|caa|gct|cct|gg-3′ <1> = Codons of ADEFGHIKLMNPQRSTVWY 1:1 (ON-R1top):5′-cctactgtct|tcc|gga|ttc|act|ttc|tct-3′ (ON-R1bot)[RC]:5′-tgg|gtt|cgc|caa|gct|cct|ggttgctcactc-3′ CDR1 - 7 residues(ON-R1V2vg):5′-ct|tcc|gga|ttc|act|ttc|tct|<6>|<7>|<7>|tac|tac|tgg|<7>|tgg|gtt|cgc|caa|gct|cct|gg-3′ <6> = Codons for ST, 1:1 <7> = 0.2025(Codons for SG)+ 0.035(Codons for ADEFHIKLMNPQRTVWY) CDR1 - 14 residues (ON-R1V3vg):5′-ct|tcc|gga|ttc|act|ttc|tct|atc|agc|ggt|ggt|tct|atc|tcc|<1>|<1>|<1>|-tac|tac|tgg|<1>|tgg|gtt|cgc|caa|gct|cct|gg-3′ <1> = Codons forADEFGHIKLMNPQRSTVWY 1:1

TABLE 3 Oligonucleotides used to variegate CDR2 of human HC CDR2 - 17residues (ON-R2V1vg):5′-ggt|ttg|gag|tgg|gtt|tct|<2>|atc|<2>|<3>|tct|ggt|ggc|<1>|act|<1>|tat|gct|-gac|tcc|gtt|aaa|gg-3′ (ON-R2top):5′-ct|tgg|gtt|cgc|caa|gct|cct|ggt|aaa|ggt|ttg|gag|tgg|gtt|tct-3′(ON-R2bot)[RC]:5′-tat|gct|gac|tcc|gtt|aaa|ggt|cgc|ttc|act|atc|tct|aga|ttcctgtcac-3′<1> = Codons for A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Wand Y (equimolar mixture) <2> = Codons for Y, R, W, V, G and S(equimolar mixture) <3> = Codons for P and S (equimolar mixture) or P, Sand G (equimolar mixture) (ON-R2V2vg):5′-ggt|ttg|gag|tgg|gtt|tct|<1>|atc|<4>|<1>|<1>|ggt|<5>|<1>|<1>|<1>|tat|gct|-gac|tcc|gtt|aaa|gg-3′ <4> = Codons for DINSWY (equimolar mixture)<5> = Codons for SGDN, (equimolar mixture) CDR2 - 16 residues(ON-R2V3vg): 5′-ggt|ttg|gag|tgg|gtt|tct|<1>|atc|<4>|<1>|<1>|ggt|<5>|<1>|<1>|tat|aac|cct|tcc|ctt|aag|gg-3′ (ON-R2bo3)[RC]:5′-tat|aac|cct|tcc|ctt|aag|ggt|cgc|ttc|act|atc|tct|aga|tcctgtcac-3′CDR2 - 19 residues (ON-R2V4vg):5′-ggt|ttg|gag|tgg|gtt|tct|<1>|atc|<8>|agt|<1>|<1>|<1>|ggt|ggt|act|act|<1>|tat|gcc|gct|tcc|gtt|aag|gg-3′ (ON7R2bo4)[RC]:5′-tat|gcc|gct|tcc|gtt|aag|ggt|cgc|ttc|act|atc|tct|aga|ttcctgtcac-3′<1>, <2>, <3>, <4> and <5> are as defined above <8> is 0.27 R and 0.027each of ADEFGHIKLMNPQSTVWY

TABLE 4 Preferred Components of HC CDR3 Preferred Fraction of AdjustedComponent Length Complexity Library Fraction 1 YYCA21111YFDYWG. 8 2.6× 10⁵ .10 .02 (1 = any amino acid residue, except C; 2 = K and R) 2YYCA2111111YFDYWG. 10 9.4 × 10⁷ .14 .14 (1 = any amino acid residue,except C; 2 = K and R) 3 YYCA211111111YFDYTG. 12 3.4 × 10¹⁰ .25 .25 (1= any amino acid residue, except C; 2 = K and R) 4YYCAR111S2S3111YFDYWG. 14 1.9 × 10⁸ .13 .14 (1 = any amino acid residue,except C; 2 = S and G 3 = Y and W) 5 YYCA2111CSG11CY1YFDYWG. 15 9.4× 10⁷ .13 .14 (1 = any amino acid residue, except C; 2 = K and R) 6YYCA211S1TIFG11111YFDYWG. 17 1.7 × 10¹⁰ .11 .12 (1 = any amino acidresidue, except C; 2 = K and R) 7 YYCAR111YY2S33YY111YFDYWG. 18 3.8× 10⁸ .04 .08 (1 = any amino acid residue, except C; 2 = D or G; 3 = Sand G) 8 YYCAR1111YC2231CY111YFDYWG. 19 2.0 × 10¹¹ .10 .11 (1 = anyamino acid residue, except C; 2 = S and G; 3 = T, D and G)

TABLE 5 Oligonucleotides used to variegate the eight components of HCCDR3 (Ctop25): 5′-gctctggtcaac|tta|agg|gct|gag|g-3′ (CtprmA):5′-gctctggtcaac|tta|agg|gct|gag|gac|acc|gct|gtc|tac|tac|tgc|gcc-3′              AflII... (CBprmB) [RC]:5′-|tac|ttc|gat|tac|tgg|ggc|caa|ggt|acc|ctg|gtc|acc|tcgctccacc-3′                                          BstEII... (CBot25) [RC]:5′-|ggt|acc|ctg|gtc|acc|tcgctccacc-3′ The 20 bases at 3′ end of CtprmAare identical to the most 5′ 20 bases of each of the vgDNA molecules.Ctop25 is identical to the most 5′ 25 bases of CtprmA. The 23 most3′ bases of CBprmB are the reverse complement of the most 3′ 23 bases ofeach of the vgDNA molecules. CBot25 is identical to the 25 bases at the5′ end of CBprmB. Component 1 (C1t08):5′-cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|<1>|<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3′<1> = 0.095 Y + 0.095 G + 0.048 each of the residues ADEFHIKLMNPQRSTVW,no C; <2> = K and R (equimolar mixture) Component 2 (C2t10):5′-cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|<1>|<1>|<1>|<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3′ <1> = 0.095 Y + 0.095 G + 0.048 each ofADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture) Component 3(C3t12):5′-cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|<1>|<1>|<1>|<1>|<1>|<1>|tac|ttc|gat|tac|-tgg|ggc|caa|gg-3′ <1> = 0.095 Y + 0.095 G + 0.048 each ofADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture) Component 4(C4t140):5′-cc|gct|gtc|tac|tac|tgc|gcc|cgt|<1>|<1>|<1>|tct|<2>|tct|<3>|<1>|<1>|<1>|tac|ttc|gat|-tac|tgg|ggc|caa|gg-3′ <1> = 0.095 Y + 0.095 G + 0.048 each ofADEFHIKLMNPQRSTVW, no C; <2> = S and G (equimolar mixture); <3> = Y andW (equimolar mixture) Component 5 (C5t15):5′-cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|<1>|tgc|tct|ggt|<1>|<1>|tgc|tat|<1>|tac|-ttc|gat|tac|tgg|ggc|caa|gg-3′ <1> = 0.095 Y + 0.095 G + 0.048 each ofADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture) Component 6(C6t17):5′-cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|tct|<1>|act|atc|ttc|ggt|<1>|<1>|<1>|<1>|-<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3′ <1> = 0.095 Y + 0.095 G + 0.048each of ADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture)Component 7 (C7t18):5′-cc|gct|gtc|tac|tac|tgc|gcc|cgt|<1>|<1>|<1>|tat|tac|<2>|tct|<3>|<3>|tac|tat|-<1>|<1>|<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3′ <1> = 0.095 Y + 0.095 G+ 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = D and G (equimolarmixture); <3> = S and G (equimolar mixture) Component 8 (c8t19):5′-cc|gct|gtc|tac|tac|tgc|gcc|cgt|<1>|<1>|<1>|<1>|tat|tgc|<2>|<2>|<3>|<1>|tgc|tat|-<1>|<1>|<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3′ <1> = 0.095 Y + 0.095 G+ 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = S and G (equimolarmixture); <3> = TDG (equimolar mixture);

TABLE 6 3-23::JH4 Stuffers in place of CDRs                          FR1(DP47/V3-23)---------------           20  21  22     23  24  25  26  27  28  29  30            A   M   A      E   V   Q   L   L   E   S   G ctgtctgaac  ccatg gcc   gaa|gtt|caa|ttg|tta|gag|tct|ggt|Scab......  NcoI....             MfeI  --------------FR1--------------------------------------------   31  32  33  34  35  36  37  38  39  40  41  42  43  44  45    G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A  |ggc|ggt|ctt|gtt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct|  ----FR1-------------------->|...CDR1 stuffer....|---FR2------   46  47  48  49  50  51  52  53  54  55  56  57  58  59  60    A   S   G   F   T   F   S   S   Y   A   |   |   W   V   R  |gct|tcc|gga|ttc|act|ttc|tct|tcg|tac|gct|tag|taa|tgg|gtt|cgc|        BspEI                     BsiWI                       BstXI.  -------FR2-------------------------------->|...CDR2 stuffer.  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75   Q   A   P   G   K   G   L   E   W   V   S   |   p   r   |  |caa|gct|cct|ggt|aaa|ggt|ttg|gag|tgg|gtt|tct|taa|cct|agg|tag|...BstXI                                         AvrII..  .....CDR2stuffer....................................|---FR3---    91  92  93  94  95  96  97  98  99 100 101 102 103 104 105    T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M  |act|atc|tct|aga|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|            XbaI   ---FR3-----------..> CDR3 Stuffer------------->|   106 107 108 109 110     N   S   L   R   A   |aac|agc|tta|agg|gct|tagtaa agg cct taa           AflII                StuI...   |----- FR4---(JH4)-----------------------------------------   Y   F   D   Y   W   G   Q   G   T   L   V   T   V   S   S  |tat|ttc|gat|tat|tgg|ggt|caa|ggt|acc|ctg|gtc|acc|gtc|tct|agt|...                           KpnI     BstEII

TABLE 7 A27:JH1 Human Kappa light chain gene  gaggacc attgggccccctccgagact ctcgagcgca  Scab...... EcoO109I           XhoI..           ApaI. acgcaattaa tgtgagttag ctcactcatt aggcacccca ggctttacactttatgcttc       ..-35..          Plac                    ..-10.cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatgaccatgatta cgccaagctt tggagccttt tttttggaga ttttcaac   PflMI.......      Hind III M13 III signal sequence (AAseq)--------------------------->  1   2   3   4   5   6   7   8   9  10  11  12  13  14  15  M   K   K   L   L   F   A   I   P   L   V   V   P   F   Y  gtg aag aagctc cta ttt gct atc ccg ctt gtc gtt ccg ttt tac--Signal-->FR1-------------------------------------------> 16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  S   H   S   A   Q   S   V   L   T   Q   S   P   G   T   L|agc|cat|agt|gca|caa|tcc|gtc|ctt|act|caa|tct|cct|ggc|act|ctt|          ApaLI... ----- FR1------------------------------------->| CDR1------> 31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  S   L   S   P   G   E   R   A   T   L   S   C   R   A   S |tcg|cta|agc|ccg|ggt|gaa|cgt|gct|acc|tta|agt|tgc|cgt|gct|tcc|    EspI.....                       AflII...             XmaI.... ForCDR1: <1> ADEFGHIKLMNPQRSTVWY 1:1 <2> S(0.2) ADEFGHIKLMNPQRTVWY (0.044each) <3> Y(0.2) ADEFGHIKLMNPQRSTVW (0.044 each) (CDR1 installed asAflII-(SexAI or KasI) cassette.) For the most preferred 11 length codon51 (XXX) is omitted; for the preferred 12 length this codon is <2>         ------- CDR1 --------------------->|--- FR2 --------------->             <1>     <2> <2> xxx <3>         46  47  48  49  50  51  52  53  54  55  56  57  58  59  60          Q   -   V   -   -   -   -  L   A   W   Y   Q   Q   K   P       |cag| - |gtt| - | - | - | - |ctt|gct|tgg|tat|caa|cag|aaa|cct|                                                              SexAI...For CDR2: <1> ADEFGHIKLMNPQRSTVWY 1:1 <2> S(0.2) ADEFGHIKLMNPQRTVWY(0.044 each) <4> A(0.2) DEFGHIKLMNPQRSTVWY (0.044 each) CDR2 installedas (SexAI or KasI) to (BamHI or RsrII) cassette.)          ----- FR2------------------------->|------- CDR2 ---------->                                            <1>         <2>     <4>         61  62  63  64  65  66  67  68  69  70  71  72  73  74  75          G   Q   A   P   R   L   L   I   Y   -   A   S   -   R   -       |ggt|cag|gcg|ccg|cgt|tta|ctt|att|tat| - |gct|tct| - |cgc| - |   SexAI....  KasI....       CDR2-->|--- FR3----------------------------------------------->           <1>          76  77  78  79  80  81  82  83  84  85  86  87  88  89  90           -   G   I   P   D   R   F   S   G   S   G   S   G   T   D        | - |ggg|atc|ccg|gac|cgt|ttc|tct|ggc|tct|ggt|tca|ggt|act|gac|               BamHI...                       RsrII.....          ------FR3 ------------------------------------------------->          91  92  93  94  95  96  97  98  99 100 101 102 103 104 105            F   T   L   T   I   S   R   L   E   P   E   D   F   A   V        |ttt|acc|ctt|act|att|tct|aga|ttg|gaa|cct|gaa|gac|ttc|gct|gtt|                               XbaI... For CDR3 (Length 9):<1> ADEFGHIKLMNPQRSTVWY 1:1 <3> Y(0.2) ADEFGHIKLMNPQRTVW (0.044 each)For CDR3 (Length 8): QQ33111P 1 and 3 as defined for Length 9 For CDR3(Length 10): QQ3211PP1T 1 and 3 as defined for Length 9 2 S(0.2) and0.044 each of ADEFGHIKLMNPQRTVWY CDR3 installed as XbaI to (StyI orBsiWI) cassette.         ----------->|----CDR3-------------------------->|-----FR4--->                              <3> <1> <1> <1>    <1>          106 107108 109 110 111 112 113 114 115 116 117 118 119 120           Y   Y   C   Q   Q   -   -   -   -   P   -   T   F   G   Q         |tat|tat|tgc|caa|cag| - | - | - | - |cct| - |act|ttc|ggt|caa|                    BstXI...........-----FR4------------------->|    <------- Ckappa ------------ 121 122123 124 125 126 127       128 129 130 131 132 133 134  G   T   K   V   E   I   K        R   T   V   A   A   P   S|ggt|acc|aag|gtt|gaa|atc|aag|   |cgt|acg|gtt|gcc|gct|cct|agt|      StyI....                    BsiWI.. 135 136 137 138 139 140 141142 143 144 145 146 147 148 149  V   F   I   F   P   P   S   D   E   Q   L   K   S   G   T|gtg|ttt|atc|ttt|cct|cct|tct|gac|gaa|caa|ttg|aag|tca|ggt|act|                                     MfeI... 150 151 152 153 154 155 156157 158 159 160 161 162 163 164  A   S   V   V   C   L   L   N   N   F   Y   P   R   E   A|gct|tct|gtc|gta|tgt|ttg|ctc|aac|aat|ttc|tac|cct|cgt|gaa|gct|                                              BssSI...  165 166 167 168169 170 171 172 173 174 175 176 177 178 179  K   V   Q   W   K   V   D   N   A   L   Q   S   G   N   S|aaa|gtt|cag|tgg|aaa|gtc|gat|aac|gcg|ttg|cag|tcg|ggt|aac|agt|                              MluI....  180 181 182 183 184 185 186 187188 189 190 191 192 193 194  Q   E   S   V   T   E   Q   D   S   K   D   S   T   Y   S|caa|gaa|tcc|gtc|act|gaa|cag|gat|agt|aag|gac|tct|acc|tac|tct|  195 196197 198 199 200 201 202 203 204 205 206 207 208 209  L   S   S   T   L   T   L   S   K   A   D   Y   E   K   H|ttg|tcc|tct|act|ctt|act|tta|tca|aag|gct|gat|tat|gag|aag|cat|  210 211212 213 214 215 216 217 218 219 220 221 222 223 224  K   V   Y   A   C   E   V   T   H   Q   G   L   S   S   P|aag|gtc|tat|GCt|TGC|gaa|gtt|acc|cac|cag|ggt|ctg|agc|tcc|cct|                                               SacI....  225 226 227 228229 230 231 232 233 234   V   T   K   S   F   N   R   G   E   C|gtt|acc|aaa|agt|ttc|aac|cgt|ggt|gaa|tgc|taa|tag ggcgcgcc                       DsaI....                  AscI....                                                  BssHII acgcatctctaagcggccgc aacaggaggag              NotI....

TABLE 8 2a2:JH2 Human lambda-chain gene gaggaccattgggcccc   ttactccgtgac Scab...... EcoO109I            ApaI..        -----------FR1-------------------------------------------->         1   2   3   4   5   6   7   8   9  10  11  12  13  14  15 S   A   Q   S   A   L   T   Q   P   A   S   V   S   G   S   P   Gagt|gca|caa|tcc|gct|ctc|act|cag|cct|gct|agc|gtt|tcc|ggg|tca|cct|ggt| ApaLI...                           NheI...          BstEII...                                                          SexAI.... ForCDR1 (length 14): <1> = 0.27 T, 0.27 G, 0.027 each of ADEFHIKLMNPQRSVWY,no C <2> = 0.27 D, 0.27 N, 0.027 each of AEFGHIKLMPQRSTVWY, no C<3> = 0.36 Y, 0.0355 each of ADEFGHIKLMNPQRSTVW, no C                              T   G  <1>  S   S  <2>  V   G------FR1------------------> |-----CDR1--------------------- 16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  Q   S   I   T   I   S   C   T   G   -   S   S   -   V   G|caa|agt|atc|act|att|tct|tgt|aca|ggt| - |tct|tct| - |gtt|ggc|                         BsrGI.. <1> <3> <2> <3>  V   S = vg Scheme #1,length = 14 -----CDR1------------->|--------FR2-------------------------31  32  33  34  35  36  37  38  39  40  41  42  43  44  45 -   -   -   -   V   S   W   Y   Q   Q   H   P   G   K   A | - | - | -| - |gtt|tct|tgg|tat|caa|caa|cac|ccg|ggc|aag|gcg|                                          XmaI....    KasI.....                                          AvaI.... A second Vg schemefor CDR1 gives segments of length 11:T₂₂G<2><4>L<4><4><4><3><4><4> where <4> = equimolar mixture of each ofADEFGHIKLMNPQRSTVWY, no C <3> = as defined above for the alternativeCDR1 For CDR2: <2> and <4> are the same variegation as for CDR1                        <4> <4> <4> <2>  R   P   S--FR2-----------------> |------CDR2--------------->|-----FR3-46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 P   K   L   M   I   Y   -   -   -   -   R   P   S   G   V|ccg|aag|ttg|atg|atc|tac| - | - | - | - |cgt|cct|tct|ggt|gtt| KasI....-------FR3---------------------------------------------------- 61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  S   N   R   F   S   G   S   K   S   G   N   T   A   S   L|agc|aat|cgt|ttc|tcc|gga|tct|aaa|tcc|ggt|aat|acc|gca|agc|tta|                 BspEI..                           HindIII.                      BsaBI........(blunt)-------FR3-------------------------------------------------->| 76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  T   I   S   G   L   Q   A   E   D   E   A   D   Y   Y   C|act|atc|tct|ggt|ctg|cag|gct|gaa|gac|gag|gct|gac|tac|tat|tgt|                 PstI... CDR3 (Length 11): <2> and <4> are the samevariegation as for CDR1 <5> = 0.36 S, 0.0355 each of ADEFGHIKLMNPQRTVWYno C CDR3 (Length 10): <5> SY <1> <5> S <5> <1> <4> V <1> is anequimolar mixture of ADEFGHIKLMNPQRSTVWY, no C <4> and <5> are asdefined for Length 11 <4> <5> <4> <2> <4> S <4> <4> <4> <4> V-----CDR3---------------------------------->|---FR4--------- 91  92  93  94  95  96  97  98  99  100 101 102 103 104 105  -   -   -   -   -   S   -   -   -   -    V   F   G   G   G | - | - | -| - | - |tct| - | - | - | - |gtc|ttc|ggc|ggt|ggt|                                                         KpnI...-------FR4-------------->  106 107 108 109 110 111 112 113 114 115 116117 118 119 120  T   K   L   T   V   L   G   Q   P   K   A   A   P   S   V|acc|aaa|ctt|act|gtc|ctc|ggt|caa|cct|aag|gct|gct|cct|tcc|gtt|KpnI...                   HincII..                                Bsu36I...  121 122 123 124 125 126 127128 129 130 131 132 133 134 135  T   L   F   P   P   S   S   E   E   L   Q   A   N   K   A|act|ctc|ttc|cct|cct|agt|tct|gaa|gag|ctt|caa|gct|aac|aag|gct|                             SapI.....  136 137 138 139 140 141 142 143144 145 146 147 148 149 150  T   L   V   C   L   I   S   D   F   Y   P   G   A   V   T|act|ctt|gtt|tgc|ttg|atc|agt|gac|ttt|tat|cct|ggt|gct|gtt|act|                  BclI.... 151 152 153 154 155 156 157 158 159 160 161162 163 164 165  V   A   W   K   A   D   S   S   P   V   K   A   G   V   E|gtc|gct|tgg|aaa|gcc|gat|tct|tct|cct|gtt|aaa|gct|ggt|gtt|gag|                                                         BsmBI...  166167 168 169 170 171 172 173 174 175 176 177 178 179 180  T   T   T   P   S   K   Q   S   N   N   K   Y   A   A   S|acg|acc|act|cct|tct|aaa|caa|tct|aac|aat|aag|tac|gct|gcg|agc|BsmBI....                                              SacI....  181 182183 184 185 186 187 188 189 190 191 192 193 194 195  S   Y   L   S   L   T   P   E   Q   W   K   S   H   K   S|tct|tat|ctt|tct|ctc|acc|cct|gaa|caa|tgg|aag|tct|cat|aaa|tcc| SacI... 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210  Y   S   C   Q   V   T   H   E   G   S   T   V   E   K   T|tat|tcc|tgt|caa|gtt|act|cat|gaa|ggt|tct|acc|gtt|gaa|aag|act|                       BspHI...  211 212 213 214 215 216 217 218 219  V   A   P   T   E   C   S   .   .|gtt|gcc|cct|act|gag|tgt|tct|tag|tga|ggcgcgcc                                    AscI....                                     BssHII aacgatgttc aag gcggccgcaacaggaggag                NotI.... Scab.......

TABLE 9 Oligonucleotides For Kappa and Lambda Light Chain Variegation(Ctop25): 5′-gctctggtcaac|tta|agg|gct|gag|g-3′ (CtprmA):5′-gctctggtcaac|tta|agg|gct|gag|gac|acc|gct|gtc|tac|tac|tgc|gcc-3′              AflII... (CBprmB) [RC]:5′-|tac|ttc|gat|tac|ttg|ggc|caa|ggt|acc|ctg|gtc|acc|tcgctccacc-3′                                          BstEII... (CBot25) [RC]:5′-|ggt|acc|ctg|gtc|acc|tcgctccacc-3′ Kappa chains: CDR1 (“1”), CDR2(“2”), CDR3 (“3”) CDR1 (Ka1Top610):5′-ggtctcagttg|cta|agc|ccg|ggt|gaa|cgt|gct|acc|tta|agt|tgc|cgt|gct|tcc|cag-3′(Ka1STp615): 5′-ggtctcagttg|cta|agc|ccg|ggt|g-3′ (Ka1Bot620) [RC]:5′-ctt|gct|tgg|tat|caa|cag|aaa|cct|ggt|cag|gcg|ccaagtcgtgtc-3′(Ka1SB625) [RC]: 5′-cct|ggt|cag|gcg|ccaagtcgtgtc-3′ (Ka1vg600):5′-gct|acc|tta|agt|tgc|cgt|gct|tcc|cag-|<1>|gtt|<2>|<2>|<3>|ctt|gct|tgg|tat|caa|cag|aaa|cc-3′ (Ka1vg600-12):5′-gct|acc|tta|agt|tgc|cgt|gct|tcc|cag-|<1>|gtt|<2>|<2>|<2>|<3>|ctt|gct|tgg|tat|caa|cag|aaa|cc-3′ CDR2(Ka2Tshort657): 5′-cacgagtccta|cct|ggt|cag|gc-3′ (Ka2Tlong655):5′-cacgagtccta|cct|ggt|cag|gcg|ccg|cgt|tta|ctt|att|tat-3′(Ka2Bshort660): [RC]: 5′-|gac|cgt|ttc|tct|ggt|tctcacc-3′ (Ka2vg650):5′-cag|gcg|ccg|cgt|tta|ctt|att|tat|<1>|gct|tct|<2>|-|cgc|<4>|<1>|ggg|atc|ccg|gac|cgt|ttc|tct|ggt|tctcacc-3′ CDR3(Ka3Tlon672):5′-gacgagtccttct|aga|ttg|gaa|cct|gaa|gac|ttc|gct|gtt|tat|tat|tgc|caa|c-3′(Ka3BotL682) [RC]:5′-act|ttc|ggt|caa|ggt|acc|aag|gtt|gaa|atc|aag|cgt|acg|tcacaggtgag-3′(Ka3Bsho694) [RC]: 5′-gaa|atc|aag|cgt|acg|tcacaggtgag-3′ (Ka3vg670):5′-gac|ttc|gct|gtt|-|tat|tat|tgc|caa|cag|<3>|<1>|<1>|<1>|cct|<1>|act|ttc|ggt|caa|-|ggt|acc|aag|gtt|g-3′ (Ka3vg670-8): 5′-gac|ttc|gct|gtt|-|tat|tat|tgc|caa|cag|<3>|<3>|<1>|<1>|<1>|cct|ttc|ggt|caa|-|ggt|acc|aag|gtt|g-3′ (Ka3vg670-10): 5′-gac|ttc|gct|gtt|tat|-|tat|tgc|caa|cag|<3>|<2>|<1>|<1>|cct|cct|<1>|act|ttc|ggt|caa|-|ggt|acc|aag|gtt|g-3′ Lambda Chains: CDR1 (“1”), CDR2 (“2”), CDR3 (“3”)CDR1 (Lm1TPri75): 5′-gacgagtcctgg|tca|cct|ggt|-3′ (Lm1tlo715):5′-gacgagtcctgg|tca|cct|ggt|caa|agt|atc|act|att|tct|tgt|aca|ggt-3′(Lm1blo724) [rc]:5′-gtt|tct|tgg|tat|caa|caa|cac|ccg|ggc|aag|gcg|agatcttcacaggtgag-3′(Lm1bsh737) [rc]: 5′-gc|aag|gcg|agatcttcacaggtgag-3′ (Lm1vg710b):5′-gt|atc|act|att|tct|tgt|aca|ggt|<2>|<4>|ctc|<4>|<4>|<4>|-|<3>|<4>|<4>|tgg|tat|caa|caa|cac|cc-3′ (Lm1vg710):5′-gt|atc|act|att|tct|tgt|aca|ggt|<1>|tct|tct|<2>|gtt|ggc|-|<1>|<3>|<2>|<3>|gtt|tct|tgg|tat|caa|caa|cac|cc-3′ CDR2 (Lm2TSh757):5′-gagcagaggac|ccg|ggc|aag|gc-3′ (Lm2TLo753):5′-gagcagaggac|ccg|ggc|aag|gcg|ccg|aag|ttg|atg|atc|tac|-3′ (Lm2BLo762)[RC]: 5′-cgt|cct|tct|ggt|gtc|agc|aat|cgt|ttc|tcc|gga|tcacaggtgag-3′(Lm2BSh765) [RC]: 5′-cgt|ttc|tcc|gga|tcacaggtgag-3′ (Lm2vg750):5′-g|ccg|aag|ttg|atg|atc|tac|-<4>|<4>|<4>|<2>|cgt|cct|tct|ggt|gtc|agc|aat|c-3′ CDR3 (Lm3TSh822):5′-ctg|cag|gct|gaa|gac|gag|gct|gac-3′ (Lm3TLo819):5′-ctg|cag|gct|gaa|gac|gag|gct|gac|tac|tat|tgt|-3′ (Lm3BLo825) [RC]:5′-gtc|ttc|ggc|ggt|ggt|acc|aaa|ctt|act|gtc|ctc|ggt|caa|cct|aag|g-acacaggtgag-3′ (Lm3BSh832) [RC]: 5′-c|ggt|caa|cct|aag|gacacaggtgag-3′(Lm3vg817): 5′-gac|gag|gct|gac|tac|tat|tgt|-|<4>|<5>|<4>|<2>|<4>|tct|<4>|<4>|<4>|<4>|-Gtc|ttc|ggc|ggt|ggt|acc|aaa|ctt|ac-3′ (Lm3vg817-10):5′-gac|gag|gct|gac|tac|tat|tgt|-|<5>|agc|tat|<1>|<5>|tct|<5>|<1>|<4>|gtc|ttc|ggc|ggt|ggt|-|acc|aaa|ctt|ac-3′

TABLE 10 A27:JH1 Kappa light chain gene with stuffers in place of CDRsEach stuffer contains at least one stop codon and a restriction sitethat will be unique within the diversity vector. gaggacc attgggccccctccgagact ctcgagcgca   Scab.....EcoO109I            ApaI.                              XhoI.. acgcaattaa tgtgagttag ctcactcattaggcacccca ggctttacac tttatgcttc      ..-35..         Plac                    ..-10. cggctcgtatgttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatgac catgattacgccaagctt tggagccttt tttttggaga ttttcaac           PflMI.......            Hind3. M13 III signal sequence (AAseq)--------------------------->  1   2   3   4   5   6   7   8   9  10  11  12  13  14  15  M   K   K   L   L   F   A   I   P   L   V   V   P   F   Y  gtg aag aagctc cta ttt gct atc ccg ctt gtc gtt ccg ttt tac--Signal--> FR1-------------------------------------------> 16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  S   H   S   A   Q   S   V   L   T   Q   S   P   G   T   L|agc|cat|agt|gca|caa|tcc|gtc|ctt|act|caa|tct|cct|ggc|act|ctt|          ApaLI... ----- FR1--------------------------------->|-------Stuffer-> 31  32  33  34  35  36  37  38  39  40  41  42  43  S   L   S   P   G   E   R   A   T   L   S   |   ||tcg|cta|agc|ccg|ggt|gaa|cgt|gct|acc|tta|agt|tag|taa|gct|ccc|   EspI.....                       AflII...            XmaI.... -Stuffer for CDR1--> FR2 ------- FR2 ------>|-----------Stuffer for CDR2                      59  60  61  62  63  64  65  66                       K   P   G   Q   A   P   R|agg|cct|ctt|tga|tct|g|aaa|cct|ggt|cag|gcg|ccg|cgt|taa|tga|aagcgctaatggccaacagtg StuI...                 SexAI...    KasI....              AfeI..   MscI..Stuffer-->|--- FR3 ----------------------------------------------->       76  77  78  79  80  81  82  83  84  85  86  87  88  89  90        T   G   I   P   D   R   F   S   G   S   G   S   G   T   D      |act|ggg|atc|ccg|gac|cgt|ttc|tct|ggc|tct|ggt|tca|ggt|act|gac|            BamHI...                    RsrII..... ------ FR3----->----------------STUFFER for CDR3------------------> 91  92  93  94  95  96  97   F   T   L   T   I   S   R   |   ||ttt|acc|ctt|act|att|tct|aga|taa|tga| gttaac tag acc tacgta acc tag                     XbaI...          HpaI..         SnaBI.-----------------CDR3 stuffer------------------>|-----FR4--->                                                118 119 120                                                  F   G   Q                                                |ttc|ggt|caa|-----FR4------------------->|      <------- Ckappa ------------ 121 122123 124 125 126 127        128 129 130 131 132 133 134  G   T   K   V   E   I   K         R   T   V   A   A   P   S|ggt|acc|aag|gtt|gaa|atc|aag|           |cgt|acg|gtt|gcc|gct|cct|agt|      StyI....                     BsiWI..  135 136 137 138 139 140 141142 143 144 145 146 147 148 149  V   F   I   F   P   P   S   D   E   Q   L   K   S   G   T|gtg|ttt|atc|ttt|cct|cct|tct|gac|gaa|caa|ttg|aag|tca|ggt|act|                                       MfeI... acgcatctctaa gcggccgcaacaggaggag             NotI....              EagI..

TABLE 11 2a2:JH2 Human lambda-chain gene with stuffers in place of CDRsgaggaccatt gggcccc   ttactccgtgac Scab...... EcoO109I            ApaI..        -----------FR1-------------------------------------------->         1   2   3   4   5   6   7   8   9  10  11  12  13  14  15 S   A   Q   S   A   L   T   Q   P   A   S   V   S   G   S   P   Gagt|gca|caa|tcc|gct|ctc|act|cag|cct|gct|agc|gtt|tcc|ggg|tca|cct|ggt| ApaLI...                           NheI...          BstEII...                                                          SexAI....------FR1------------------> |-----stuffer for CDR1--------- 16  17  18  19  20  21  22  23   Q   S   I   T   I   S   C   T|caa|agt|atc|act|att|tct|tgt|aca|tct tag tga ctc                         BsrGI..-----Stuffer--------------------------->-------FR2----------> 31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  R   S   |   |   P   |                     H   P   G   K   A aga tcttaa tga ccg tag                 cac|ccg|ggc|aag|gcg| BglII                                     XmaI....    KasI.....                                           AvaI.... --|-------------Stuffer for CDR2----------------------------------------------->   P |ccg|taa|tga|atctcg tac g                               ct|ggt|gtt|KasI....          BsiWI...-------FR3---------------------------------------------------- 61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  S   N   R   F   S   G   S   K   S   G   N   T   A   S   L|agc|aat|cgt|ttc|tcc|gga|tct|aaa|tcc|ggt|aat|acc|gca|agc|tta|                 BspEI..                           HindIII.                      BsaBI........(blunt)-------FR3------------->|--Stuffer for CDR3----------------->| 76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  T   I   S   G   L   Q |act|atc|tct|ggt|ctg|cag|gtt ctg tag ttc caattgctt tag tga ccc                  PstI...                 MfeI..-----Stuffer------------------------------->|---FR4---------                                                103 104 105                                                 G   G   G                                               |ggc|ggt|ggt|                                                         KpnI...-------FR4-------------->  106 107 108 109 110 111 112 113 114 115 116117 118 119 120  T   K   L   T   V   L   G   Q   P   K   A   A   P   S   V|acc|aaa|ctt|act|gtc|ctc|ggt|caa|cct|aag|gct|gct|cct|tcc|gtt|KpnI...                   HincII..                                 Bsu36I...  121 122 123 124 125 126 127128 129 130 131 132 133 134 135  T   L   F   P   P   S   S   E   E   L   Q   A   N   K   A|act|ctc|ttc|cct|cct|agt|tct|gaa|gag|ctt|caa|gct|aac|aag|gct|                             SapI.....  136 137 138 139 140 141 142 143144 145 146 147 148 149 150  T   L   V   C   L   I   S   D   F   Y   P   G   A   V   T|act|ctt|gtt|tgc|ttg|atc|agt|gac|ttt|tat|cct|ggt|gct|gtt|act|                  BclI....

The invention relates to generation of useful diversity in syntheticantibody (Ab) gene, especially to Ab genes having frameworks derivedfrom human Abs.

BACKGROUND OF THE INVENTION

Antibodies are highly useful molecules because of their ability to bindalmost any substance with high specificity and affinity and theirability to remain in circulation in blood for prolonged periods astherapeutic or diagnostic agents. For treatment of humans, Abs derivedfrom human Abs are much preferred to avoid immune response to the Ab.For example, murine Abs very often cause Human Anti Mouse Antibodies(HAMA) which at a minimum prevent the therapeutic effects of the murineAb. For many medical applications, monoclonal Abs are preferred.Nowadays the preferred method of obtaining a human Ab having aparticular binding specificity is to select the Ab from a library ofhuman-derived Abs displayed on a genetic package, such as filamentousphage.

Libraries of phage-displayed Fabs and scFvs have been produced inseveral ways. One method is to capture the diversity of donors, eithernaive or immunized. Another way is to generate libraries havingsynthetic diversity. The present invention relates to methods ofgenerating useful diversity in human Ab scaffolds.

As is well known, typical Abs consist of two heavy chains (HC) and twolight chains (LC). There are several types of HCs: gamma, mu, epsilon,delta, etc. Each type has an N-terminal V domain followed by three ormore constant domains. The LCs comprise an N-terminal V domain followedby a constant domain. LCs come in two types: kappa and lambda.

Within each V domain (LC or HC) there are seven canonical regions, namedFR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4, where “FR” stands for“Framework Region” and “CDR” stands for “Complementarity DeterminingRegion”. For LC and HC, the FR and CDR GLGs have been selected over timeto be secretable, stable, non-antigenic and these properties should bepreserved as much as possible. Actual Ab genes contain mutations in theFR regions and some of these mutations contribute to binding, but suchuseful FR mutations are rare and are not necessary to obtainhigh-affinity binding. Thus, the present invention will concentratediversity in the CDR regions.

In LC, HU up to FR3 and part of CDR3 comes from a genomic collection ofgenes called “V-genes”. The remainder of CDR3 and FR4 comes from agenomic collection of genes called “7-genes”. The joining may involve acertain degree of mutation, allowing diversity in CDR3 that is notpresent in the genomic sequences. After the LC gene is formed, somaticmutations can give rise to mature, rearranged LC genes that have higheraffinity for an antigen (Ag) than does any LC encoded by genomicsequences. A large fraction of somatic mutations occur in CDRs.

The HC V region is more complicated. A V gene is joined to a J gene withthe possible inclusion of a D segment. About half of HC Abs sequencescontain a recognizable D segment in CDR3. The joining is achieved withan amazing degree of molecular sloppiness. Roughly, the end of the Vgene may have zero to several bases deleted or changed, the D segmentmay have zero to many bases removed or changed at either end, a numberof random bases may be inserted between V and D or between D and J, andthe 5′ end of J may be edited to remove or change several bases. Withal,it is amazing that human heavy chains work, but they do. The upshot isthat the CDR3 is highly diverse both in encoded amino-acid sequences andin length. In designing synthetic libraries, there is the temptation tojust throw in a high degree of synthetic diversity and let the phagesort it out. Nevertheless, D regions serve a function. They cause the Abrepertoire to be rich in sequences that a) allow Abs to fold correctly,and b) are conducive to binding to biological molecules, i.e. antigens.

One purpose of the present invention is to show how a manageablecollection of diversified sequences can confer these advantages onsynthetic Ab libraries. Another purpose of the present invention is todisclose analysis of known mature Ab sequences that lead to improveddesigns for diversity in the CDR1 and CDR2 of HC and the three CDRs oflambda and kappa chains.

BRIEF STATEMENT OF THE INVENTION

The invention is directed to methods of preparing synthetically diversepopulations of Ab genes suitable for display on genetic packages (suchas phage or phagemids) or for other regimens that allow selection ofspecific binding. Said populations concentrate the diversity intoregions of the Ab that are likely to be involved in determining affinityand specificity of the Ab for particular targets. In particular, acollection of actual Ab genes has been analyzed and the sites of actualdiversity have been identified. In addition, structural considerationswere used to determine whether the diversity is likely to greatlyinfluence the binding activity of the Ab. Schemes of variegation arepresented that encode populations in which the majority of members willfold correctly and in which there is likely to be a plurality of membersthat will bind to any given Ag. Specifically, a plan of variegation ispresented for each CDR of the human heavy chain, kappa light chain, andlambda light chain. The variegated CDRs are presented in synthetic HCand LC frameworks.

In one embodiment, the invention involves variegation of human HCvariable domains based on a synthetic 3-23 domain joined to a JH4segment in which the variability in CDR1 and CDR2 comprises sequencevariation of segments of fixed length while in CDR3 there are severalcomponents such that the population has lengths roughly corresponding tolengths seen in human Abs and having embedded D segments in a portion ofthe longer segments. In the light chains, the kappa chain is built in anA27 framework and a JK1 while lambda is built in a 2a2 framework with anL2 J region.

EXAMPLES Choice of a Heavy-Chain V Domain

The HC Germ-Line Gene (GLG) 3-23 (also known as VP-47) accounts forabout 12% of all human Abs and it suitable for the framework of thelibrary. Certain types of Ags elicit Abs having particular types of VHgenes; in some cases, the types elicited are otherwise rarely found.This apparent Ag/Ab type specificity has been ascribed to possiblestructural differences between the various families of V genes. It isalso possible that the selection has to do with the availability ofparticular AA types in the GLG CDRs. Suppose, for example, that thesequence YR at positions 4 and 5 of CDR2 is particularly effective inbinding a particular type of Ag. Only the V gene 6-1 provides thiscombination. Most Abs specific for the Ag will come from GLG 6-1. IfY4-R5 were provided in other frameworks, then other frameworks arelikely to be as effective in binding the Ag.

Analysis of HC CDR1 and CDR2:

In CDR1 and CDR2 of HCs, the GLGs provide limited length diversity asshown in Table 15P. Note that GLGs provide CDR1s only of the lengths 5,6, and 7. Mutations during the maturation of the V-domain gene leads toCDR1s having lengths as short as 2 and as long as 16. Nevertheless,length 5 predominates. The preferred length for the present invention is5 AAs in CDR1 with a possible supplemental components having lengths of7 and 14.

GLGs provide CDR2s only of the lengths 15-19, but mutations duringmaturation result in CDR2s of length from 16 to 28 AAs. The lengths 16and 17 predominate in mature Ab genes and length 17 is the mostpreferred length for the present invention. Possible supplementarycomponents of length 16 and 19 may also be incorporated.

Table 20P shows the AA sequences of human GLG CDR1s and CDR2. Table 21Pshows the frequency of each amino-acid type at each position in theGLGs. The GLGs as shown in Table 20P have been aligned by inserting gapsnear the middle of the segment so that the ends align.

The 1398 mature V-domain genes used in studying D segments (vide infra)were scanned for examples in which CDR1 and CDR2 could be readilyidentified. Of this sample 1095 had identifiable CDR1, 2, and 3. TheCDRs were identified by finding subsequences of the GLGs in an openreading frame. There are 51 human HC V genes. At the end of FR1, thereare 20 different 9-mers. At the start of FR2, there are 11 different9-mers. At the end of FR2 there are 14 different 9-mers. At the start ofFR3, there are 14 different 9-mers. At the end of FR3, there are 13different 9-mers. At the start of JR, there are three different 9-mers.These motifs were compared to the reported gene in frame and a match, atthe site of maximum similarity, of seven out of nine was deemedacceptable. Only when all three CDRs were identified were any of theCDRs included in the analysis. In addition, the type of the gene wasdetermined by comparing the framework regions to the GLG frameworks; theresults are shown in Table 22P.

Design of HC CDR1 and CDR2 Diversity.

Diversity in CDR1 and CDR2 was designed from: a) the diversity of theGLGs, b) observed diversity in mature HC genes, and c) structuralconsiderations. In CDR1, examination of a 3D model of a humanized Abshowed that the side groups of residues 1, 3, and 5 were directed towardthe combining pocket. Consequently, we allow each of these positions tobe any amino-acid type except cysteine. Cysteine can form disulfidebonds. Disulfide bonds are an important component of the canonical Igfold. Having free thiol groups could interfere with proper folding ofthe HC and could lead to problems in production or manipulation ofselected Abs. Thus, I exclude cysteine from the menu. The side groups ofresidue 2 is directed away from the combining pocket. Although thisposition shows substantial diversity, both in GLG and mature genes, Ifixed this residue as Tyr because it occurs in 681/820 mature genes(Table 21P). Position 4 is fixed as Met. There is some diversity here,but almost all mature genes have uncharged hydrophobic AA types: M, W,I, V, etc. (Table 21P). Inspection of a 3D model shows that the sidegroup of residue 4 is packed into the innards of the HC. Since we areusing a single framework (3-23), we retain the Met that 3-23 has becauseit is likely to fit very well into the framework of 3-23. Thus, the mostpreferred CDR1 library consists of XYXMX where X can be any one of[A,D,E,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y] (no C). The DNA that encodesthis is preferably synthesized using trinucleotide building blocks sothat each AA type is present in essentially equimolar amounts.Specifically, the X codons are synthesized using a mixture of the codons[get, gat, gag, ttt, ggt, cat, att, aag, atg, aat, cct, cag, cgt, tct,act, gtt, tgg, tat]. This diversity is shown in the context of asynthetic 3-23 gene in Table 18P. The diversity oligonucleotide (ON) issynthesized from BspEI to BstXI and can be incorporated either by PCRsynthesis using overlapping ONs or introduced by ligation ofBspEI/BstXI-cut fragments. Table 22P shows ONs that embody the specifiedvariegation. PCR using ON-R1V1vg, ON-R1top, and ON-R1bot gives a dsDNAproduct of 73 base pairs, cleavage with BspEI and BstXI trims 11 and 13bases from the ends and provides cohesive ends that can be ligated tosimilarly cut vector having the synthetic 3-23 domain shown in Table18P. Replacement of ON-R1V 1vg with either ONR1V2vg or ONR1V3vg allowssynthesis of the two alternative diversity patterns given below.

Alternatively, one can include CDR1s of length 7 and/or 14. For length7, a preferred diversity is (S/T)₁(S/G/x)₂(S/G/x)₃Y₄Y₅W₆(S/G/x)₇; where(S/T) indicates an equimolar mixture of Ser and Thr codons; (S/G/x)indicates a mixture of 0.2025 S, 0.2025 G, and 0.035 for each of A, D,E, F, H, I, K, L, M, N, P, Q, R, T, V, W, Y. Other proportions could beused. The design gives a predominance of Ser and Gly at positions 2, 3,and 7, as occurs in mature HC genes. For length 14, a preferred patternof diversity is VSGGSISXXXYYWX where X can be any AA type except Cys.This pattern appears to arise by insertions into the GLG sequences(SGGYYWS (4-30.1 and 4-31) and similar sequences. There is a preferencefor a hydrophobic residue at position 1 (V or C) with a second insertionof SISXXX between GG and YY. Diversity ONs having CDR1s of length 7 or14 are synthesized from BspEI to BstXI and introduced into the libraryin appropriate proportions to the CDR1 of length 5. The componentsshould be incorporated in approximately the ratios in which they areobserved in antibodies selected without reference to the length of theCDRs. For example, the sample of 1095 HC genes examined here have themin the ratios (L=5:L=7:L=14::820:175:23::0.80:0.17:0.02).

CDR2

Diversity at CDR2 was designed with the same considerations: GLGsequences, mature sequences and 3D structure. A preferred length forCDR2 is 17, as shown in Table 18P. Examination of a 3D model suggeststhat the residues shown as varied in Table 18P are the most likely tointeract directly with Ag. Thus a preferred pattern of variegation is:<2>I<2><3>SGG<1>T<1>YADSVKG, where <2> indicates a mixture of YRWVGS,<3> is a mixture of P and S, and <1> is a mixture of ADEFGHIKLMNPQRSTVWY(no C). ON-R2V1vg shown in Table 22P embodies this diversity pattern.PCR with ON-R2V1vg, ON-R2top, and ONR2bot gives a dsDNA product of 122base pairs. Cleavage with BstXI and XbaI removes about 10 bases fromeach end and produces cohesive ends that can be ligated to similarly cutvector that contains the 3-23 gene shown in Table 18P.

An alternative pattern would include the variability seen in matureCDR2s as shown in Table 21P: <1>I<4><1><1>G<5><1><1><1>YADSVKG, where<4> indicates a mixture of DINSWY, and <5> indicates a mixture of SGDN.This diversity pattern is embodied in ON-R2V2vg shown in Table 22P. Foreither case, the variegated ONs would be synthesized so that fragmentsof dsDNA containing the BstXI and XbaI site can be generated by PCR.ON-R2V2vg embodies this diversity pattern.

Alternatively, one can allow shorter or longer CDR2s. Table 22P showsON-R2V3vg which embodies a CDR2 of length 16 and ON-R2V4vg whichembodies a CDR2 of length 19. Table 22P shows ON-R2V3vg is PCR amplifiedwith ON-R2top and ON-R2bo3 while ON-R2V4vg is amplified with ON-R2topand ONR2-bo4.

Analysis of HC CDR3:

CDR3s of HC vary in length and in sequence. About half of human HCsconsist of the components: V::nz::D::ny::JHn where V is a V gene, nz isa series of bases (mean 12) that are essentially random, D is a Dsegment, often with heavy editing at both ends, ny is a series of bases(mean 6) that are essentially random, and JH is one of the six JHsegments, often with heavy editing at the 5′ end. In HCs that have noidentifiable D segment, the structure is V::nz::JHn where JH is usuallyedited at the 5′ end. Our goal is to mimic the diversity of CDR3, butnot to duplicate it (which would be impossible). The D segments appearto provide spacer segments that allow folding of the IgG. The greatestdiversity is at the junctions of V with D and of D with JH. The plannedCDR3 library will consist of several components. Some of these will haveonly sequence diversity. Others will have sequence diversity withembedded D segments to extend the length while incorporating sequencesknown to allow Igs to fold.

There are many papers on D segments. Corbett et al. (1997) show which Dsegments are used in which reading frames. My analysis basicallyconfirms their findings. They did not report, however, the level ofediting of each D segment and this information is needed for design ofan effective library.

The following diversified sequences would be incorporated in theindicated proportions: “1” stands for 0.095 [G, Y] and 0.048 [A, D, E,F, H, I, K, L, M, N, P, Q, R, S, T, V, W]; double dose of Gly and Tyrplus all other AAs except Cys at equal level.

The amount of each component is assigned from the tabulation of lengthsof the collection of natural VH genes. Component 1 represents all thegenes having length 0 to 8 (counting from the YYCAR motif to the WGdipeptide motif). Component 2 corresponds the all the chains havinglength 9 or 10. Component 3 corresponds to the genes having length 11 or12 plus half the genes having length 13. Component 4 corresponds tothose having length 14 plus half those having length 13. Component 5corresponds to the genes having length 15 and half of those havinglength 16. Component 6 corresponds to genes of length 17 plus half ofthose with length 16. Component 7 corresponds to those with length 18.Component 8 corresponds to those having length 19 and greater.

The composition has been adjusted because the first component is notcomplex enough to justify including it as 10% of the library. If thefinal library were to be 1. E 9, then 1. E 8 sequences would come fromcomponent 1, but it has only 2.6 E 5 CDR3 sequences so that each onewould occur in ˜385 CDR1/2 contexts. I think it better to have thisshort CDR3 diversity occur in ˜77 CDR1/2 contexts and have the other,longer CDR3s occur more often.

The ONs would be PCR amplified with the primers CtprmA and CBprmB, cutwith AflII and BstEII, and ligated to similarly cut V3-23.

This set of components was designed after studying the sequences of 1383human HC sequences as described below. The proposed components are meantto fulfill the goals:

1) approximately the same distribution of lengths as seen in real Abgenes,2) high level of sequence diversity at places having high diversity inreal Ab genes, and3) incorporation of constant sequences often seen in real Ab genes.

Note that the design uses JH4 (YFDYWGQGTLVTVSS), which is found moreoften, instead of JH3 (AFDIWGQGTMVTVSS). This involves three changes inAA sequence, shown as double underscored bold. An alternative JH segmentis shown.

How the Library Components were Designed:

The processing of sequence data was accomplished by a series ofcustom-written FORTRAN programs, each of which carries out a fairlysimple transformation on the data and writes its results as one or moreASCII files. The next program then uses these files as input.

A set of 2049 human heavy-chain genes was selected from the version ofGenBank that was available at Dyax on the Sun server on 26 Jun. 2000. Aprogram named “Reformat” changed the format of the files to that ofGenBank from the GCG format, creating one file per sequence. A secondprogram named “IDENT_CDR3” processed each of these files as follows.Files were tested for duplication by previous entries, duplicates werediscarded. Each reading frame was tested. Most entries had a single openreading frame (ORF), none had two, and some had none. Entries withmultiple stops in every reading frame were discarded because thisindicates poor quality of sequencing. The sequence was written intriplets in the ORF or in all three reading frames if no ORF was found.The sequence was examined for three motifs: a) AA sequence=“YYCxx”, b)DNA sequence=“tgg ggc (=WG)”, and DNA sequence=“g gtc acc (=BstEII)”.FR3 ends with a conserved motif YYCAR or a close approximation. Whenwriting the DNA sequence, IDENT_CDR3 prints the DNA mostly in lowercase. Cysteine codons (TGT or TGC) are printed in uppercase. When themotif “tay tay tgy” is found, IDENT_CDR3 starts a new line that contains“< > xxx xxx xxx xxx xxx” where the xxx's stand for the actual fivecodons that encode YYC and the next two codons (most often AR or AK).The following DNA is printed in triplets on new lines. A typicalprocessed entry appears as in Table 1P.

Following the YYC motif, IDENT_CDR3 seeks the sequence “TGG GGC” (the“WG” motif) in the correct reading frame, 5/6 bases is counted as a hit.If found, the DNA is made uppercase. Following the WG motif (if found)or the YYC motif (if no WG found), IDENT_CDR3 seeks the sequence “G GTCACC” (the BstEII site) in the correct reading frame, 6/7 bases iscounted as a hit. If found, the bases are made upper case. If either theWG or BstEII motif are not found, a note is inserted saying that thefeature was not identified. The output of IDENT_CDR3 was processed byhand. In many cases, the lacking YYC motif could be seen as a closelyrelated sequence, such as YFC, FYC, or HYC. When this was supported byan appropriately positioned WG and/or BstEII site, the effective YYCsite was marked and the sequence retained for further analysis. If theYYC motif could not be identified or if the WG or BstEII sites could notbe found, the entry was discarded. For example, the entry in Table 2Phad no YYC motif.

The double underscored sequence encodes YHCAS and is taken as the end ofFR3. Note that there is a WG motif at bases 403-408 (bold upper case)and a BstEII site at bases 420-426 (bold upper case). Using WordPerfect,I first made all occurrences of TGC and TGT bold. I then searched for“YYC not found”. If I could see the “YYC”-related sequence quickly, Iedited the entry so that a YYC was shown. The entry above would beconverted to that shown in Table 3P. This processing reduced the list ofentries to 1669.

A third program named “New_DJ” processed the output of IDENT_CDR3. Theend of the YYC motif (including the two codon following TGy=Cys) wastaken as the end of FR3. The WG motif was taken as the end of the regionthat might contain a D segment. If WG was not observed and BstEII was,the WG site was assumed to be 17 bases upstream of BstEII. Using the WGmotif for alignment, the sequence was compared to each human GLG JHsegment (1-6) and the best one identified (New_DJ always assigned a JHsegment). Starting from the WG motif of JH and moving toward the 5′ end,the program looked for the first codon having more than one mismatch.The region from YYCxx to this codon was taken as the region that mightcontain a D segment.

The region that might contain a D segment was tested against all thegerm-line genes (GLGs) of human D segments and the best D segment wasidentified. The scoring involved matching the observed sequence to theGLG sequence in all possible ways. Starting at each base, multiply by 4for a match and divide by 4 for a mismatch. Record the maximum valueobtained for this function. The match was deemed significant if 7/7,8/9, 9/11, etc. or more bases matched. Of the 1383 sequences examinedfor D segments,

“Assign_D” processes the output of New_DJ. For each sequence that had asignificant match with a GLG D segment, a file was written containingthe putative D segment, the DJ segment, the identified GLG D segment,the identified JH segment, the phase of the match between observed andGLG gene. For example, “D1_(—)1-01_Phz0_hsa239356.txt” is a filerecording the match of entry hsa239356 with D1-01 in phase 0. The filecontains the information shown in Table 4P. The final DV of the secondsequence immediately precedes the WG in JH and is ascribed to JH3. Otherfiles that begin D1_(—)1-01Phz0 match the same GLG D segment and thesecan be aligned by sliding amino-acid sequences across each other.

Table 5P shows how sequence hs6d4xb7 is first assigned to JH4 and thento D3-22. Note that the DNA sequence TGGGGG is aligned to the TGG GGC ofthe GLG and that the sequence is truncated on the left to fit. Theprogram finds that JH4 has the best fit (5 misses and 18 correct out of23). From the right, the program sees that DYWGQ (underscored) come fromJH, but then the match drops off and the rest of the sequence on theleft comes either from added bases or a D segment.

The lower part of Table 5P shows that the possible D segment matchesD#13 (3-23) is a very good match.

Of 1383 files accepted by Assign_D, 757 had identifiable D segments. Thetally of JHs in Table 6P shows that JH4 is by far the most common.

JH4 is most common, JH6 next, followed by JH3 and JH5. JH1 and JH2 areseldom used. Table 7P shows the length distributions of each JH class;they do not differ significantly class to class. These lengths countonly amino-acids that are not accounted for by JH and so are shorterthat the lengths given in Table 8P which cover from YYCAR to WG.

Table 8P contains the distribution of lengths for a) all the CDR3segments, b) the CDR3 segments with identified D segments, and c) theCDR3 segments having no identifiable D segment. The CDR3s withidentifiable D segments (13.9) are systematically longer than are thosethat lack D segments (11.2).

The identified CDR3 segments can be collated in two ways: aligned to theleft (looking for a pattern following YYCAR) or aligned to the right(looking for a pattern preceding WG). Table 9P shows the collation ofleft-aligned sequences while Table 10P shows the right-alignedsequences. For each position, I have tabulated the frequency of each AAtype (A-M in the first block and N-Y in the second). The column headed“#” shows how many sequences have some AA at that position. The finalcolumn shows all of the AA types seen at that position with the mostfrequent first and the least frequent last. In the left-alignedsequences, we see that Gly is highly over-represented in the first sevenpositions while Tyr is over-represented at positions 8-16.

In Table 11P, I have tabulated the AA frequencies for the sequenceshaving between 7 and 15 AAs between YYCAR and WG. The last fourpositions can be viewed as coming from JH and so would be given lowerlevels of diversity than would earlier positions. From thesetabulations, I conclude that most AA types are allowed at all thepositions, but there is a fairly strong tendency to have Gly at theearly positions and to end in Asp-Tyr (DY). We could use thesetendencies in designing a pattern of variegation. I would not excludeany AA except Cys, but I might increase the frequency of Gly in thefirst several positions and Tyr in the last few.

There are 80 sequences (5.8%) having a pair of cysteines in CDR3. It ismore surprising that 53 (3.8%) have a single Cys in CDR3.

MS-DOS was used to make a list of the files written by Assign_D.“Filter” converts the output of MS-DOS Dir into a form that can be readinto WordPerfect and sorted to bring a files

belonging to the same D region together.

“Filter2” collects the sequences and produces a draft table ofsequences, grouped by the D-segment used, and written so that thesequences can be aligned. The output of Filter2 were edited by hand. Foreach group, the translation of the GLG was inserted and the collectionof observed sequences was aligned to the conserved part of the GLG.“Filter3” collated the aligned sequences. Table 12P shows an example ofan alignment and the tabulation of AA types. The entries are as follows:“Entry” is the name used in the data base, “Seq1” is the sequence fromthe YYCAR motif to the first amino acid not assigned to JH and “L1” isthe length of the segment. The segments are shown aligned to theidentified D segment. Seq2 is the sequence from the YYCAR motif to theWG motif (i.e. including part of JH) and “L2” is the length of thatsequence. JH is the identified JH segment for this sequence. “P” is thephase of the match. For positive values of P, P bases are found in theobserved sequence that do not correspond to any from the GLG, i.e. theobserved sequence has had that many bases inserted. For negative valuesof P, there are |P| bases in the GLG sequence for which there are nocorresponding bases in the observed sequence. “Score” is approximately1/(probability of accidental match). This is calculated by looking atall possible alignments. For each alignment, the score is first set to1.0. Base by base, the score is multiplied by 4. if the bases match anddivided by 4. if they do not. This is done for all starting points andending points and the maximum value is recorded.

Table 13P is a summary of how often each D segment was identified and inwhich reading frame. I have not been consistent with Corbett et al. inassigning the phases of the GLG D segments. The MRC Web page that I tookthe GLGs from did not have D segments D1-14, D4-11, D5-18, or D6-25.None of these contribute to any great extent and this omission isunlikely to have any serious effect on the conclusions. The columnheaded “%” contains the percentage of the sequences examined here. Thecolumn headed “C %” contains the percentage reported by Corbett et al. Iassume that the data used in Corbett et al. is mostly included in mycollection. Nevertheless, the observed frequencies differ in detail. Forexample, my compilation shows that 10.7% of the collection contains a Dsegment encoding two cysteines while they have only 4.16% in thiscategory. In D3 phase “0”, I see 19.4% of the collection while theyreport 11.8%.

The most common actual D segments were further analyzed. The GLGs areheavily edited at either end. The aligned sequences were aligned. Foreach D-segment having more than seven examples, Filter3 produced a tableof the frequency of each amino-acid type at each position. From thesetabulations, library components shown in Table 17P were designed. Ateach position where at least half the examples have an amino acid, Ientered either the dominant AA type or “x”. An AA type was “dominant” ifit occurred more than 50% of the time. L is the length and f is thenumber of sequences observed that have related sequences.

Table 14P shows possible library components for a library of CDR3's. “L”is the length of the insert and “f” is the frequency of the motif in theassayed collection. Table 17P shows vgDNA that embodies each of thecomponents shown in Table 14P. In Table 17P, the oligonucleotides (ON)Ctop25, CtprmA, CBprmB, and CBot25 allow PCR amplification of each ofthe variegated ONs (vgDNA): C1t08, C2t10, C3t12, C4t14, C5t15, C6t17,C7t18, and c8t19. After amplification, the dsDNA can be cleaved with NMand BstEII (or KpnI) and ligated to similarly cleaved vector thatcontains the remainder of the 3-23 synthetic domain. Preferably, thisvector already contains diversity in CDR1 and CDR2 as disclosed herein.Preferably, the recipient vector contains a stuffer in place of CDR3 sothat there will be no parental sequence that would then occur in theresulting library. Table 50P shows a version of the V3-23 gene segmentwith each CDR replaced by a short segment that contains both stop codonsand restriction sites that will allow specific cleavage of any vectorthat does not have the stuffer removed. The stuffer can either be shortand contain a restriction enzyme site that will not occur in the finishlibrary, allowing removal of vectors that are not cleaved by both AflIIand BstEII (or KpnI) and religated. Alternatively, the stuffer could be200-400 bases long so that uncleaved or once cleaved vector can bereadily separated from doubly cleaved vector.

In the vgDNA for HC CDR3, <1> means a mixture comprising 0.27 Y, 0.27 G,and 0.027 of each of the amino-acid codons {A, D, E, F, H, I, K, L, M,N, P, Q, R, S, T, V, W}; <2> means an equimolar mixture of K and R; and<3> means an equimolar mixture of S and G.

Analysis of Human Kappa Light Chains and Preferred Variegation Scheme:

A collection of 285 human kappa chains was assembled from the publicdata base. Table 27 shows the names of the entries used. The GLGsequences of nine bases at each end of the framework regions were usedto find the FR/CDR junctions. Only in cases where all six junctionscould be found was the sequences included. Table 25P shows thedistribution of lengths in CDRs in human kappas. CDR1s with lengths of11, 12, 13, 16, and 17 were observed with 11 being predominant and 12well represented. CDR2 exhibits only length 7. CDR3 exhibits lengths of1, 4, 6, 7, 8, 9, 10, 11, 12, 13, and 19. Essentially all examples arein the 8, 9, or 10 length groups.

Table 26P shows the distribution of V and J genes seen in the sample.A27 is the most common V and JK1 is the most common J. Thus, a suitablesynthetic kappa gene comprises A27 joined to JK1. Table 30P shows asuitable synthetic kappa chain gene, including a PlacZ promoter,ribosome-binding site, and signal sequence (M13 III signal). The DNAsequence encodes the GLG amino-acid sequence, but does not comprise theGLG DNA sequence. Restriction sites are designed to fall within eachframework region so that diversity can be cloned into the CDRs. XmaI andEspI are in FR1, SexAI is in FR2, RsrII is in FR3, and KpnI (or Acc651)are in FR4. Additional sites are provided in the constant kappa chain tofacilitate construction of the gene.

Table 30P also shows a suitable scheme of variegation for kappa. InCDR1, a preferred length is 11 codons. The A27 GLG has a CDR1 of 12codons, but the sample of mature kappa chains has length 11predominating. One could also introduce a component of kappas havinglength 12 in CDR1 by introducing codon 52 as <2> (i.e. a Ser-biasedmixture). CDR2 of kappa is always 7 codons. Table 31P shows a tally of285 CDR2s and a preferred variegation scheme for CDR2. The predominantlength of CDR3 in kappa chains is 9 codons. Table 32P shows a tally of166 CDR3s from human kappas and a preferred variegation scheme (which isalso shown in Table 30P).

Analysis of Lambda Chains and Preferred Variegation Scheme:

A collection of 158 lambda sequences was obtained from the public database. Of these 93 contained sequences in which the FR/CDR boundariescould be identified automatically. Table 33P shows the distribution oflengths of CDRs.

Method of Construction:

The diversity of HC, kappa, and lambda are best constructed in separatevectors. First a synthetic gene is designed to embody each of thesynthetic variable domains. The light chains are bounded by restrictionsites for ApaLI (positioned at the very end of the signal sequence) andAsd (positioned afer the stop codon). The heavy chain is bounded by SfiI(positioned within the PelB signal sequence) and NotI (positioned in thelinker between CH1 and the anchor protein. The initial genes are madewith “stuffer” sequences in place of the desired CDRs. A “Staffer” is asequence the is to be cut away and replaced by diverse DNA but whichdoes not allow expression of a functional antibody gene. For example,the stuffer may contain several stop codons and restriction sites thatwill not occur in the correct finished library vector. In Table 40P, thestuffer for CDR1 of kappa A27 contains a StuI site. The vgDNA for CDR1is introduced as a cassette from EspI, XmaI, or AflII to either SexAI orKasI. After the ligation, the DNA is cleaved with StuI; there should beno StuI sites in the desired vectors.

REFERENCES

-   Corbett, S J, Tomlinson, I M, Sonnhammer, E L L, Buck, D, Winter, G.    “Sequences of the Human Immunoglobulin Diversity (D) Segment Locus:    A Systematic Analysis Provides No Evidence for the Use of DIR    Segments, Inverted D Segments, ‘Minor’ D Segments or D-D    Recombination”. J Molec Biol (1997) 270:587-597.

Tables

TABLE 1P Typical entry in which YYC motif is found.++++C:\tmp\haj10335.txt LOCUS HAJ10335 306 bp mRNA PRI 18-AUG-1998DEFINITION Homo sapiens mRNA for immunoglobulin heavy chain variableregion, clone ELD16/6. ACCESSION AJ010335 VERSION AJ010335.1 GI: 3445266Ngene = 306 Stop codons in reading frame  1    49 115 124 253 277 Nostops in reading frame  2 Stop codons in reading frame  3    12  60  81147 204 213   1   t ttg ggg tcc ctg aga ctc tcc TGT gca gcc tct gga ttcacc  44 gtc agt agc aac tac atg acc tgg gtc cgc cag gct cta ggg aag  89ggg ctg gag tgg gtc tca gtt att tat agc ggt ggt agc aca tac 134 tac gcagac tcc gtg aag ggc gga ttc acc atc tcc aga gac aat 179 tcc aag aac acactg tat ctt caa atg aac agc ctg aga ccc gag 224 gac acg gct gtg <  > TAT TAC TGT gcg aca 251 ggt aat cgc ctg gaa atg gct gca att aac TGGGGC caa gga acc 263 ctG GTC ACC aa

TABLE 2P entry in which YYC motif was not automatically identified++C:\tmp\hs202g3.txt !!NA_SEQUENCE 1.0 LOCUS HS202G3 522 bp mRNA PRI03-AUG-1995 DEFINITION H. sapiens mRNA for immunoglobulin variableregion (clone 202-G3). ACCESSION Z47259 VERSION Z47259.1 GI: 619470Ngene = 522 No stops in reading frame  1 Stop codons in reading frame  2   89 110 305 314 Stop codons in reading frame  3    84 192 321 351 369  1 atg gac tgg acc tgg agg ttc ctc ttt gtg gtg gca gca gct aca  46 ggtgtc cag tcc cag gtg cag ctg gtg cag tct ggg gct gag gtg  91 aag aag cctggg tcc tcg gtg aag gtc tcc TGC aag gct tct gga 136 ggc acc ttc agc agctat gct atc agc tgg gtg cga cag gcc cct 181 gga caa ggg ctt gag tgg atggga ggg atc atc cct atc ttt ggt 226 aca gca aac tac gca cag aag ttc cagggc aga gtc acg att acc 271 gcg gac gaa tcc acg agc aca gcc tac atg gagctg agc agc ctg 316 aga tct gag gac acg gcc gtg tat cac TGT gcg agt gaggga tgg 361 gag agt TGT agt ggt ggt ggc TGC tac gac ggt atg gac gtc TGG406 GGC caa ggg acc acG GTC ACC gtc tcc tca gct tcc acc aag ggc 451 ccatcg gtc ttc ccc ctg gcg ccc TGC tcc agg agc acc tct ggg 496 ggc aca gcggcc ctg ggc TGC ctg YYC not found !!!

TABLE 3P Entry of Table 2P after editting. ++C:\tmp\hs202g3.txt!!NA_SEQUENCE 1.0 LOCUS HS202G3 522 bp mRNA PRI 03-AUG-1995 DEFINITIONH. sapiens mRNA for immunoglobulin variable region (clone 202-G3).ACCESSION Z47259 VERSION Z47259.1 GI: 619470 Ngene = 522 No stops inreading frame 1 Stop codons in reading frame 2    89 110 305 314 Stopcodons in reading frame 3    84 192 321 351 369   1 atg gac tgg acc tggagg ttc ctc ttt gtg gtg gca gca gct aca  46 ggt gtc cag tcc cag gtg cagctg gtg cag tct ggg gct gag gtg  91 aag aag cct ggg tcc tcg gtg aag gtctcc TGC aag gct tct gga 136 ggc acc ttc agc agc tat gct atc agc tgg gtgcga cag gcc cct 181 gga caa ggg ctt gag tgg atg gga ggg atc atc cct atcttt ggt 226 aca gca aac tac gca cag aag ttc cag ggc aga gtc acg att acc271 gcg gac gaa tcc acg agc aca gcc tac atg gag ctg agc agc ctg 316 agatct gag gac acg gcc gtg <YHCAS> tat cac TGT gcg agt gag gga tgg 361 gagagt TGT agt ggt ggt ggc TGC tac gac ggt atg gac gtc TGG 406 GGC caa gggacc acG GTC ACC gtc tcc tca gct tcc acc aag ggc 451 cca tcg gtc ttc cccctg gcg ccc TGC tcc agg agc acc tct ggg 496 ggc aca gcg gcc ctg ggc TGCctg YYC not found !!!

contents of file D1_1-01_Phz0_hsa239356.txt DRGGKYQLAPKGGMDRGGKYQLAPKGGMDV JH3 D# 1 Phase 15 Score 6.55D+04

TABLE 5P alignment of a CDR3::JH segment to GLG JHs and D-segments.+c:\tmp\hs6d4xb7.txt          1    1    2    2    3    3   31234567890    5    0    5    0    5   9 ObservedtatgatagtagtgggtcatactccgactacTGGGGGcag JH1------------gctgaatacttccagcactggggccagggcaccctggtcaccgtctcctcag-- Miss= 9 Nt = 27 JH2-----------ctactggtacttcgatctctggggccgtggcaccctggtcactgtctcctcag-- Miss= 13 Nt = 28 JH3--------------tgatgcttttgatatctggggccaagggacaatggtcaccgtctcttcag-- Miss= 14 Nt = 25 JH4----------------actactttgactactggggccagggaaccctggtcaccgtctcctcag-- Miss= 5 Nt = 23 JH5-------------acaactggttcgacccctggggccagggaaccctggtcaccgtctcctcag-- Miss= 11 Nt = 26 JH6-attactactactactacggtatggacgtctggggccaagggaccacggtcaccgtctcctcag-- Miss= 23 Nt = 38 4 tat gat agt agt ggg tca TAC Tcc GAC TAC TGG GGg CAG Y   D   S   S   G   S   Y   S   D   Y   W   G   Q JH4 --- --- --- ------ -ac tac ttt gac tac tgg ggc cag gga acc ctg gtc acc gtc tcc tca g-- -   -   -   -   -   -   Y   F   D   Y   W   G   Q   G   T   L   V   T   V   S   S   -Fract = 0.783 = 18/23 Matching the rest to D segments: D#13--------gtattactatgatagtagtggttattactac GLGgatcgccacaattactatgatagtagtgggtcatactcc Observed--------gt...................t.at....a. . = match D#13 Phase =  9 Score=   4.3980E+12

TABLE 6P Number of sequences identified as having JH derived from GLGJHn JH 1 2 3 4 5 6 # sequences 17 40 198 707 160 261

TABLE 7P Distribution of CDR3 fragments that might contain D segments.For JH1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 0 0 1 1 3 1 1 2 0 3 1 1 1 2Total = 17 Median = 8.0 For JH2 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 0 0 00 0 2 4 6 2 6 3 4 5 2 3 15 16 17 18 2 0 0 1 Total = 40 Median = 9.0 ForJH3 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 0 0 2 6 16 12 17 17 15 22 20 2018 13 4 15 16 17 18 19 8 3 2 1 2 Total = 198 Median = 8.6 For JH4 0 1 23 4 5 6 7 8 9 10 11 12 13 14 0 0 7 15 19 40 63 82 81 77 81 53 57 44 3015 16 17 18 19 20 21 22 23 24 25 26 27 28 29 15 23 8 3 5 2 0 1 0 0 0 0 00 0 30 31 32 33 34 35 0 0 0 0 0 1 Total = 707 Median = 8.6 For JH5 0 1 23 4 5 6 7 8 9 10 11 12 13 14 0 0 0 3 4 6 13 19 12 14 22 18 10 18 10 1516 17 18 19 20 21 22 23 24 25 26 27 28 29 5 1 1 0 0 1 1 0 0 0 0 0 0 0 030 31 32 33 34 35 36 37 38 39 40 41 42 43 44 0 0 0 0 0 0 0 0 0 0 0 0 1 00 45 46 0 1 Total = 160 Median = 9.4 For JH6 0 1 2 3 4 5 6 7 8 9 10 1112 13 14 2 0 1 2 5 15 20 18 22 29 29 28 23 16 10 15 16 17 18 19 20 14 99 4 2 3 Total = 261 Median = 9.6

TABLE 8P Lengths of CDR3 segments from YYCAR to WG. Distribution oflengths from end of FR3 to WG motif all sequences. L 0 1 2 3 4 5 6 7 8 9N 6 0 0 4 2 9 13 38 61 88 Sum(N) 6 6 6 10 12 21 34 72 133 221 f .004.004 .004 .007 .009 .015 .025 .052 .096 .160 L 10 11 12 13 14 15 16 1718 19 N 101 118 154 150 118 125 105 84 61 46 SN 322 440 594 744 862 9871092 1176 1237 1283 f .233 .318 .430 .538 .623 .714 .790 .850 .894 .928L 20 21 22 23 24 25 26 27 28 29 N 42 16 17 7 9 2 1 0 2 1 SN 1325 13411358 1365 1374 1376 1377 1377 1379 1380 f .958 .970 .982 .987 .993 .995.996 .996 .997 .998 L 30 31 32 33 34 35 36 37 38 39 N 0 0 0 0 0 0 0 1 00 SN 1380 1380 1380 1380 1380 1380 1380 1381 1381 1381 f .998 .998 .998.998 .998 .998 .998 .999 .999 .999 L 40 41 42 43 44 45 46 N 0 0 1 0 0 01 SN 1381 1381 1382 1382 1382 1382 1383 f .999 .999 .999 .999 .999 .9991.0 Median = 12.65 Distribution of lengths from end of FR3 to WG motifwith assigned D. L 0 1 2 3 4 5 6 7 8 9 N 3 0 0 0 0 0 3 9 21 15 SN 3 3 33 3 3 6 15 36 51 f .004 .004 .004 .004 .004 .004 .008 .019 .046 .065 L10 11 12 13 14 15 16 17 18 19 N 39 64 77 97 72 77 75 63 45 35 SN 90 154231 328 400 477 552 615 660 695 f .115 .196 .294 .418 .510 .608 .703.783 .841 .885 L 20 21 22 23 24 25 26 27 28 29 N 38 15 15 6 9 2 1 0 1 1SN 733 748 763 769 778 780 781 781 782 783 f .934 .953 .972 .980 .991.994 .995 .995 .996 .997 L 30 31 32 33 34 35 36 37 38 39 N 0 0 0 0 0 0 01 0 0 SN 783 783 783 783 783 783 783 784 784 784 f .997 .997 .997 .997.997 .997 .997 .999 .999 .999 L 40 41 42 43 44 45 46 N 0 0 0 0 0 0 1 SN784 784 784 784 784 784 785 f .999 .999 .999 .999 .999 .999 1.0 Median =13.90 Distribution of lengths from end of FR3 to WG motif with noassigned D. L 0 1 2 3 4 5 6 7 8 9 N 3 0 0 4 2 9 10 29 40 73 SN 3 3 3 7 918 28 57 97 170 f .005 .005 .005 .012 .015 .030 .047 .095 .162 .284 L 1011 12 13 14 15 16 17 18 19 N 62 54 77 53 46 48 30 21 16 11 SN 232 286363 416 462 510 540 561 577 588 f .388 .478 .607 .696 .773 .853 .903.938 .965 .983 L 20 21 22 23 24 25 26 27 28 29 N 4 1 2 1 0 0 0 0 1 0 SN592 593 595 596 596 596 596 596 597 597 f .990 .992 .995 .997 .997 .997.997 .997 .998 .998 L 30 31 32 33 34 35 36 37 38 39 N 0 0 0 0 0 0 0 0 00 SN 597 597 597 597 597 597 597 597 597 597 f .998 .998 .998 .998 .998.998 .998 .998 .998 .998 L 40 41 42 N 0 0 1 SN 597 597 598 f .998 .9981.0 Median = 11.17 L is the length N is the number of examples Sum(N) =SN is the sum of the Ns f is the cumulative fraction seen

TABLE 9P Tally of left-aligned CDR3 sequences A C D E F G H I K L M # 174 6 278 109 11 319 50 18 11 60 8 1383 GDERVASLHTNQPIWYFKMCX 2 50 9 6432 29 249 43 42 41 109 22 1377 GRPSLDVYTANHIQKEFMWCX 3 81 18 74 39 25214 29 42 16 83 19 1377 GSYRTVLADPIWEQHNFMCK| 4 70 23 92 49 50 228 23 5821 70 16 1373 GSYDRVALTIPFEWNCHQKMX 5 86 28 106 32 59 217 21 41 16 72 191371 GYSDAVTLRFIPWNECHMQK|X 6 88 17 104 28 94 171 17 48 12 50 17 1362GYSDFATVRWPLINEQCHMK| 7 69 15 110 21 89 176 22 50 15 81 12 1349GSYDFVLTAPRWINHEQCKM|X 8 53 19 141 17 90 150 18 47 17 68 11 1311YSGDFLTVWAPIRNCHEKQM| 9 44 21 120 24 102 174 24 36 20 71 11 1250YGSDFLNVRTAWPIEHCKQM| 10 39 31 129 23 124 116 23 42 9 58 32 1162YDFGSLIARPTVWNMCEHQK 11 36 12 158 17 137 83 13 18 10 40 21 1061YDFGSPLVANWMTRIEHCKQX 12 34 11 164 10 82 74 34 30 1 31 20 943YDFGPSVAHLINMRTWCEQKX 13 32 2 121 6 84 56 10 26 7 43 32 789YDFGLSPVAMIWRTHNKQEC 14 23 131 5 59 65 10 16 4 25 34 639YDGFMVLAPISWNRHTQEKX 15 15 4 107 5 43 42 1 23 20 34 521YDFGVMILWAPRSENCQTH| 16 4 2 80 3 33 26 4 5 1 10 29 396YDVFMGPSLNTRIWAHECQ|K 17 3 1 63 19 19 9 13 12 21 291 DYVMFGILHPSTWAQRCNX18 3 47 16 13 1 4 7 23 207 DYVMFGPSLTIAHN 19 5 1 39 1 4 13 3 3 1 14 146DYVMGAFHINRSCELPQW 20 2 17 4 5 3 4 12 100 VYDMGFLIPSARWQ 21 17 3 8 1 1 458 DVGYMFHINTW 22 1 7 6 1 1 5 42 VDFMYSAGITW 23 9 1 1 1 1 25 DVYGILMPS24 1 2 1 1 1 18 VYDAHLMPT 25 1 3 9 GVDPSY 26 2 2 7 GMSTV 27 2 1 1 6DKMST 28 1 1 1 6 VADGS 29 1 4 DPSV 30 1 3 FST 31 1 1 3 KLV 32 1 1 3 FGP33 1 3 PG 34 1 1 3 HLS 35 1 3 AVW 36 1 1 3 DFP 37 3 PSY 38 1 2 LS 39 1 12 AK 40 2 PS 41 2 ST 42 2 S 43 1 1 K 44 1 S 45 1 T 46 1 S 816 220 2186421 1166 2428 358 568 205 920 421 N P Q R S T V W Y | X # 1 35 23 31 10863 50 94 16 13 6 1383 GDERVASLHTNQPIWYFKMCX 2 44 114 42 169 114 59 62 2160 2 1377 GRPSLDVYTANHIQKEFMWCX 3 26 73 37 110 140 97 89 42 122 1 1377GSYRTVLADPIWEQHNFMCK| 4 48 51 22 79 141 65 77 49 139 2 1373GSYDRVALTIPFEWNCHQKMX 5 37 41 18 61 157 75 85 38 158 2 2 1371GYSDAVTLRFIPWNECHMQK|X 6 32 54 23 67 152 80 78 64 165 1 1362GYSDFATVRWPLINEQCHMK| 7 44 59 18 58 157 73 85 54 139 1 1 1349GSYDFVLTAPRWINHEQCKM|X 8 38 48 14 41 167 68 59 59 185 1 1311YSGDFLTVWAPIRNCHEKQM| 9 52 40 14 47 123 45 48 41 192 1 1250YGSDFLNVRTAWPIEHCKQM| 10 33 37 12 39 73 36 36 35 235 1162YDFGSLIARPTVWNMCEHQK 11 33 49 7 20 68 21 37 29 251 1 1061YDFGSPLVANWMTRIEHCKQX 12 30 53 10 19 45 19 42 18 215 1 943YDFGPSVAHLINMRTWCEQKX 13 10 34 7 22 40 15 33 25 184 789YDFGLSPVAMIWRTHNKQEC 14 13 22 6 12 15 10 26 14 148 1 639YDGFMVLAPISWNRHTQEKX 15 5 12 3 12 12 3 40 20 119 1 521YDFGVMILWAPRSENCQTH| 16 10 24 2 6 12 7 49 5 82 2 396YDVFMGPSLNTRIWAHECQ|K 17 1 8 2 2 8 5 42 4 58 1 291 DYVMFGILHPSTWAQRCNX18 1 13 8 5 31 35 207 DYVMFGPSLTIAHN 19 2 1 1 2 2 24 1 29 146DYVMGAFHINRSCELPQW 20 3 1 2 3 23 2 19 100 VYDMGFLIPSARWQ 21 1 1 14 1 758 DVGYMFHINTW 22 2 1 12 1 5 42 VDFMYSAGITW 23 1 1 5 5 25 DVYGILMPS 24 11 5 5 18 VYDAHLMPT 25 1 1 2 1 9 GVDPSY 26 1 1 1 7 GMSTV 27 1 1 6 DKMST28 1 2 6 VADGS 29 1 1 1 4 DPSV 30 1 1 3 FST 31 1 3 KLV 32 1 3 FGP 33 2 3PG 34 1 3 HLS 35 1 1 3 AVW 36 1 3 DFP 37 1 1 1 3 PSY 38 1 2 LS 39 2 AK40 1 1 2 PS 41 1 1 2 ST 42 2 2 S 43 1 K 44 1 1 S 45 1 1 T 46 1 1 S 495769 270 876 1518 741 1104 540 2572 10 17 18621

TABLE 10P Tally of right-aligned sequences A C D E F G H I K L M # 5 1 1G 6 1 S 7 1 1 G 8 1 1 G 9 2 RV 10 2 RV 11 1 1 2 GI 12 2 V 13 2 TY 14 1 13 DGN 15 1 3 ISY 16 1 3 DSY 17 1 3 APY 18 1 1 1 3 DFM 19 2 1 3 DG 20 1 13 ILV 21 3 WP 22 3 4 GS 23 2 1 6 GHQSV 24 1 3 1 6 GALR 25 1 2 1 7 DTAIS26 1 1 1 1 1 1 1 9 ACDGKLMST 27 2 5 1 2 1 1 18 DAGVEILNQRS 28 2 2 3 1 225 TGQSDELPRIV 29 3 5 6 7 1 1 1 42 GEDVAPQRSKLMTY| 30 2 9 1 9 1 4 5 2 58DGRLSIVPAMQTFHNY 31 4 2 19 9 2 18 1 2 1 3 100 DGSERVYALPTCFINHKW 32 10 518 5 3 16 3 3 2 14 1 146 DGLRVAPYSTCEQFHINWKM 33 20 18 10 7 34 7 8 2 6 1207 GARDPSYTEVIFHLQWKM 34 13 4 31 18 9 37 8 16 4 14 4 291GDRYPVEILASTFHQWCKMNX| 35 17 5 32 23 10 70 12 10 6 25 1 396GRSDYLEVTPAHNFIWKCQM| 36 23 6 51 21 9 79 19 15 14 36 9 521GDSYRLTVPAEHIKNFMWCQ| 37 35 12 56 23 15 110 14 17 5 24 4 639GYDVRSTAPLEIFHNCWQKMX 38 28 19 68 27 29 133 26 31 12 43 7 789GSYDVRLPTIFAEHCNWKQM 39 51 25 80 27 33 162 16 30 18 55 15 943GSDRYVLATPFWIECKHMQNX 40 44 14 73 36 46 161 27 32 17 59 8 1061GSRDYVTLPFAEIWHQNKCM 41 54 21 74 25 23 178 23 52 15 57 11 1162GSYTDRVLPAIWNQEFHCKMX| 42 57 13 82 40 42 190 14 39 15 82 15 1250GSYDLVRTANPFEIWQKMHC| 43 75 18 54 25 35 242 13 29 18 49 12 1311GYSTARVPDLWNFIQECKHM| 44 63 17 79 15 43 197 20 38 14 76 8 1349YGSTDLRAPVWNFIQHCEKM 45 59 16 69 35 55 165 26 23 23 75 9 1362YGSLRTDNAFPVWEHIKCQM 46 41 19 125 26 27 208 31 14 16 38 8 1371YGDSNRWATLPHFEVQCKIM 47 160 10 24 13 53 332 36 16 11 40 10 1373GYAWPSFRLHTVNDIEKCMQX 48 21 4 8 5 680 27 4 44 5 145 288 1377FMLISGVYPAWTDNQREKCHX 49 23 2 1181 29 1 30 15 4 2 8 1 1377DGEAHNQSYVLPTIRCKW|FMX 50 7 7 15 42 3 41 135 3 59 4 1383YVIPSLFHNDTACXMGKQRW| 816 220 2186 421 1166 2428 358 568 205 920 421 N PQ R S T V W Y | X # 5 1 G 6 1 1 S 7 1 G 8 1 G 9 1 1 2 RV 10 1 1 2 RV 112 GI 12 2 2 V 13 1 1 2 TY 14 1 3 DGN 15 1 1 3 ISY 16 1 1 3 DSY 17 1 1 3APY 18 3 DFM 19 3 DG 20 1 3 ILV 21 1 2 3 WP 22 1 4 GS 23 1 1 1 6 GHQSV24 1 6 GALR 25 1 2 7 DTAIS 26 1 1 9 ACDGKLMST 27 1 1 1 1 2 18DAGVEILNQRS 28 2 3 2 3 4 1 25 TGQSDELPRIV 29 3 3 2 2 1 5 1 1 42GEDVAPQRSKLMTY| 30 1 3 2 7 5 2 4 1 58 DGRLSIVPAMQTFHNY 31 2 3 7 10 3 7 16 100 DGSERVYALPTCFINHKW 32 3 9 4 12 8 6 12 3 9 146 DGLRVAPYSTCEQFHINWKM33 16 6 19 15 12 10 3 13 207 GARDPSYTEVIFHLQWKM 34 2 20 5 31 12 12 20 523 1 2 291 GDRYPVEILASTFHQWCKMNX| 35 12 18 5 39 35 19 23 7 26 1 396GRSDYLEVTPAHNFIWKCQM| 36 11 24 6 42 47 29 28 7 44 1 521GDSYRLTVPAEHIKNFMWCQ| 37 14 33 9 54 52 37 55 11 58 1 639GYDVRSTAPLEIFHNCWQKMX 38 18 33 12 46 77 32 58 17 73 789GSYDVRLPTIFAEHCNWKQM 39 11 38 12 70 94 42 61 33 68 2 943GSDRYVLATPFWIECKHMQNX 40 24 52 27 74 140 61 66 29 71 1061GSRDYVTLPFAEIWHQNKCM 41 31 55 29 70 156 76 61 51 97 1 2 1162GSYTDRVLPAIWNQEFHCKMX| 42 48 47 24 68 171 68 70 39 125 1 1250GSYDLVRTANPFEIWQKMHC| 43 38 58 28 73 164 76 66 43 194 1 1311GYSTARVPDLWNFIQECKHM| 44 48 60 24 69 131 86 57 52 252 1349YGSTDLRAPVWNFIQHCEKM 45 62 51 16 75 116 74 50 39 324 1362YGSLRTDNAFPVWEHIKCQM 46 97 38 21 55 110 39 26 55 377 1371YGDSNRWATLPHFEVQCKIM 47 25 54 9 44 54 34 32 122 292 2 1373GYAWPSFRLHTVNDIEKCMQX 48 8 22 7 6 28 10 25 16 23 1 1377FMLISGVYPAWTDNQREKCHX 49 15 6 13 4 13 5 9 2 11 2 1 1377DGEAHNQSYVLPTIRCKW|FMX 50 23 122 3 3 67 9 350 3 480 1 6 1383YVIPSLFHNDTACXMGKQRW| 50 495 769 270 876 1518 741 1104 540 2572 10 1718621

TABLE 11P Tallies of AA frequencies in all CDR3 by length Tally ofsequences of length 7 # = 38 A C D E F G H I K L M # 1 1 8 1 1 14 1 1 538 GDLRWAEFHKS 2 1 1 2 6 3 2 1 1 38 RGNHVFKTYADLMW 3 1 4 1 5 1 2 2 38GSDWYPVILTAFHN 4 3 1 1 12 1 1 1 38 GYSANRVDFHILPT 5 2 1 14 3 4 1 3 3 38FIGLMARVYEKP 6 26 1 1 38 DVPTHISWY 7 1 2 2 3 1 38 YVINDHSALR 9 42 2 1940 9 11 4 13 4 N P Q R S T V W Y | X # 1 3 1 2 38 GDLRWAEFHKS 2 6 7 2 31 2 38 RGNHVFKTYADLMW 3 1 3 5 2 3 4 4 38 GSDWYPVILTAFHN 4 2 1 2 4 1 2 638 GYSANRVDFHILPT 5 1 2 2 2 38 FIGLMARVYEKP 6 2 1 2 3 1 1 38 DVPTHISWY 73 1 2 7 16 38 YVINDHSALR 12 7 15 13 7 20 8 31 266 Tally of sequences oflength 8 # = 61 A C D E F G H I K L M # 1 3 7 3 14 2 2 5 61GDLTVRSAEHINWPQY 2 1 9 1 1 15 1 2 1 61 GDTNRSVKWYAEFILPQ 3 2 3 1 10 1 17 1 61 GLSTYVDPRAFHIMNQW 4 4 1 3 1 1 15 1 4 61 GYRALQDSWVCEFHNPT 5 10 21 9 5 1 5 1 61 AGYHLTPRVDSEKMW 6 5 1 24 2 7 5 2 61 FIALPSVYGMCQRW 7 5 372 4 1 2 61 DAHSELNVIP| 8 1 2 3 1 12 3 61 YISFLVDNAHPRT 31 2 63 8 30 6514 24 3 32 4 N P Q R S T V W Y | X # 1 2 1 1 4 4 5 5 2 1 61GDLTVRSAEHINWPQY 2 6 1 1 4 3 8 3 2 2 61 GDTNRSVKWYAEFILPQ 3 1 3 1 3 7 75 1 7 61 GLSTYVDPRAFHIMNQW 4 1 1 4 5 3 1 2 3 11 61 GYRALQDSWVCEFHNPT 5 44 2 5 4 1 7 61 AGYHLTPRVDSEKMW 6 3 1 1 3 3 1 3 61 FIALPSVYGMCQRW 7 2 1 42 1 61 DAHSELNVIP| 8 2 1 1 7 1 3 24 61 YISFLVDNAHPRT 14 15 8 22 33 27 2710 55 1 488 Tally of sequences of length 9 # = 88 A C D E F G H I K L M# 1 9 12 4 21 1 1 2 5 88 GDARNVLEQTKWHIPSY 2 2 2 3 3 13 4 3 7 2 88GPSRLNTHEFKYADMQW 3 4 2 3 3 3 15 1 1 88 GTPSQNRVWYADEFCLM 4 5 1 6 3 6 222 4 1 6 1 88 GSDFLARITYENPWHVCKM 5 7 1 4 3 4 14 2 7 2 88GSYALNDFVERWHMQTCP 6 13 2 1 3 13 6 2 1 4 1 88 YAGHNLPSVFTWDIEKMQR 7 4 241 2 3 1 14 5 88 FLMAPWIDGSVKNQTY 8 1 1 73 2 2 1 2 88 DEGLSACHNQRV 9 1 14 1 3 8 2 88 YVISFHPLNTCDGR 45 6 105 19 64 103 19 18 8 48 12 N P Q R S TV W Y | X # 1 7 1 3 8 1 3 7 2 1 88 GDARNVLEQTKWHIPSY 2 5 11 2 10 11 5 23 88 GPSRLNTHEFKYADMQW 3 5 7 6 5 7 11 5 5 5 88 GTPSQNRVWYADEFCLM 4 3 3 57 4 2 3 4 88 GSDFLARITYENPWHVCKM 5 6 1 2 3 12 2 4 3 11 88GSYALNDFVERWHMQTCP 6 5 4 1 1 4 3 4 3 17 88 YAGHNLPSVFTWDIEKMQR 7 1 4 1 21 2 4 1 88 FLMAPWIDGSVKNQTY 8 1 1 1 2 1 88 DEGLSACHNQRV 9 2 3 1 8 2 9 4388 YVISFHPLNTCDGR 35 34 16 34 54 31 34 22 85 792 Tally of sequences oflength 10 # = 101 A C D E F G H I K L M # 1 8 1 19 7 1 16 3 2 3 2 101DGNAERTSQVHLWKMYCF 2 3 8 3 5 13 5 15 2 101 LGRDSPVFINTAEQYMW 3 6 9 1 261 3 1 4 1 101 GSYDAVTLNRIPWFHKMQ 4 7 6 1 25 1 5 4 1 101GSYARDINPLTVWQFHM 5 6 5 9 4 16 1 3 4 101 GYTESANDPRFLVKQWH 6 6 1 6 5 423 2 4 3 3 1 101 GYRSWADEFINKLTHCMQV 7 13 3 1 5 9 3 1 4 1 101YASGPRWFTVLDHNEIMQ 8 2 1 1 57 3 4 15 4 101 FLIMSGWANPVCEY 9 3 78 2 6 1 11 101 DGAQENIKLPRSW 10 3 4 4 13 1 101 YIPSVFHNDL 54 3 137 28 82 137 1536 10 54 12 N P Q R S T V W Y | X # 1 9 4 6 5 6 4 3 2 101DGNAERTSQVHLWKMYCF 2 5 6 3 11 8 4 6 1 3 101 LGRDSPVFINTAEQYMW 3 4 3 1 414 5 6 2 10 101 GSYDAVTLNRIPWFHKMQ 4 5 5 3 7 11 4 4 4 8 101GSYARDINPLTVWQFHM 5 6 5 2 5 8 10 4 2 11 101 GYTESANDPRFLVKQWH 6 4 1 8 73 1 7 12 101 GYRSWADEFINKLTHCMQV 7 2 7 1 7 11 5 5 6 17 101YASGPRWFTVLDHNEIMQ 8 2 2 4 2 3 1 101 FLIMSGWANPVCEY 9 2 1 3 1 1 1 101DGAQENIKLPRSW 10 4 8 7 5 52 101 YIPSVFHNDL 43 37 18 49 76 37 37 29 1161010 Tally of sequences of length 11 # = 118 A C D E F G H I K L M # 1 71 21 11 23 5 2 7 118 GDEVRALQHSPTINCWY 2 1 2 9 1 1 24 5 6 2 7 3 118GSRDYLPIVHQTMNCKWAEFX 3 4 4 2 4 13 2 3 1 7 2 118 SGTVRLYWADFNQIEHMKP 410 3 3 2 25 1 2 4 3 118 SGARTWYLVDEMQFINPH 5 5 2 10 1 4 24 2 1 5 1 118GSVYDTNALRFWCHQEKM 6 6 4 2 7 19 2 3 1 5 1 118 GSYWTFAVLRDINEHQKMP 7 4 18 5 2 20 4 1 2 1 118 GYSNRDWTEPAHFLQVCIM 8 13 2 6 1 8 12 4 2 7 118YAGWFLDPRSTHCKVE 9 2 2 68 2 5 14 7 118 FLMYVITADGP 10 2 1 100 5 3 2 1 1118 DEGAHCLMNPQ 11 2 6 1 7 1 6 1 118 YPVISFLNDHKM 54 9 169 31 102 165 2829 8 65 20 N P Q R S T V W Y | X # 1 2 4 7 8 5 3 10 1 1 118GDEVRALQHSPTINCWY 2 3 7 4 10 11 4 6 2 9 1 118 GSRDYLPIVHQTMNCKWAEFX 3 41 4 8 25 12 9 6 7 118 SGTVRLYWADFNQIEHMKP 4 2 2 3 9 26 8 4 6 5 118SGARTWYLVDEMQFINPH 5 6 2 5 15 9 11 4 11 118 GSVYDTNALRFWCHQEKM 6 3 1 2 516 9 6 11 15 118 GSYWTFAVLRDINEHQKMP 7 9 5 2 9 11 6 2 7 19 118GYSNRDWTEPAHFLQVCIM 8 6 5 5 5 2 11 29 118 YAGWFLDPRSTHCKVE 9 1 4 6 7 118FLMYVITADGP 10 1 1 1 118 DEGAHCLMNPQ 11 3 13 7 11 60 118 YPVISFLNDHKM 3341 25 59 121 60 67 48 163 1 1298 Tally of sequences of length 12 # = 154A C D E F G H I K L M # 1 5 31 12 37 6 1 1 7 3 154 GDRESVLHAPMNQTWYIK 25 1 7 6 1 25 3 7 3 13 2 154 GSRLPDIQEAVYHKNTMWCF 3 10 2 7 5 1 19 5 4 122 154 GRSYLATVPDQEIKWCMNF 4 8 9 6 8 27 6 5 6 1 154 GVSDNAFRTYEILKWPQM 518 1 8 5 6 42 1 9 1 7 3 154 GSAIDYLFPTEQVMNWCHK 6 13 12 4 10 23 1 7 8 1154 GAVDSFYTLPRWINEQHM 7 11 2 4 3 10 15 1 4 12 154 YGSPLRAFWTNVDIECQH 83 2 18 3 3 25 4 2 5 6 154 YGDSNLTKRWHPAEFCIQV 9 15 1 2 8 33 4 7 1 5 1154 GYWARFISPLHTDQCKMN 10 1 1 2 1 79 1 2 5 1 19 26 154FMLIPYDHVWACEGKNQRST 11 2 135 2 4 2 154 DGYAEHSVNR 12 1 1 6 1 9 16 4 154YVPIHFSLNCDGW 91 11 236 47 132 252 33 69 21 99 39 N P Q R S T V W Y | X# 1 3 4 3 14 10 3 10 2 2 154 GDRESVLHAPMNQTWYIK 2 3 11 7 22 24 3 5 2 4154 GSRLPDIQEAVYHKNTMWCF 3 2 8 6 17 17 9 9 4 15 154 GRSYLATVPDQEIKWCMNF4 9 4 4 7 17 7 18 5 7 154 GVSDNAFRTYEILKWPQM 5 3 6 4 20 6 4 2 8 154GSAIDYLFPTEQVMNWCHK 6 5 8 3 8 11 9 13 8 10 154 GAVDSFYTLPRWINEQHM 7 5 142 12 15 6 5 9 24 154 YGSPLRAFWTNVDIECQH 8 10 4 2 5 15 6 2 5 34 154YGDSNLTKRWHPAEFCIQV 9 1 6 2 10 7 3 18 30 154 GYWARFISPLHTDQCKMN 10 1 4 11 1 1 2 2 3 154 FMLIPYDHVWACEGKNQRST 11 1 1 2 2 3 154 DGYAEHSVNR 12 2 185 32 1 58 154 YVPIHFSLNCDGW 45 87 34 97 144 53 102 58 198 1848 Tally ofsequences of length 13 # = 150 A C D E F G H I K L M # 1 4 2 28 9 3 37 83 3 5 150 GDTESHRVLPAQFIKCNW 2 11 4 4 1 2 32 3 1 5 11 3 150GRSPALTKVCDYHMQWFEIN 3 7 2 8 4 4 23 11 1 4 6 2 150 GSYHQTDPRAVLEFKNCMWI4 6 2 6 4 6 30 1 8 6 1 150 GSWYTIADFLPVEQRCHMNX 5 8 10 4 2 28 1 2 22 3150 GLSYDATWPREQMNVFIH 6 10 2 11 1 6 21 2 2 5 1 150 GYSPTDAQVFRLNWCIKEM7 5 1 8 1 4 19 1 6 5 21 2 150 LGYSTDPIRVAKFNWMQCEH 8 7 5 22 5 3 12 3 3 38 1 150 YDSGLARTCEQVNPFHIKWM 9 1 2 12 3 1 26 7 2 4 7 2 150NGYDSWHLPRKETVCIMAFQ 10 19 1 2 2 17 24 5 2 5 1 150 YGAFWHLPTNSVDEIQRCM11 1 1 105 2 2 1 13 14 150 FMLYGIVAEKPQRSWX 12 130 3 5 1 150 DGYEQNHT 131 2 5 5 14 18 1 150 YVLIPSFHTDAMN 80 21 243 38 158 259 46 46 27 127 31 NP Q R S T V W Y | X # 1 2 5 4 8 9 11 8 1 150 GDTESHRVLPAQFIKCNW 2 1 13 320 17 7 5 3 4 150 GRSPALTKVCDYHMQWFEIN 3 3 8 11 8 16 11 7 2 12 150GSYHQTDPRAVLEFKNCMWI 4 1 6 4 4 18 10 6 16 14 1 150 GSWYTIADFLPVEQRCHMNX5 3 6 4 5 19 8 3 7 15 150 GLSYDATWPREQMNVFIH 6 3 15 8 6 16 13 8 3 17 150GYSPTDAQVFRLNWCIKEM 7 4 7 2 6 15 14 6 4 19 150 LGYSTDPIRVAKFNWMQCEH 8 44 5 7 15 7 5 2 29 150 YDSGLARTCEQVNPFHIKWM 9 31 5 1 5 10 3 3 9 16 150NGYDSWHLPRKETVCIMAFQ 10 3 5 2 2 3 4 3 15 35 150 YGAFWHLPTNSVDEIQRCM 11 11 1 1 2 1 3 1 150 FMLYGIVAEKPQRSWX 12 2 3 1 5 150 DGYEQNHT 13 1 14 13 421 51 150 YVLIPSFHTDAMN 58 89 48 72 152 93 77 63 220 2 1950 Tally ofsequences of length 14 # = 118 A C D E F G H I K L M # 1 6 29 7 2 32 8 11 2 118 GDVHERTAFLPSIKNQ 2 4 10 1 5 22 7 3 4 7 118 GPDRYSVHLFAKIQTENW 311 2 7 2 3 25 5 1 9 2 118 GVARYLSDITFWCEMPK 4 5 2 7 7 3 12 4 4 3 6 118SGVYPDELRTANHIFKWC 5 6 5 12 2 18 2 2 2 4 1 118 GYSDTVARCLPFHIKNWMQ 6 610 5 4 16 5 3 2 1 118 YGSTDRAEIFVKWLPQMN 7 4 4 1 4 32 2 2 2 1 118GSVTYNADFHIKPQRWEM 8 6 1 5 1 4 18 2 5 3 2 118 GSYTWAPRDIFNVLHMCE 9 5 2 41 2 11 2 1 5 9 1 118 YSGTLVAKNRDWCFHPEIM 10 2 5 9 2 3 21 2 2 4 118YGSDNTCQLRFWAEIKPV 11 12 1 3 5 25 2 2 1 118 YGWAPVFNEHLTDMQR 12 1 64 5 15 12 16 118 FMLGIPSVAHQTY 13 3 97 4 5 1 1 1 1 118 DGEANQHIKLV 14 2 3 412 6 118 YVPILHFANS 73 17 195 34 104 242 35 48 24 67 25 N P Q R S T V WY | X # 1 1 2 1 7 2 7 10 118 GDVHERTAFLPSIKNQ 2 1 13 2 10 8 2 8 1 10 118GPDRYSVHLFAKIQTENW 3 2 11 8 4 13 3 10 118 GVARYLSDITFWCEMPK 4 5 8 6 13 612 3 12 118 SGVYPDELRTANHIFKWC 5 2 3 1 6 15 10 7 2 18 118GYSDTVARCLPFHIKNWMQ 6 1 2 2 7 16 12 4 3 19 118 YGSTDRAEIFVKWLPQMN 7 5 22 2 18 12 13 2 10 118 GSVTYNADFHIKPQRWEM 8 4 6 6 16 12 4 9 14 118GSYTWAPRDIFNVLHMCE 9 5 2 5 14 10 8 4 27 118 YSGTLVAKNRDWCFHPEIM 10 6 2 54 13 6 2 3 27 118 YGSDNTCQLRFWAEIKPV 11 4 7 1 1 2 6 14 32 118YGWAPVFNEHLTDMQR 12 4 1 4 1 3 1 118 FMLGIPSVAHQTY 13 2 2 1 118DGEANQHIKLV 14 2 14 2 20 53 118 YVPILHFANS 38 67 17 65 129 84 111 44 2331652 Tally of sequences of length 15 # = 125 A C D E F G H I K L M # 1 726 8 3 29 1 3 10 125 GDLREASTVNFIPYH 2 6 2 3 22 3 4 1 9 125RGPLNSTYAVIQEHWDK 3 4 4 5 7 2 19 2 6 2 9 2 125 GRYLSVEPIDTACQWFHKMN 4 74 14 6 6 15 2 7 5 7 4 125 GDYAILVEFRKSTCMNPWHQ 5 6 3 10 2 5 18 4 2 3 2125 GSYVDRWAFTICLNEKMP 6 6 2 7 2 5 10 1 5 7 1 125 SRYGTDLWAPFIVNCEQHM 78 4 14 2 2 22 3 3 1 9 1 125 GSDLAVRPYCTHIWEFNKM 8 6 2 4 22 2 2 3 125GYSVWRATDNPLCIKQ 9 4 3 8 4 20 4 3 1 6 125 YGSDLPTRVAFHQCINKW 10 3 4 5 88 17 1 3 7 125 YGEFNTLSRDVCPAIWH 11 4 2 15 3 3 17 1 1 1 125YGDSNPAWEFRTCQHIKV 12 22 3 2 31 3 1 3 3 125 GYAWPSNCHLMFQRVITX 13 71 1 46 30 125 FMLISQTVGPRY 14 115 2 1 1 1 125 DNEFGHPQ 15 3 5 1 1 20 7 1 125YVILPFSCNGHMQ 83 34 225 43 117 245 23 66 15 86 44 N P Q R S T V W Y | X# 1 4 3 10 7 6 6 2 125 GDLREASTVNFIPYH 2 8 11 4 23 7 7 5 3 7 125RGPLNSTYAVIQEHWDK 3 2 7 3 13 9 5 8 3 13 125 GRYLSVEPIDTACQWFHKMN 4 4 4 16 5 5 7 3 13 125 GDYAILVEFRKSTCMNPWHQ 5 3 2 8 18 5 11 8 15 125GSYVDRWAFTICLNEKMP 6 3 6 2 12 24 9 4 7 12 125 SRYGTDLWAPFIVNCEQHM 7 2 67 21 4 8 3 5 125 GSDLAVRPYCTHIWEFNKM 8 4 4 2 7 19 5 12 10 21 125GYSVWRATDNPLCIKQ 9 3 6 4 5 19 6 5 1 23 125 YGSDLPTRVAFHQCINKW 10 8 4 6 78 5 2 29 125 YGEFNTLSRDVCPAIWH 11 7 5 2 3 14 3 1 4 39 125YGDSNPAWEFRTCQHIKV 12 4 7 2 2 6 1 2 8 24 1 125 GYAWPSNCHLMFQRVITX 13 1 21 4 2 2 1 125 FMLISQTVGPRY 14 3 1 1 125 DNEFGHPQ 15 2 7 1 5 33 39 125YVILPFSCNGHMQ 57 74 24 103 165 66 109 52 243 1 1875 Distribution of D-JHwith number of cys's 0 1 2 3 4 1248 53 80 1 1 Tally of AAs in the YYCarmotif A C D E F G H I K L M # 1 1 1 14 1 1383 YFDEH 2 4 1 92 11 4 1383YFHCLSWDR 3 1379 1383 CRS 4 1207 3 2 12 2 2 1383 AVTSGNDFILRQX 5 14 1 418 17 9 187 4 1 1383 RKTSGHAIVNFLQYPEM| 1221 1383 5 2 112 30 29 11 18710 1 N P Q R S T V W Y | X # 1 1366 1383 YFDEH 2 1 3 2 1265 1383YFHCLSWDR 3 2 2 1383 CRS 4 4 1 2 17 51 79 1 1383 AVTSGNDFILRQX 5 7 2 3992 55 56 9 3 1 1383 RKTSGHAIVNFLQYPEM| 11 2 4 997 77 107 88 2 2634 1 16915

TABLE 12P Alignment and tabulation of sequences having 3-22 D segmentsD3:3-22_Phz0 YYYDSSGYYY = GLG Entry Seq1 L1 Seq2 L2 JH P Score  1hs3d6hcv GRDYYDSGGYFT 12 GRDYYDSGGYFTVAFDI 17 3 6 1.76D+13  2 hs6d4xb7DRHNYYDSSGSYS 13 DRHNYYDSSGSYSDY 15 4 9 4.40D+12  3 hs6d4xg3DCPAPAKMYYYGSGICT 17 DCPAPAKMYYYGSGICTFDY 20 4 3 6.55D+04  4 hs83x6f2AFYDSAD 7 AFYDSADDY 9 4 −4 2.62D+05  5 hsa230644 RDYYDSSGPEAG 12RDYYDSSGPEAGFDI 15 3 3 6.87D+10  6 hsa239386 DGTLIDTSAYYYL 13DGTLIDTSAYYYLY 14 4 6 6.87D+10  7 hsa234232 NSSDSS 6 NSSDSSVLDV 10 6 −46.55D+04  8 hsa239378 DQVFDSGGYNHR 12 DQVFDSGGYNHRFDS 15 4 3 1.07D+09  9hsa239367 DLEYYYDSGGHYSP 14 DLEYYYDSGGHYSPFHY 17 4 9 1.10D+12 10hsa239339 DDSSGY 6 DDSSGYYYIDY 11 4 −10 1.72D+10 11 hsa245311GHYYDSPGQYSYS 13 GHYYDSPGQYSYSEY 15 4 3 1.07D+09 12 hsa240578GGFRPPPYDYESSAYRTYR 19 GGFRPPPYDYESSAYRTYRLDF 22 4 21 2.75D+11 13hsa245359 DSDTRAY 7 DSDTRAYYWYFDL 13 2 −7 1.68D+07 14 hsa245028GRHYYDSSGYYSTPE 15 GRHYYDSSGYYSTPENYFDY 20 4 6 1.80D+16 15 hsa245019DPSYYYDSSGLPL 13 DPSYYYDSSGLPLHGMDV 18 6 9 4.40D+12 16 hsa244991TYYYDSSGYLLTR 13 TYYYDSSGYLLTRYFQH 17 1 3 4.50D+15 17 hsa244945NAPHYDSSGYYQT 13 NAPHYDSSGYYQTFDY 16 4 6 7.04D+13 18 hsa244943 GYHSSSYA8 GYHSSSYADAFDI 13 3 −7 6.71D+07 19 hsa245289 PIGYCSGGSC 10PIGYCSGGSCYSFDY 15 4 −4 2.62D+05 20 hsa240554 THGTYVTSGYYPKI 14THGTYVTSGYYPKI 14 4 6 2.68D+08 21 hsa279533 GATYYYESSGNYP 13GATYYYESSGNYPDY 15 4 9 7.04D+13 22 hsa389177 AFYHYDSTGYPNRRY 15AFYHYDSTGYPNRRYYFDY 19 4 6 4.29D+09 23 hsa7321 SYSYYYDSSGYWGG 14SYSYYYDSSGYWGGYFDY 18 4 9 4.50D+15 24 hsaj2772 LSPYYYDSSSYH 12LSPYYYDSSSYHDAFDI 17 3 6 2.62D+05 25 hsb7g4f08 EEDYYDSSGQAS 12EEDYYDSSGQASYNWFXP 18 5 6 2.75D+11 26 hsb7g3b02 ETNYYDSGGYPG 12ETNYYDSGGYPGFDF 15 4 6 4.40D+12 27 hsb7g3c12 GDHYYDRSGYRH 12GDHYYDRSGYRHSYYYYAMDV 21 6 6 2.75D+11 28 hsb8g3b07 DRSSGN 6DRSSGNYFDGMDV 13 6 −10 6.55D+04 29 hsfog1h GRSRYSGYG 9 GRSRYSGYGFYSGMDV16 6 −4 2.62D+05 30 hsgvh0209 DDTSGYGP 8 DDTSGYGPYYFYYGMDV 17 6 −102.68D+08 31 hsgvh55 RAYYDTSFYFEY 12 RAYYDTSFYFEYY 13 4 3 1.72D+10 32hsgvh0304 DRIDYYKSGYYLGSA 15 DRIDYYKSGYYLGSADS 17 4 6 1.68D+07 33hsgvh0332 DTDSSSHYG 9 DTDSSSHYGRFDP 13 5 −7 1.68D+07 34 hsgvh0328VSISHYDSSGRPQRVF 16 VSISHYDSSGRPQRVFYGMDV 21 6 9 1.07D+09 35 hsgvh536QARENVFYDSSGPTAP 16 QARENVFYDSSGPTAPFDH 19 4 15 1.72D+10 36 hshcmg42VPAGNYYDTSGPDN 14 VPAGNYYDTSGPDNAD 16 4 12 1.72D+10 37 hsig001vhWYYFDTSGYYPRNFYYMDV 19 WYYFDTSGYYPRNFYYMDV 19 4 3 2.81D+14 38 hsig13g10GYYYDSGGNYNG 12 GYYYDSGGNYNGDY 14 4 3 1.10D+12 39 hsighpat3 DLRSYDPSGYYN12 DLRSYDPSGYYNDGFDI 17 3 6 2.75D+11 40 hsigh13g7 GYYYDRGGNCNG 12GYYYDRGGNCNGDY 14 4 3 6.87D+10 41 hsigh13g1 GYYYDRGGNYNG 12GYYYDRGGNYNGDY 14 4 3 1.10D+12 42 hsighxx20 THYDSSGL 8 THYDSSGLDAFDI 133 −4 1.72D+10 43 hsihr9 DDSSGS 6 DDSSGSYYFDY 11 4 −10 1.07D+09 44hsihv11 LSGGYYS 7 LSGGYYSDFDY 11 4 −13 2.68D+08 45 hs ej1f GDYSDSSDSYI11 GDYSDSSDSYIDAFDV 16 3 3 1.10D+12 46 hsmvh51 GETYYYDSRGYA 12GETYYYDSRGYAFDH 15 4 6 2.62D+05 47 hsmvh517 PTRDSSGY 8 PTRDSSGYYVGY 12 4−4 1.07D+09 48 hsmvh0406 GSFYYDSSGYPP 12 GSFYYDSSGYPPFDC 15 4 6 6.87D+1049 hst14x14 GPYYYDSSGYYL 12 GPYYYDSSGYYLLDY 15 4 6 1.80D+16 50 hsvhig2EEGYYDSSGYYSLGA 15 EEGYYDSSGYYSLGASDY 18 4 6 4.50D+15 51 hsvhia2RPDSSGSRW 9 RPDSSGSRWYFDY 13 4 −7 6.71D+07 52 hsy14936 GYYDISGYYF 10GYYDISGYYFDAFNI 15 3 −4 2.81D+14 53 hsy14934 DRGYDSSGYYGN 12DRGYDSSGYYGNLDC 15 4 3 1.76D+13 54 hsy14935 DRGYDSIGYYGN 12DRGYDSIGYYGNLDC 15 4 3 1.10D+12 55 hsz80519 AEDLTYYYDRSGWGVHGLL 19AEDLTYYYDRSGWGVHGLLYYFDY 24 4 15 4.40D+12 56 hsz80429 LYPHYDSSGYYYV 13LYPHYDSSGYYYVLDY 16 4 6 4.50D+15 57 hsz80461 DRVGYYDSSGYPPGSP 16DRVGYYDSSGYPPGSPLDY 19 4 9 1.76D+13Frequency of each AA type at each position in 57 Sequenceshaving D3-22 segments Pos A C D E F G H I K L M N P Q R S T V W Y | X # 1 1 1  2 1 1  3 1 1 1 3  4 1 1 1 1 4  5 5 1 1 2 1 1 1 12  6 3 3 4 6 3 12 2 2 1 1 28 x  7 1 5 4 1 7 2 1 1 1 3 5 3 4 1 1 1 41 x  8 2 1 4 1 5 3 14 4 1 3 1 3 1 14 48 x  9 4 2 3 5 1 1 1 2 2 2 1 28 52 Y 10 1 4 2 1 1 1 14 1 40 56 Y 11 46 2 1 1 1 2 1 3 57 D 12 1 1 1 1 1 1 4 39 7 1 57 S 13 1 81 1 1 1 43 1 57 S 14 3 2 1 45 1 1 3 56 G 15 2 2 2 5 3 2 1 4 1 33 55 Y 162 1 1 1 2 3 1 1 1 6 3 1 1 1 24 49 x 17 3 1 1 1 5 2 1 4 6 6 2 7 2 1 1 346 x 18 8 1 1 2 2 2 4 3 1 3 27 19 2 1 1 1 3 4 1 13 20 2 1 2 1 1 1 1 9 211 1 1 3 22 1 1 2 23 1 1 2 24 1 1 25 1 1 Average Dseg = 11.9 Average DJ =15.7 Median D = 12 12 Shortest 6 Longest 19 Median DJ = 15 15 Shortest 9Longest 24

TABLE 13P Frequency of D-segments. D seg “0” % C % GLG “1” % C % GLG “2”% C % GLG 1-01 1 0.13 0 VQLERX 4 0.53 0.22 GTTGTX 5 0.66 0.34 YNWND 1-070 0 0 V|LELX 3 0.4 0.11 GITGTX 9 1.19 0.34 YNWNY 1-20 0 0 0 V|LERX 10.13 0.22 GITGTX 4 0.53 0.45 YNWND 1-26 4 0.53 0 V|WELLX 13 1.72 0.90GIVGATX 36 4.76 0.78 YSGSYY 2-02 31 4.1 2.47 GYCSSTSCYT 4 0.53 0.22RIL||YQLLYX 9 1.19 2.47 DIVVVPAAIX 2-08 5 0.66 0.56 GYCTNGVCYT 0 0 0RILY|WCMLYX 3 0.4 0.56 DIVLMVYAIX 2-15 29 3.83 1.57 GYCSGGSCYS 2 0.260.11 RIL|WW|LLLX 7 0.92 1.57 DIVVVVAATX 2-21 16 2.11 0.67 AYCGGDCYS 0 00 SILWW|LLFX 7 0.92 0.67 HIVVVTAIX 3-03 32 4.23 2.80 YYDFWSGYYT 7 0.920.90 VLRFLEWLLYX 27 3.57 1.12 ITIFGVVIIX 3-09 13 1.72 1.35 YYDILTGYYN 50.66 0.78 VLRYFDWLL|X 0 0 0 ITIF|LVIIX 3-10 42 5.55 4.26 YYYGSGSYYN 131.72 0.89 VLLWFGELL|X 11 1.45 2.91 ITMVRGVIIX 3-16 18 2.38 0.67YYDYVWGSYRYT 8 1.06 0 VL|LRLGELSLYX 5 0.66 0.34 IMITFGGVIVIX 3-22 577.53 3.36 YYYDSSGYYY 1 0.13 0.11 VLL|||WLLLX 6 0.79 0.34 ITMIVVVITX 4-045 0.66 0.28 DYSNY 2 0.26 0 |LQ|LX 2 0.26 0.06 TTVTX 4-17 29 3.83 1.45DYGDY 0 0 0 |LR|LX 20 2.64 0.90 TTVTX 4-23 10 1.32 0.56 DYGGNS 1 0.13 0|LRW|LX 4 0.53 0.56 TTVVTX 5-05 3 0.4 0.06 WIQLWLX 10 1.32 0.39 VDTAMVX31 4.1 0.73 GYSYGY 5-12 0 0 0 WI|WLRLX 8 1.06 0.45 VDIVATIX 14 1.85 1.12GYSGYDY 5-24 11 1.45 0 |RWLQLX 5 0.66 0.34 VEMATIX 13 1.72 0.44 RDGYNY6-06 11 1.45 0.78 SIAARX 9 1.19 0.48 EYSSSS 1 0.13 0.11 V|QLVX 6-13 192.51 1.01 GIAAAGX 35 4.62 2.13 GYSSSWY 2 0.26 0.31 V|QQLVX 6-19 14 1.852.12 GIAVAGX 48 6.34 2.02 GYSSGWY 4 0.53 0.56 V|QWLVX D7: 7-27 1 0.13 0|LGX 2 0.26 0.68 LTGX 2 0.26 0.22 NWG Total = 757 “|” stands for a stopcodon.

TABLE 14P Possible library components. Component L f D2_2-02_Phz0xxxYCSSTSCxxx 13, 31, D3_3-16_Phz0 xxxxYVWGSYxxx 13, 18, D5_5-12_Phz2xxxxxxxSGYxxx 13, 14, D3_3-09_Phz0 xxxYDILTGYYxx 13, 13, D2_2-02_Phz2xxxVVVPAAxxxx 13, 9, D3_3-22_Phz0 xxxYYDSSGYxx 12, 57, D3_3-03_Phz0xxxDFWSGxxxx 12, 32, D3_3-03_Phz2 xxxTIFGVxxxx 12, 27, D5_5-12_Phz1xxxxIVATxxxx 12, 8, D3_3-10_Phz0 xxxYGSGSYYx 11, 42, ! could add oneD5_5-05_Phz2 xxxxYSYGxxx 11, 31, x at either end D2_2-15_Phz0xxxCSGxxCYx 11, 29, D6_6-13_Phz0 xxxxAAAGxxx 11, 19, D4_4-23_Phz0xGxxxGGNxxx 11, 10, D1_1-26_Phz2 xxxSGSYxxx 10, 35, D6_6-13_Phz1xxxSSSWxxx 10, 35, D4_4-17_Phz2 xxxxTTVTTx 10, 20, D2_2-21_Phz0xxxC(SG)GDxCx 10, 16, D6_6-19_Phz0 xxx(IV)AVAGxx 10, 14, D3_3-10_Phz1xxLWFGELxx 10, 13, D5_5-24_Phz0 GxxWLxxxxF 10, 11, D5_5-05_Phz1xxxDTxMVxx 10, 10, D3_3-16_Phz1 xxxxxGExxx 10, 8, D6_6-19_Phz1 xxxxSGWxx9, 48, D5_5-24_Phz2 xxxxGYNxx 9, 13, D3_3-10_Phz2 xxxVRGVxx 9, 11,D6_6-06_Phz0 xxxIAAxxx 9, 11, D1_1-07_Phz2 xxYxWNxxx 9, 9, D4_4-17_Phz0xxxYGDxx 8, 29, D1_1-26_Phz1 xxVGATxx 8, 13, D6_6-06_Phz1 xxxYSSSx 8, 9,

TABLE 15P Lengths of CDRs: 1095 actual VH domains and 51 VH GLGs. Length0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 CDR1 0 0 10 0 1 820 38 175 11 5 1 11 0 23 1 7 0 GLG 0 0 0 0 0 38 3 10 0 0 . . . CDR2 0 0 0 0 0 2 0 00 0 0 0 0 0 0 0 464 579 GLG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 17 28 CDR3 00 0 4 2 8 6 28 40 65 77 90 117 117 88 105 86 81 Length 18 19 20 21 22 2324 25 26 27 28 29 30 31 32 (33 or more) CDR2 9 31 1  3 3 1 0 0 0 0 2 0 0. . . GLG 1 4 0 0 . . . CDR3 45 36 36 16 16 8 8 2 3 0 2 1 0 0 1 5

TABLE 16P Library of HC CDR3 Component Fraction of Length #X Complexitylibrary Adjusted 1: YYCA21111YFDYWG. 8 4 2.6E 5 .10 (0-8) .02 (2 = KR)2: YYCA2111111YFDYWG. 10 6 9.4E 7 .14 (9-10) .14 (2 = KR) 3:YYCA211111111YFDYTG. 12 8 3.4E 10 .25 (11 + 12 + 13/2) .25 (2 = KR) 4:YYCAR111S2S3111YFDYWG. 14 6 1.9e 8 .13 (14 + 13/2) .14 (2 = SG 3 = YW)5: YYCA2111CSG11CY1YFDYWG. 15 6 9.4E 7 .13 (15 + 16/2) .14 (2 = KR) 6:YYCA211S1TIFG11111YFDYWG. 17 8 1.7E 10 .11 (17 + 16/2) .12 (2 = KR) 7:YYCAR111YY2S33YY111YFDYWG. 18 6 3.8E 8 .04 (18) .08 (2 = D|G; 3 = S|G)8: YYCAR1111YC2231CY111YFDYWG. 19 8 2.0E 11 .10 (19 on) .11 (2 =S|G; 3 = T|D|G) Allowed lengths: 8, 10, 12, 14, 15, 17, 18, & 19

TABLE 17P vgDNA encoding the CDR3 elements of the libraryCDR3 library components (Ctop25) 5′-gctctggtcaa C|TTA|AGg|gct|gag|g-3′(CtprmA) 5′-gctctggtcaa C|TTA|AGg|gct|gag|gac-                AflII...|acc|gct|gtc|tac|tac|tgc|gcc-3′ (CBprmB) [RC]5′-|tac|ttc|gat|tac|ttg|ggc|caa|GGT|ACC|ctG|GTC|ACC|tcgctccacc-3′                                          BstEII... (CBot25) [RC]5′-|GGT|ACC|ctG|GTC|ACC|tcgctccacc-3′ N.B. [RC]means the the actual oligonucleotide is the reverse complementof the one shown. N.B. The 20 bases at 3′end of CtprmA are identical to the most 5′ 20 basesof each of the vgDNA molecules. N.B. Ctop25 is identical to the most 5′25 bases of CtprmA. N.B. The 23 most 3′bases of CBprmB are the reverse complement of the most 3′23 bases of each of the vgDNA molecules.N.B. CBot25 is identical to the 25 bases at the 5′ end of CBprmB.(C1t08) 5′-cc|gct|gtc|tac|tac|tgc|gcc|- <2>|<1>|<1>|<1>|<1>-|tac|ttc|gat|tac|ttg|ggc|caa|GG-3′ 2 = KR, 1 = 0.27Y + 0.27G +0.027{ADEFHIKLMNPQRSTVW} no C (C2t10) 5′-cc|gct|gtc|tac|tac|tgc|gcc|-<2>|<1>|<1>|<1>|<1>|<1>|<1>|- tac|ttc|gat|tac|ttg|ggc|caa|GG-3′ 2 =KR, 1 = 0.27Y + 0.27G + 0.027{ADEFHIKLMNPQRSTVW} no C (C3t12)5′-cc|gct|gtc|tac|tac|tgc|gcc|- <2>|<1>|<1>|<1>|<1>|<1>|<1>|<1>|<1>|-tac|ttc|gat|tac|ttg|ggc|caa|GG-3′ 2 = KR, 1 = 0.27Y + 0.27G +0.027{ADEFHIKLMNPQRSTVW} no C (C4t14)5′-cc|gct|gtc|tac|tac|tgc|gcc|cgt|-|<1>|<1>|<1>|tct|<2>|tct|<3>|<1>|<1>|<1>|-tac|ttc|gat|tac|ttg|ggc|caa|GG-3′ 2 = SG, 1 = 0.27Y + 0.27G +0.027{ADEFHIKLMNPQRSTVW} no C, 3 = YW (C5t15)5′-cc|gct|gtc|tac|tac|tgc|gcc|-<2>|<1>|<1>|<1>|tgc|tct|ggt|<1>|<1>|tgc|tat|<1>|-tac|ttc|gat|tac|ttg|ggc|caa|GG-3′ 2 = KR, 1 = 0.27Y + 0.27G +0.027{ADEFHIKLMNPQRSTVW} no C (C6t17) 5′-cc|gct|gtc|tac|tac|tgc|gcc|-<2>|<1>|<1>|tct|<1>|act|atc|ttc|ggt|<1>|<1>|<1>|<1>|<1>|-tac|ttc|gat|tac|ttg|ggc|caa|GG-3′ 2 = KR, 1 = 0.27Y + 0.27G +0.027{ADEFHIKLMNPQRSTVW} no C (C7t18)5′-cc|gct|gtc|tac|tac|tgc|gcc|cgt|-|<1>|<1>|<1>|tat|tac|<2>|tct|<3>|<3>|tac|tat|<1>|<1>|<1>|-tac|ttc|gat|tac|ttg|ggc|caa|GG-3′ 2 = DG, 1 = 0.27Y + 0.27G +0.027{ADEFHIKLMNPQRSTVW} no C, 3 = SG (c8t19)5′-cc|gct|gtc|tac|tac|tgc|gcc|cgt|-|<1>|<1>|<1>|<1>|tat|tgc|<2>|<2>|<3>|<1>|tgc|tat|<1>|<1>|<1>|-tac|ttc|gat|tac|ttg|ggc|caa|GG-3′ 2 = SG, 1 = 0.27Y + 0.27G +0.027{ADEFHIKLMNPQRSTVW} no C, 3 = TDG

TABLE 19 Names of 1398 GeneBank entries examined haj10335 hsa006167hsa234193 hsa234294 hsa239370 hsa241345 hsa244970 hs201e3 hsa006169hsa234194 hsa234296 hsa239371 hsa241346 hsa244971 hs201g1 hsa006171hsa234196 hsa234298 hsa239372 hsa241347 hsa244972 hs201m2 hsa006173hsa234197 hsa235649 hsa239373 hsa241348 hsa244973 hs202e2 hsa131921hsa234199 hsa235658 hsa239375 hsa241349 hsa244974 hs202g3 hsa132847hsa234202 hsa235662 hsa239376 hsa241350 hsa244975 hs202g9 hsa132849hsa234203 hsa235664 hsa239377 hsa241351 hsa244976 hs202m3 hsa132850hsa234205 hsa235665 hsa239378 hsa241353 hsa244977 hs203e1 hsa132851hsa234206 hsa235667 hsa239379 hsa241354 hsa244978 hs203g1 hsa132852hsa234207 hsa235671 hsa239380 hsa241355 hsa244979 hs203m5 hsa224746hsa234208 hsa235675 hsa239381 hsa241356 hsa244980 hs204e1 hsa225092hsa234209 hsa235677 hsa239382 hsa241357 hsa244981 hs204g1 hsa225093hsa234211 hsa238036 hsa239383 hsa241420 hsa244982 hs3d6hcv hsa230634hsa234212 hsa238037 hsa239384 hsa241421 hsa244983 hs6d4xa7 hsa230635hsa234214 hsa238038 hsa239385 hsa242555 hsa244984 hs6d4xb7 hsa230636hsa234217 hsa238039 hsa239386 hsa242556 hsa244985 hs6d4xf1 hsa230637hsa234221 hsa238040 hsa239387 hsa243108 hsa244986 hs6d4xf2 hsa230638hsa234224 hsa238326 hsa239388 hsa243110 hsa244987 hs6d4xg3 hsa230639hsa234227 hsa238327 hsa239390 hsa244928 hsa244988 hs6d4xh5 hsa230640hsa234229 hsa238328 hsa239391 hsa244929 hsa244989 hs83x6b2 hsa230641hsa234230 hsa239330 hsa240553 hsa244930 hsa244990 hs83x6b5 hsa230643hsa234232 hsa239331 hsa240554 hsa244931 hsa244991 hs83x6c3 hsa230644hsa234235 hsa239332 hsa240555 hsa244932 hsa244992 hs83x6c4 hsa230645hsa234238 hsa239333 hsa240556 hsa244933 hsa244993 hs83x6c5 hsa230646hsa234239 hsa239334 hsa240557 hsa244934 hsa244994 hs83x6d4 hsa230647hsa234242 hsa239335 hsa240558 hsa244935 hsa244995 hs83x6f1 hsa230648hsa234245 hsa239336 hsa240559 hsa244936 hsa244996 hs83x6f2 hsa230649hsa234248 hsa239337 hsa240560 hsa244937 hsa244997 hs83x6f3 hsa230650hsa234249 hsa239338 hsa240561 hsa244938 hsa244998 hs83x6f5 hsa230651hsa234251 hsa239339 hsa240562 hsa244939 hsa244999 hs83x6h3 hsa230652hsa234252 hsa239340 hsa240563 hsa244940 hsa245000 hs83x9a6 hsa230653hsa234255 hsa239341 hsa240564 hsa244941 hsa245001 hs83x9b6 hsa230654hsa234256 hsa239342 hsa240565 hsa244942 hsa245002 hs83x9b9 hsa230655hsa234257 hsa239343 hsa240566 hsa244943 hsa245003 hs83x9c8 hsa230656hsa234258 hsa239344 hsa240567 hsa244944 hsa245004 hs83x9d6 hsa230657hsa234259 hsa239345 hsa240568 hsa244945 hsa245005 hs83x9d7 hsa230658hsa234260 hsa239346 hsa240569 hsa244946 hsa245006 hs83x9e6 hsa234156hsa234262 hsa239347 hsa240570 hsa244947 hsa245007 hs83x9e8 hsa234158hsa234263 hsa239348 hsa240571 hsa244948 hsa245008 hs83x9e9 hsa234160hsa234264 hsa239349 hsa240572 hsa244949 hsa245009 hs83x9f6 hsa234161hsa234266 hsa239350 hsa240573 hsa244950 hsa245010 hs83x9g6 hsa234163hsa234268 hsa239351 hsa240575 hsa244951 hsa245011 hs9d4x10 hsa234164hsa234269 hsa239353 hsa240576 hsa244952 hsa245012 hs9d4x7 hsa234166hsa234270 hsa239354 hsa240578 hsa244953 hsa245013 hs9d4x8 hsa234168hsa234272 hsa239355 hsa240580 hsa244954 hsa245014 hs9d4x9 hsa234169hsa234273 hsa239356 hsa240581 hsa244955 hsa245015 hs9d4xa6 hsa234171hsa234274 hsa239357 hsa240582 hsa244956 hsa245016 hs9d4xa7 hsa234172hsa234276 hsa239358 hsa240585 hsa244957 hsa245017 hs9d4xb6 hsa234175hsa234277 hsa239359 hsa240586 hsa244958 hsa245018 hs9d4xc2 hsa234178hsa234279 hsa239360 hsa240588 hsa244959 hsa245019 hs9d4xd6 hsa234180hsa234281 hsa239361 hsa240589 hsa244960 hsa245020 hs9d4xe6 hsa234181hsa234282 hsa239362 hsa240590 hsa244961 hsa245021 hs9d4xf3 hsa234183hsa234283 hsa239363 hsa240592 hsa244962 hsa245022 hs9d4xh4 hsa234184hsa234284 hsa239364 hsa240593 hsa244963 hsa245023 hs9d4xh5 hsa234186hsa234286 hsa239365 hsa240594 hsa244965 hsa245024 hsa005975 hsa234187hsa234287 hsa239366 hsa240595 hsa244966 hsa245025 hsa005977 hsa234189hsa234288 hsa239367 hsa240599 hsa244967 hsa245026 hsa006161 hsa234190hsa234290 hsa239368 hsa240604 hsa244968 hsa245027 hsa006165 hsa234191hsa234291 hsa239369 hsa241344 hsa244969 hsa245028 hsa245029 hsa245225hsa245319 hsa279536 hsasighc hsb8g3g01 hsfs11hc hsa245030 hsa245226hsa245320 hsa279537 hsavh510 hsb8g3g03 hsfs9whc hsa245031 hsa245228hsa245321 hsa279543 hsavh512 hsb8g3g05 hsgad2h hsa245032 hsa245229hsa245322 hsa279544 hsavh513 hsb8g3g10 hsgvh0117 hsa245033 hsa245230hsa245323 hsa279545 hsavh514 hsb8g3h01 hsgvh0118 hsa245034 hsa245231hsa245325 hsa279552 hsavh515 hsb8g4c02 hsgvh0119 hsa245035 hsa245232hsa245326 hsa389169 hsavh516 hsb8g4e01 hsgvh0120 hsa245036 hsa245233hsa245338 hsa389170 hsavh517 hsb8g4e05 hsgvh0121 hsa245037 hsa245234hsa245342 hsa389171 hsavh519 hsb8g4f11 hsgvh0122 hsa245039 hsa245235hsa245343 hsa389172 hsavh520 hsb8g4h09 hsgvh0123 hsa245040 hsa245236hsa245345 hsa389173 hsavh523 hsb8g4h10 hsgvh0124 hsa245041 hsa245237hsa245346 hsa389174 hsavh524 hsb8g5d10 hsgvh0201 hsa245042 hsa245238hsa245347 hsa389175 hsavh526 hsb8g5h08 hsgvh0202 hsa245043 hsa245239hsa245348 hsa389176 hsavh529 hsbel1 hsgvh0203 hsa245044 hsa245240hsa245349 hsa389177 hsavh53 hsbel14 hsgvh0204 hsa245045 hsa245241hsa245350 hsa389178 hsavh56 hsbel28 hsgvh0205 hsa245046 hsa245246hsa245352 hsa389179 hsb3g4a07 hsbel29 hsgvh0206 hsa245047 hsa245251hsa245353 hsa389180 hsb73g04n hsbel3 hsgvh0207 hsa245048 hsa245255hsa245355 hsa389181 hsb74a08n hsbel34 hsgvh0208 hsa245049 hsa245258hsa245356 hsa389182 hsb7g1a11 hsbel43 hsgvh0209 hsa245050 hsa245260hsa245357 hsa389183 hsb7g2b01 hsbel45 hsgvh0210 hsa245051 hsa245261hsa245358 hsa389184 hsb7g3a01 hsbel5 hsgvh0211 hsa245052 hsa245262hsa245359 hsa389185 hsb7g3a05 hsbel54 hsgvh0213 hsa245053 hsa245263hsa249378 hsa389186 hsb7g3a10 hsbel69 hsgvh0214 hsa245054 hsa245265hsa249628 hsa389187 hsb7g3b02 hsbo1vhig hsgvh0215 hsa245055 hsa245266hsa249629 hsa389188 hsb7g3b03 hsbo3vhig hsgvh0216 hsa245056 hsa245268hsa249630 hsa389190 hsb7g3b05 hsbr1vhig hsgvh0217 hsa245057 hsa245272hsa249631 hsa389191 hsb7g3c03 hsbradh3 hsgvh0218 hsa245058 hsa245273hsa249632 hsa389192 hsb7g3c12 hscal4ghc hsgvh0219 hsa245059 hsa245275hsa249633 hsa389193 hsb7g3d07 hsd4xd10 hsgvh0220 hsa245060 hsa245277hsa249634 hsa389194 hsb7g3e01 hsd4xf21 hsgvh0221 hsa245061 hsa245278hsa249635 hsa389195 hsb7g3f02 hsd4xg2 hsgvh0222 hsa245062 hsa245279hsa249636 hsa389927 hsb7g3f10 hsd4xi10 hsgvh0223 hsa245063 hsa245280hsa249637 hsa389929 hsb7g3g02 hsd4xi4 hsgvh0224 hsa245064 hsa245281hsa271600 hsa6351 hsb7g3g04 hsd4xk9 hsgvh0302 hsa245065 hsa245282hsa271601 hsa7321 hsb7g4a08 hsd4xl3 hsgvh0304 hsa245066 hsa245283hsa271602 hsa7322 hsb7g4c05 hsd5hc hsgvh0306 hsa245067 hsa245284hsa271603 hsa7323 hsb7g4d09 hsdo1vhig hsgvh0307 hsa245068 hsa245285hsa271604 hsa7325 hsb7g4f08 hseliepa1 hsgvh0308 hsa245069 hsa245286hsa279513 hsa7326 hsb7g4g07 hseliepa3 hsgvh0309 hsa245071 hsa245287hsa279514 hsa7328 hsb7g5g03 hseliepa4 hsgvh0310 hsa245072 hsa245288hsa279515 hsa7438 hsb8g1c04 hseliepb2 hsgvh0311 hsa245073 hsa245289hsa279516 hsa7440 hsb8g1e04 hseliepd2 hsgvh0312 hsa245201 hsa245290hsa279517 hsa7441 hsb8g1f03 hselilpb1 hsgvh0314 hsa245203 hsa245291hsa279519 hsa7442 hsb8g1g04 hsevh51a1 hsgvh0315 hsa245204 hsa245292hsa279520 hsa7443 hsb8g1h02 hsevh51b1 hsgvh0318 hsa245208 hsa245294hsa279521 hsa7444 hsb8g2f09 hsevh52a1 hsgvh0320 hsa245209 hsa245298hsa279522 hsaarma1 hsb8g2g08 hsevh52a2 hsgvh0321 hsa245210 hsa245299hsa279523 hsabhiv8 hsb8g3b07 hsevh52a3 hsgvh0322 hsa245214 hsa245301hsa279524 hsadeigvh hsb8g3c07 hsevh52a4 hsgvh0323 hsa245215 hsa245305hsa279526 hsaj2768 hsb8g3c08 hsevh52a5 hsgvh0324 hsa245217 hsa245307hsa279527 hsaj2769 hsb8g3c12 hsevh52b1 hsgvh0325 hsa245218 hsa245309hsa279528 hsaj2771 hsb8g3d03 hsevh53a1 hsgvh0326 hsa245219 hsa245311hsa279529 hsaj2772 hsb8g3d04 hsevh53a2 hsgvh0327 hsa245220 hsa245312hsa279530 hsaj2773 hsb8g3d07 hsfog1h hsgvh0328 hsa245221 hsa245313hsa279531 hsaj2776 hsb8g3d08 hsfog3h hsgvh0329 hsa245222 hsa245315hsa279532 hsaj2777 hsb8g3e02 hsfogbh hsgvh0330 hsa245223 hsa245317hsa279533 hsaj4083 hsb8g3e03 hsfom1h hsgvh0331 hsa245224 hsa245318hsa279535 hsaj4899 hsb8g3f03 hsfs10hc hsgvh0332 hsgvh0333 hsigathchsighxx10 hsigvhc26 hsld1117 hsmvh51 hst14x23 hsgvh0334 hsigdvrhchsighxx11 hsigvhc27 hsld152 hsmvh510 hst14x24 hsgvh0335 hsigg1khhsighxx12 hsigvhc28 hsld21 hsmvh511 hst14x25 hsgvh0336 hsigg1klhsighxx14 hsigvhc29 hsld217 hsmvh512 hst14x3 hsgvh0419 hsigg1lhhsighxx16 hsigvhc30 hsld218 hsmvh515 hst14x6 hsgvh0420 hsigghc85hsighxx18 hsigvhc31 hsld25 hsmvh516 hst14x7 hsgvh0421 hsigghcv3 hsighxx2hsigvhc32 hsmad2h hsmvh517 hst14x8 hsgvh0422 hsigghevr hsighxx20hsigvhc33 hsmbcl5h4 hsmvh53 hst14x9 hsgvh0423 hsiggvdj1 hsighxx21hsigvhc35 hsmica1h hsmvh54 hst22x1 hsgvh0424 hsiggvdj2 hsighxx22hsigvhc36 hsmica3h hsmvh55 hst22x11 hsgvh0428 hsiggvhb hsighxx23hsigvhc37 hsmica4h hsmvh56 hst22x12 hsgvh0429 hsiggvhc hsighxx25hsigvhc38 hsmica5h hsmvh57 hst22x13 hsgvh0430 hsigh10g1 hsighxx26hsigvhc39 hsmica6h hsmvh58 hst22x14 hsgvh0517 hsigh10g2 hsighxx28hsigvhc40 hsmica7h hsmvh59 hst22x15 hsgvh0519 hsigh10g3 hsighxx29hsigvhc41 hsmt11ige hsnamembo hst22x18 hsgvh0522 hsigh10g4 hsighxx3hsigvhc42 hsmt12ige hsnpb346e hst22x20 hsgvh0523 hsigh10g5 hsighxx30hsigvhc43 hsmt13ige hsoak3h hst22x21 hsgvh0526 hsigh10g7 hsighxx31hsigvhls hsmt14ige hsog31h hst22x22 hsgvh0527 hsigh10g8 hsighxx32hsigvhttd hsmt15ige hspag1h hst22x23 hsgvh0531 hsigh10g9 hsighxx34hsigvp151 hsmt16ige hsrael hst22x25 hsgvh511 hsigh13g1 hsighxx36hsigvp152 hsmt17ige hsregah hst22x26 hsgvh512 hsigh13g7 hsighxx37hsigvp153 hsmt21ige hsrfabh37 hst22x27 hsgvh513 hsigh14g1 hsighxx38hsigvp154 hsmt22ige hsrighvja hst22x28 hsgvh515 hsigh14g2 hsighxx5hsigvp155 hsmt23ige hsrighvjb hst22x30 hsgvh519 hsigh2f2 hsighxx6hsigvp156 hsmt24ige hsrou10 hst22x9 hsgvh521 hsigh3135 hsighxx7hsigvp157 hsmt25ige hsrou11 hsu24687 hsgvh526 hsigh35 hsighxx8 hsigvp158hsmt26ige hsrou111 hsu24688 hsgvh530 hsigh44 hsighxx9 hsigvp251hsmt27ige hsrou112 hsu24690 hsgvh533 hsigh4c2 hsigkrf hsigvp255hsmutuiem hsrou119 hsu24691 hsgvh534 hsigh9e1 hsigmhavh hsigvp256hsmvh0001 hsrou122 hsv52a512 hsgvh535 hsighadi2 hsigrhe15 hsigvp257hsmvh0002 hsrou126 hsvdj10h hsgvh536 hsighadi3 hsigtgk1h hsigvp360hsmvh0003 hsrou127 hsvdj12h hsgvh55 hsighcvr hsigtgk4h hsigvp363hsmvh0004 hsrou129 hsvgcg1 hsh217e hsighcza hsigtgl9h hsigvp369hsmvh0005 hsrou13 hsvgcm1 hsh241e hsighczb hsigvarh1 hsigvp39 hsmvh0006hsrou131 hsvgcm1 hsh28e hsighczc hsigvhc hsihr8 hsmvh0007 hsrou18hsvh1djh6 hsha3d1ig hsighczd hsigvhc01 hsihr9 hsmvh0009 hsrou219hsvh3djh4 hshambh hsighczf hsigvhc02 hsihv1 hsmvh0010 hsrou221 hsvh4djhshcmg42 hsighczg hsigvhc03 hsihv11 hsmvh0011 hsrou222 hsvh4djh6hshcmg43 hsigheavy hsigvhc04 hsihv18 hsmvh0012 hsrou233 hsvh4r hshcmg44hsighpat2 hsigvhc05 hsim9vch hsmvh0401 hsrt792hc hsvh52a43 hshcmg46hsighpat3 hsigvhc06 hsimghc1 hsmvh0403 hsrt79hc hsvh52a55 hshcmt42hsighpat4 hsigvhc07 hsimghc2 hsmvh0404 hssm1vhig hsvh5dj hshcmt47hsighpat5 hsigvhc08 hsimghc3 hsmvh0405 hssp46a hsvh5djh5 hsig001vhhsighpat6 hsigvhc09 hsimghc4 hsmvh0406 hst14vh hsvh710p1 hsig030vhhsighpat7 hsigvhc10 hsimghc5 hsmvh0501 hst14x1 hsvheg7 hsig033vhhsighpat8 hsigvhc11 hsin42p5 hsmvh0502 hst14x10 hsvhfa2 hsig039vhhsighpat9 hsigvhc12 hsin51p7 hsmvh0503 hst14x11 hsvhfa7 hsig040vhhsighpt11 hsigvhc14 hsin51p8 hsmvh0504 hst14x12 hsvhfb5 hsig055vhhsighpt12 hsigvhc16 hsin78 hsmvh0505 hst14x13 hsvhfc2 hsig057vhhsighpta1 hsigvhc17 hsin87 hsmvh0506 hst14x14 hsvhfd7 hsig1059 hsighvb5hsigvhc18 hsin89p2 hsmvh0507 hst14x15 hsvhfe5 hsig10610 hsighvcahsigvhc19 hsin92 hsmvh0508 hst14x16 hsvhfg9 hsig13g10 hsighvcb hsigvhc20hsin98p1 hsmvh0509 hst14x17 hsvhgd8 hsig473 hsighvcc hsigvhc21 hsjac10hhsmvh0510 hst14x18 hsvhgd9 hsig7sa11 hsighvcd hsigvhc22 hsjhba1fhsmvh0511 hst14x19 hsvhgh7 hsigaehc hsighvce hsigvhc23 hsjhbr2fhsmvh0513 hst14x20 hsvhha10 hsigaf2h2 hsighvm hsigvhc24 hsjhej1fhsmvh0515 hst14x21 hsvhia2 hsigashc hsighxx1 hsigvhc25 hsld1110hsmvh0529 hst14x22 hsvhia5 hsvhib12 hsvhp46 hsx98948 hsz74671 hsz80393hsz80438 hsz80489 hsvhib6 hsvhp48 hsx98950 hsz74672 hsz80394 hsz80439hsz80492 hsvhib8 hsvhp53 hsx98951 hsz74682 hsz80397 hsz80441 hsz80495hsvhic1 hsvhp7 hsx98952 hsz74688 hsz80400 hsz80442 hsz80496 hsvhic10hsvigd9 hsx98953 hsz74690 hsz80403 hsz80443 hsz80499 hsvhic11 hswad35vhhsx98954 hsz74693 hsz80406 hsz80445 hsz80500 hsvhic2 hswanembo hsx98955hsz74695 hsz80407 hsz80458 hsz80502 hsvhic3 hswo1vhig hsx98956 hsz80363hsz80409 hsz80459 hsz80504 hsvhid1 hsww1p10e hsx98958 hsz80364 hsz80411hsz80460 hsz80507 hsvhid5 hsx98932 hsx98963 hsz80365 hsz80412 hsz80461hsz80509 hsvhid7 hsx98933 hsy14934 hsz80367 hsz80414 hsz80462 hsz80512hsvhid9 hsx98934 hsy14935 hsz80368 hsz80415 hsz80463 hsz80513 hsvhie4hsx98935 hsy14936 hsz80372 hsz80416 hsz80465 hsz80517 hsvhif10 hsx98936hsy14937 hsz80375 hsz80417 hsz80466 hsz80519 hsvhif3 hsx98938 hsy14938hsz80377 hsz80418 hsz80473 hsz80520 hsvhif7 hsx98939 hsy14939 hsz80378hsz80421 hsz80474 hsz80527 hsvhig2 hsx98940 hsy14940 hsz80383 hsz80422hsz80475 hsz80534 hsvhp2 hsx98941 hsy14943 hsz80385 hsz80424 hsz80476hsz80538 hsvhp29 hsx98943 hsy14945 hsz80386 hsz80426 hsz80477 hsz80544hsvhp30 hsx98944 hsy18120 hsz80388 hsz80427 hsz80480 hsz80545 hsvhp32hsx98945 hsz74663 hsz80390 hsz80429 hsz80482 hsvhp34 hsx98946 hsz74665hsz80391 hsz80433 hsz80483 hsvhp4 hsx98947 hsz74668 hsz80392 hsz80436hsz80487

TABLE 20P Human GLG CDR1 & CDR2 AA seqs CDR2 CDR1          1    1   1Name 1234567 1234567890123456789 1-02 GYY--MH WINPNSGG--TNYAQKFQG 1-03SYA--MH WINAGNGN--TKYSQKFQG 1-08 SYD--IN WMNPNSGN--TGYAQKFQG 1-18SYG--IS WISAYNGN--TNYAQKLQG 1-24 ELS--MH GFDPEDGE--TIYAQKFQG 1-45YRY--LH WITPFNGN--TNYAQKFQD 1-46 SYY--MH IINPSGGS--TSYAQKFQG 1-58SSA--VQ WIVVGSGN--TNYAQKFQE 1-69 SYA--IS GIIPIFGT--ANYAQKFQG 1-e SYA--ISGIIPIFGT--ANYAQKFQG 1-f DYY--MH LVDPEDGE--TIYAEKFQG 2-05 TSGVGVGLIYWNDDK---RYSPSLKS 2-26 NARMGVS HIFSNDEK---SYSTSLKS 2-70 TSGMRVSRIDWDDDK---FYSTSLKT 3-07 SYW--MS NIKQDGSE--KYYVDSVKG 3-09 DYA--MHGISWNSGS--IGYADSVKG 3-11 DYY--MS YISSSGST--IYYADSVKG 3-13 SYD--MHAIGTAGD---TYYPGSVKG 3-15 NAW--MS RIKSKIDGGTIDYAAPVKG 3-20 DYG--MSGINWNGGS--TGYADSVKG 3-21 SYS--MN SISSSSSY--IYYADSVKG 3-23 SYA--MSAISGSGGS--TYYADSVKG 3-30 SYG--MH VISYDGSN--KYYADSVKG 3303 SYA--MHVISYDGSN--KYYADSVKG 3305 SYG--MH VISYDGSN--KYYADSVKG 3-33 SYG--MHVIWYDGSN--KYYADSVKG 3-43 DYT--MH LISWDGGS--TYYADSVKG 3-48 SYS--MNYISSSSST--IYYADSVKG 3-49 DYA--MS FIRSKAYGGTTEYTASVKG 3-53 SNY--MSVIYSGGS---TYYADSVKG 3-64 SYA--MH AISSNGGS--TYYANSVKG 3-66 SNY--MSVIYSGGS---TYYADSVKG 3-72 DHY--MD RTRNKANSYTTEYAASVKG 3-73 GSA--MHRIRSKANSYATAYAASVKG 3-74 SYW--MH RINSDGSS--TSYADSVKG 3-d SNE--MSSISGGS----TYYADSRKG 4-04 SSNW-WS EIYHSGS---TNYNPSLKS 4-28 SSNW-WGYIYYSGS---TYYNPSLKS 4301 SGGYYWS YIYYSGS---TYYNPSLKS 4302 SGGYSWSYIYHSGS---TYYNPSLKS 4304 SGDYYWS YIYYSGS---TYYNPSLKS 4-31 SGGYYWSYIYYSGS---TYYNPSLKS 4-34 GYY--WS EINHSGS---TNYNPSLKS 4-39 SSSYYWGSIYYSGS---TYYNPSLKS 4-59 SYY--WS YIYYSGS---TNYNPSLKS 4-61 SGSYYWSYIYYSGS---TNYNPSLKS 4-b SGYY-WG SIYHSGS---TYYNPSLKS 5-51 SYW--IGIIYPGDSD--TRYSPSFQG 5-a SYW--IS RIDPSDSY--TNYSPSFQG 6-1 SNSAAWNRTYYRSKWY-NDYAVSVKS 74.1 SYA--MN WINTNTGN--PTYAQGFTG CDR1 of human GLGsA C D E F G H I K L M N P Q R S T V W Y - Consens. 1 7 1 3 2 35 2 1 Sd x2 2 6 1 1 4 1 7 29 Ysg x 3 11 3 1 10 2 1 6 1 5 11 YAGS x 4 1 2 1 3 738 - 5 1 2 1 1 5 41 - 6 6 1 28 4 12 Mwi 7 1 5 16 5 1 23 SHngCDR2 of human GLGs A C D E F G H I K L M N P Q R S T V W Y - Consens. 13 2 1 5 1 2 3 1 7 4 6 7 8 X 2 1 46 1 2 1 I 3 4 1 1 2 2 8 3 12 1 1 1 15ysn x 4 2 2 4 1 10 1 11 2 1 5 12 ysp x 5 1 8 2 1 6 2 4 8 1 17 1 sd x 6 37 2 26 3 8 2 Gsd x 7 4 1 17 1 2 24 1 1 SG x 8 1 3 3 3 10 9 4 1 1 2 15-ns 9 2 3 46 - 10 1 3 47 - 11 2 4 5 1 1 35 3 T 12 1 2 2 1 3 2 1 11 2 3 122 Yn x 13 51 Y 14 31 11 1 6 1 1 An x 15 4 16 1 1 1 14 11 2 1 dpq x 16 111 1 38 Sk 17 13 15 1 22 Vlf 18 37 13 1 Kq 19 1 1 34 14 1 GS

TABLE 21P Tallies of Amino-acid frequencies in mature CDR1 and CDR2 A CD E F G H I K L M N P Q R S T V W Y | X Tally of 23 examples with length14 1 8 2 13 2 3 15 3 2 3 2 1 14 1 5 4 2 2 11 5 3 5 7 1 1 13 1 6 1 4 3 122 1 7 3 1 1 2 1 5 10 8 6 1 1 2 1 6 4 2 9 1 5 1 3 1 4 7 1 10 1 8 3 1 2 14 1 2 11 1 1 1 1 2 1 16 12 1 2 1 1 1 1 1 1 14 13 4 2 17 14 4 1 5 5 4Tally of 11 examples with length 12 1 4 7 2 1 4 4 2 3 7 4 4 1 1 1 5 2 15 1 9 1 6 2 1 3 2 3 7 3 1 3 1 3 8 1 3 2 1 2 2 9 1 1 9 10 1 10 11 11 12 21 7 1 Tally of 175 examples with length 7 1 2 1 1 2 1 3 2 153 10 2 3 2 187 1 10 1 5 61 2 2 3 3 26 1 54 1 5 1 2 76 3 1 2 4 6 1 1 6 1 2 1 11 1 1455 5 2 13 2 2 3 6 2 140 6 1 1 1 13 159 7 2 1 67 1 10 88 5 1 Tally of 38examples with length 6 1 2 34 2 2 1 2 1 8 4 22 3 3 26 9 4 1 1 29 7 5 386 10 3 22 3 Tally of 820 examples with length 5 A C D E F G H I K L M NP Q R S T V W Y Seen 1 8 81 10 151 4 8 5 3 100 4 15 364 55 8  4 SGNDT 15x 2 7 5 12 24 1 30 1 1 5 26 1 1 23 2 681 Y 15 3 202 4 24 13 13 133 10 27 5 2 3 32 14 13 112 231 YAGW 17 x 4 6 172 2 7 409 3 16 205 MWI 8 5 8 61 1 49 241 2 79 1 3 367 56 2  4 SHNT 14 x CDR2 A C D E F G H I K L M NTally of 31 examples with CDR2 of length 19  1 11  1  1  2  1 28  3  9 1  4  1  2  6  5 1 1  1  22 1  6  16 1  1 1  1  7  1 9  7  8  23  1  9 2  18 10  4  1 1  1  1 11  1 3  1 12  2 11 9  1 1  1  1 13 1  1 14  2915  25 3 1 16  1 17  1 1 18 1  27 19 1  30 Tally of 579 (n > 50, bold;over 400, underscored) examples with length 17  1  44 1 1 2 11  81 5  69 1  14 6  41  2 7 522  1  10 17  1  3  3 1 22 5  7 6  51  25  1  76  4 39 2 8 6 16  64 9  3  2  3  15  5  3 194 6 1  70 6  44  6  4 1  55  6 3 1 75 4 45 326 1  6  43  7  8 24 5 226 3  3  3  4  24  8  4 2 57 37 5 22 4  18  18  2 2 161  9  56 11  2  63 157  1 3  3 10  1 14 2 13  30 23 6  29  2 3 110 11 1 2 7 5  1  4  3 12 405 2  18  1  6  2 13  7 323 22 7 4  1  4 14  2 5 6  3 123 1  4 15  1 1 188  2  1  22 3 16  1 13  1 1332  3 2  1 17 11 1 565 Tally of 464 (over 50, bold; over 400,underscored)  1  5 13 184 8  1 7  1  2  15  6  2 6 429  3 4  3 1 13 13 4 10  5 154  4  1 12 2 6 199  2  1  3  5  5 20 1 1  18  4  9  6 13 8439  1  7 20 2  14 2  4  2  26  8  13  2  4  8  1 2  9 10 4  1 10  1  8 1 245 10 6 2 2  2 11  14 3 1  1  8 408 12  4 13  4  2  1 13  2 2 14  2 2 441 15 18 413 3  5 16  1 1  31  2  2 P Q R S T V W Y X Tally of 31examples with CDR2 of length 19  1 1 15  1  1 RF x  2  2 I  3 18  1  1 1 Rk  4  21  1 S  5 1 1  1  1  1 K x  6  3  1  6 1 A x  7  3  1  10 y x 8 1  5  1 G  9 1  1 1  7 1 G 10  1  21  1 T 11  26 T 12  2  1  2 x 13 29 Y 14  1  1 A 15 1  1 A 16  10  20 Sp 17 29 V 18 1 2 K 19 G Tally of579 (n > 50, bold; over 400, underscored) examples with length 17  1 1 434  30  19 118 66  31 VGIW x  2  3  8 10 I  3 8 262  19 1 46  46 SNI x 4 178 23 6  50  11 8 16 120 PYG x  5 4 8 133  9 7 1  27 DSGN x  6 1  63 8 1  2 GDS x  7 2 11 245  14 6  1 SG x  8  1 4 11 106  90 2 1  32 NST X 9  11 5 13  4 242 8 TKIA x 10  3 52  20  10 1 1 259 YNR x 11  5 551 Y12  3 1  89  8 44 A 13  66 138 3 1  3 DQP x 14 2 7 421  1 2  2 SK x 15 1 357  2 1 VF 16  1 199 21  4 KQ x 17  1 1 G Tally of 464 (over 50,bold; over 400, underscored)  1 3 26  65  9 14 105 EYSL x  2  1  2 19 I 3 1  12  1 250 YN x  4  4 5 2  19  28 15 165 YH x  5  1 22 365  16 1  1S x  6  1 1 1 G  7  1 12 357  20 1  2 1 S x  8  4 3  6 420 1 T  9 13  9 3 1 1 157 NY x 10 1  7 444 Y 11  4  21  2  2 N 12 418  14  7 1 P 13  6452  1  1 S 14 1 18 L 15 11 10  1  2 1 K 16 3 419  5 S

TABLE 22P Tally of VH types 1-02 16 1-03 16 1-08 13 1-18 27 1-24 5 1-450 1-46 14 1-58 1 1-69 37 1-e 16 1-f 1 2-05 13 2-26 1 2-70 2 3-07 33 3-0913 3-11 15 3-13 4 3-15 10 3-20 4 3-21 25 3-23 85 3-30 55 3303 59 3305 03-33 42 3-43 1 3-48 24 3-49 11 3-53 12 3-64 4 3-66 4 3-72 3 3-73 3 3-7412 3-d 0 4-04 29 4-28 3 4301 46 4302 7 4304 37 4-31 0 4-34 184 4-39 654-59 45 4-61 9 4-b 11 5-51 55 5-a 13 6-1 7 74.1 3

TABLE 23P Oligonucleotides used to variegate CDR1 and CDR2 of human HC(name) 5′-....DNA sequence....-3′everything to right of an exclamation point is commentary [RC]means “reverse complement” of sequence shownIf last non-comment and non-blank character is “-”, then continueon next line. Ignore case, “a” = “A”, “c” = “C”, etc. Ignore “|”and blanks. <number>means incorporate trinucleotide mixtue of given number. CDR1 (ON-R1V1vg)5′-ct|TCC|GGA|ttc|act|ttc|tct|- <1>|tac|<1>|atg|<1>|-!CDR1 of length 5, ON = 55 bases tgg|gtt|cgC|CAa|gct|ccT|GG-3′ <1> =ADEFGHIKLMNPQRSTVWY no C (ON-R1top)5′-cctactgtct |TCC|GGA|ttc|act|ttc|tct-3′ (ON-R1bot) [RC]5′-tgg|gtt|cgC|CAa|gct|ccT|GG ttgctcactc-3′ (ON-R1V2vg)5′-ct|TCC|GGA|ttc|act|ttc|tct|- <6>|<7>|<7>|tac|tac|tgg|<7>|-!CDR1 of length 7, ON = 61 bases tgg|gtt|cgC|CAa|gct|ccT|GG-3′ <6> =ST, 1:1 <7> = 0.2025(SG) + 0.035(ADEFHIKLMNPQRTVWY) no C (ON-R1V3vg)5′-ct|TCC|GGA|ttc|act|ttc|tct|-|atc|agc|ggt|ggt|tct|atc|tcc|<1>|<1>|<1>|tac|tac|tgg|<1>|-! CDR1, L = 14tgg|gtt|cgC|CAa|gct|ccT|GG-3′ ! ON = 82 bases CDR2 (ON-R2V1vg)5′-ggt|ttg|gag|tgg|gtt|tct|- <2>|atc|<2>|<3>|tct|ggt|ggc|<1>|act|<1>|-tat|gct|gac|tcc|gtt|aaa|gg-3′ ! ON = 68 bases, CDR2 = 17 AA (ON-R2top)5′-ct|tgg|gtt|cgC|CAa|gct|ccT|GGt|aaa|ggt|ttg|gag|tgg|gtt|tct-3′(ON-R2bot) [RC] 5′-tat|gct|gac|tcc|gtt|aaa|ggt|-cgc|ttc|act|atc|TCT|AGA|ttcctgtcac-3′ ! XbaI plus 10 bases of scab(ON-R2V2vg) 5′-ggt|ttg|gag|tgg|gtt|tct|-<1>|atc|<4>|<1>|<1>|ggt|<5>|<1>|<1>|<1>|- tat|gct|gac|tcc|gtt|aaa|gg-3′! ON = 68 bases, CDR2 = 17 AA <4> = DINSWY, equimolar <5> =SGDN, equimolar (ON-R2V3vg) 5′-ggt|ttg|gag|tgg|gtt|tct|-<1>|atc|<4>|<1>|<1>|ggt|<5>|<1>|<1>|- tat|aac|cct|tcc|ctt|aag|gg-3′ !ON = 65 bases, CDR2 = 16 AA (ON-R2bo3) [RC]5′-tat|aac|cct|tcc|ctt|aag|ggt|- cgc|ttc|act|atc|TCT|AGA|ttcctgtcac-3′ !XbaI plus 10 bases of scab (ON-R2V4vg) 5′-ggt|ttg|gag|tgg|gtt|tct|-<1>|atc|<8>|agt|<1>|<1>|<1>|ggt|ggt|act|act|<1>tat|gcc|gct|tcc|gtt|aag|gg-3′ ! ON = 74 bases, CDR2 = 19 AA (ON-R2bo4)[RC] 5′-tat|gcc|gct|tcc|gtt|aag|ggt|-cgc|ttc|act|atc|TCT|AGA|ttcctgtcac-3′ ! XbaI plus 10 bases of scab

TABLE 25P Lengths of CDRs in 285 human kappa chains 0 1 2 3 4 5 6 7 8 910 11 12 13 14 15 16 17 18 19 CDR1 0 0 0 0 0 0 0 0 0 0 0 154 73 3 0 0 2827 0 0 CDR2 0 0 0 0 0 0 0 285 0 0 0 0 0 0 0 0 0 0 0 0 CDR3 0 5 0 0 1 0 32 28 166 63 12 1 1 0 0 0 0 0 1

TABLE 26P Tally of kappa types: V and J V genes: O12 59 O2 0 O18 0 O8 0A20 0 A30 0 L14 0 L1 2 L15 0 L4 2 L18 0 L5 4 L19 0 L8 4 L23 0 L9 1 L24 0L11 4 L12 8 O11 10 O1 0 A17 5 A1 0 A18 3 A2 0 A19 13 A3 0 A23 4 A27 79A11 26 L2 28 L16 0 L6 11 L20 0 L25 0 B3 22 B2 0 A26 0 A10 0 A14 0 JH# 1 2 3  4 5 tally 105 64 29 78 9

TABLE 27P Names of Kappa chains analyzed AB022651 hsew1vk hsigklv39hsikcvjp6 humigky5 AB022653 hsew3vk hsigklv40 hsikcvjp7 humigky6AB022654 hsew4vk hsigklv41 hsld110vl humigl3ac AB022656 hsigdpk13hsigklv42 hsld117vl humikc AF007572 hsigg1kl hsigklv43 hsld128vl humikcaAF021036 HSIGGVKA hsigklv44 hsld140vl humikcad AF103499 hsigk123hsigklv45 hsld152vl humikcaf AF103500 hsigk319 hsigklv46 hsld184vlhumikcag AF103527 hsigklc14 hsigklv49 hsld198vl humikcah AF103873hsigklc28 hsigklv50 hsld24vl humikcai AF107244 hsigklc5 hsigklv51hsmbcl1k1 humikcaj AF107245 hsigklg31 hsigklv52 hsmbcl1k2 humikcalAF107246 hsigklv01 hsigklv53 hsmbcl2k2 humikcam AF107247 hsigklv02hsigklv54a hsmbcl5k4 humikcan AF115361 hsigklv03 hsigklv56 hss10avlhumikcas AF165099 hsigklv04 hsigklv57 hss17bvl humikcau AF165101hsigklv05 hsigklv58 hss1a15vl humikcav AF165103 hsigklv06 hsigklv59HSU44792 humikcaw AF165108 hsigklv07 hsigklv60 HSU44794 humikcaxAF165110 hsigklv09 hsigklv61 HSU94422 humikcay AF165111 hsigklv10hsigklv62 hsz84852 humikcaz AF184763 hsigklv12 hsigklv63 hsz84853humikcb AF184767 hsigklv13 hsigklv65 humigk1dm humikcba hsa004955hsigklv14 hsigklv66 humigk3am humikcbb hsa004956 hsigklv15 hsigklv68humigk3bm humikcbc hsa011133 hsigklv16 hsigklv69 humigk3cm humikcbdHSA241367 hsigklv17 hsigklv71 humigkacoa humikcbe HSA241375 hsigklv18hsigkvba humigkacob humikcbf HSA388639 hsigklv19 hsigkvbb humigkacochumikcbg HSA388640 hsigklv20 hsigkvbc humigkacoe humikcbh HSA388641hsigklv21 hsigkvbd humigkacof humikcbi HSA388642 hsigklv22 hsigkvbehumigkb1aa humikcbj HSA388643 hsigklv23 hsigkvbf humigkb1ab humikcblHSA388644 hsigklv24 hsigkvc01 humigkb1ac humikcbm HSA388645 hsigklv25hsigkvc03 humigkvra humikcbn HSA388646 hsigklv27 hsigkvc06 humigkvrbhumikcbo HSA388647 hsigklv28 hsigkvc11 humigkvrc humikcbp HSA388648hsigklv29 hsigkvc12 humigkvrd humikcbq HSA388650 hsigklv31 hsigkvc20humigkvre humikcbs HSA388651 hsigklv32 hsigkvc23 humigkvrg humikcbtHSA388652 hsigklv33 hsigkvc27 humigkvrh humikcbu HSA388653 hsigklv34hsigkvc29 humigkvri humikcbv HSA388654 hsigklv35 hsigrklc humigkxhumikcbw HSA388655 hsigklv36 hsikcvjp1 humigky1 humikcbx HSA388656hsigklv37 hsikcvjp2 humigky2 humikcbz HSA388657 hsigklv38 hsikcvjp3humigky4 humikcc humikcca humikcy humikccb humikcz humikccc S46248humikccd S82746 humikcce S82747 humikccf SU96396 humikccg SU96397humikcch humikcci humikccj humikcck humikcco humikccp humikccq humikccrhumikccs humikcct humikccu humikccv humikccw humikcd humikcf humikcghumikch humikci humikck humikcm humikcn humikco humikcp humikcq humikcrhumikcs humikct humikcu humikcv humikcva humikcvb humikcvc humikcvdhumikcve humikcvf humikcvg humikcvh humikcvi humikcvj humikcw humikcx

TABLE 28P AA types seen in 154 kappa sequences having CDR1 of length 11Tally A C D E F G H I K L M N P Q R S T V W Y 1 11 143 R 2 148 1 2 2 1 A3 152 2 S 4 1 3 3 147 Q 5 12 1 27 7 3 99 4 1 S 6 1 81 1 71 V 7 2 4 18 51 2 9 12 97 3 1 S 8 3 5 1 2 1 31 1 10 87 12 1 S 9 2 7 10 1 6 29 1 8 1377 Y 10 2 150 1 1 L 11 96 4 2 46 2 1 3 A

TABLE 30P Synthetic Kappa light chain gene 1GAGGACCATt GGGCCCC  ctccgagact Scab...... EcoO109I            ApaI. 28CTCGAG    cgca XhoI.. 38acgcaatTAA TGTgagttag ctcactcatt aggcacccca ggcTTTACAc tttatgcttc       ..-35..         Plac                    ..-10. 98cggctcgtat gttgtgtgga attgtgagcg gataacaatt tc 140 acacagga aacagctatgac160 catgatta cgCCAAGCTT TGGagccttt tttttggaga ttttcaac           PflMI.......              Hind3.M13 III signal sequence (AA seq)--------------------------->  1   2   3   4   5   6   7   8   9  10  11  12  13  14  15  M   K   K   L   L   F   A   I   P   L   V   V   P   F   Y 206gtg aag aag ctc cta ttt gct atc ccg ctt gtc gtt ccg ttt tac --Signal-->FR1-------------------------------------------> 16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  S   H   S   A   Q   S   V   L   T   Q   S   P   G   T   L 251|agc|cat|aGT|GCA|Caa|tcc|gtc|ctt|act|caa|tct|cct|ggc|act|ctt|          ApaLI... ----- FR1 ------------------------------------->|CDR1------>  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  S   L   S   P   G   E   R   A   T   L   S   C   R   A   S|tcG|CTA|AGC|CCG|GGt|gaa|cgt|gct|acC|TTA|AGt|tgc|cgt|gct|tcc|   EspI.....                       AflII...            XmaI....For CDR1: <1> ADEFGHIKLMNPQRSTVWY equimolar <2>S(0.2) ADEFGHIKLMNPQRTVWY (0.044 each) <3>Y(0.2) ADEFGHIKLMNPQRSTVW (0.044 each)In a preferred embodiment, we omit codon 52 in vgDNA for CDR1.------- CDR1 --------------------->|--- FR2 ---------------->     <1>    <2> <2> xxx <3>46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Q   S   V   S   S   S   Y   L   A   W   Y   Q   Q   K   P|cag|tct|gtt|tcc|tct|tct|tat|ctt|gct|tgg|tat|caa|cag|aaA|CCT|                                                                SexAI...For CDR2: <1> ADEFGHIKLMNPQRSTVWY equimolar <2>S(0.2) ADEFGHIKLMNPQRTVWY (0.044 each) <4>A(0.2) DEFGHIKLMNPQRSTVWY (0.044 each)----- FR2 ------------------------->|------- CDR2 ---------->                                     <1>         <2>     <4> 61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  G   Q   A   P   R   L   L   I   Y   G   A   S   S   R   A|GGT|caG|GCG|CCg|cgt|tta|ctt|att|tat|ggt|gct|tct|tcc|cgc|gct|SexAI.... KasI.... (CDR1 installed as AflII-(SexAI or KasI) cassette.)CDR2-->|--- FR3 ----------------------------------------------->  <1> 76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  T   G   I   P   D   R   F   S   G   S   G   S   G   T   D|act|gGG|ATC|CCG|GAC|CGt|ttc|tct|ggc|tct|ggt|tca|ggt|act|gac|      BamHI...              RsrII.....(CDR2 installed as (SexAI or KasI) to (BamHI or RsrII) cassette.)------ FR3 -------------------------------------------------> 91  92  93  94  95  96  97  98  99 100 101 102 103 104 105  F   T   L   T   I   S   R   L   E   P   E   D   F   A   V 477|ttt|acc|ctt|act|att|TCT|AGA|ttg|gaa|cct|gaa|gac|ttc|gct|gtt|                     XbaI...----------->|----CDR3-------------------------->|-----FR4--->                     <3> <1> <1> <1>     <1>106 107 108 109 110 111 112 113 114 115 116 117 118 119 120  Y   Y   C   Q   Q   Y   G   S   S   P   E   T   F   G   Q|tat|tat|tgC|CAa|cag|taT|GGt|tct|tct|cct|gaa|act|ttc|ggt|caa|           BstXI........... -----FR4------------------->| <------- Ckappa ------------121 122 123 124 125 126 127    128 129 130 131 132 133 134   G   T   K   V   E   I   K     R   T   V   A   A   P   S 510|ggt|aCC|AAG|Gtt|gaa|atc|aag| |CGT|ACG|gtt|gcc|gct|cct|agt|      StyI....                 BsiWI..(CDR3 installed as XbaI to (StyI or BsiWI) cassette.) 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149  V   F   I   F   P   P   S   D   E   Q   L   K   S   G   T 552|gtg|ttt|atc|ttt|cct|cct|tct|gac|gaa|CAA|TTG|aag|tca|ggt|act|                                     MfeI... 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164  A   S   V   V   C   L   L   N   N   F   Y   P   R   E   A 597|gct|tct|gtc|gta|tgt|ttg|ctc|aac|aat|ttc|tac|cCT|CGT|Gaa|gct|                                              BssSI... 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179  K   V   Q   W   K   V   D   N   A   L   Q   S   G   N   S 642|aaa|gtt|cag|tgg|aaa|gtc|gat|aAC|GCG|Ttg|cag|tcg|ggt|aac|agt|                              MluI.... 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194  Q   E   S   V   T   E   Q   D   S   K   D   S   T   Y   S 687|caa|gaa|tcc|gtc|act|gaa|cag|gat|agt|aag|gac|tct|acc|tac|tct| 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209  L   S   S   T   L   T   L   S   K   A   D   Y   E   K   H 732|ttg|tcc|tct|act|ctt|act|tta|tca|aag|gct|gat|tat|gag|aag|cat| 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224  K   V   Y   A   C   E   V   T   H   Q   G   L   S   S   P 777|aag|gtc|tat|GCt|TGC|gaa|gtt|acc|cac|cag|ggt|ctG|AGC|TCc|cct|                                               SacI.... 225 226 227 228 229 230 231 232 233 234  V   T   K   S   F   N   R   G   E   C 822|gtt|acc|aaa|agt|ttc|aaC|CGT|GGt|gaa|tgc|taa|tag GGCGCGCC                       DsaI....                  AscI....                                                  BssHII 866acgcatctctaa GCGGCCGC aacaggaggag              NotI....              EagI.. A27::JH1 with all CDRs replaced by stuffers. Eachstuffer contains at least one stop codon and a restriction site thatwill be unique within the diversity vector.

TABLE 31P Tally of 285 CDR2s of length 7 in human kappa Tally A C D E FG H I K L M N P Q R S T V W Y 1 51 62 7 95 1 11 15 2 1 2 6 6 3 22 1 x 2225 18 5 5 2 1 1 3 16 9 A 3 2 9 1 2 267 2 1 1 S 4 2 1 5 4 9 1 77 4 93 802 7 Sx 5 1 2 80 200 2 R 6 162 7 36 4 4 1 3 3 63 2 Ax 7 5 1 3 1 1 2 2 1125 144 x

TABLE 32P Tally of 166 CDR3s of length 9 from human kappa. Tally A C D EF G H I K L M N P Q R S T V W Y 1 4 8 21 131 1 1 Q 2 1 9 2 1 153 Q 3 144 4 3 6 4 1 1 3 21 16 3 4 82 Yx 4 1 9 1 2 37 4 2 2 15 1 33 2 20 7 1 29 x5 2 2 6 3 4 5 3 28 17 7 65 19 1 1 3 x 6 7 1 11 2 3 8 1 4 3 41 33 5 28 19x 7 1 2 6 146 2 2 5 2 P 8 2 4 1 2 21 7 3 5 1 38 7 4 25 1 3 1 16 25 x 9 32 1 1 2 157 T

TABLE 33P lengths of CDRs in 93 human lambda chains 0 1 2 3 4 5 6 7 8 910 11 12 13 14 15 16 17 18+ CDR1 0 0 0 0 0 0 0 0 0 0 0 23 7 15 46 0 0 02 CDR2 5 0 0 1 0 0 0 80 2 0 0 1 4 0 0 0 0 0 1 CDR3 0 0 0 0 0 0 0 0 1 1628 27 6 1 0 4 6 4 0

TABLE 34P Tally of 46 CDR1s of length 14 from human lambda chains TallyA C D E F G H I K L M N P Q R S T V W Y 1 2 2 1 41 T 2 43 3 G 3 2 1 1 636 TGx 4 1 45 S 5 5 1 40 S 6 39 1 4 2 DNx 7 8 1 37 V 8 1 42 2 1 G 9 4 135 1 2 3 TGx 10 1 1 3 1 2 38 Yx 11 4 1 35 6 DNx 12 3 1 2 1 1 2 36 Yx 131 2 43 V 14 1 4 41 S

TABLE 35P Synthtic human lambda-chain gene 1 GAGGACCATtGGGCCCC   ttactccgtgac Scab...... EcoO109I            ApaI..        -----------FR1-------------------------------------------->         1   2   3   4   5   6   7   8   9  10  11  12  13  14  15 S   A   Q   S   A   L   T   Q   P   A   S   V   S   G   S   P   G 30aGT|GCA|Caa|tcc|gct|ctc|act|cag|cct|GCT|AGC|gtt|tcc|gGG|TcA|CCt|GGT| ApaLI...                           NheI...          BstEII...                                                          SexAI.... ForCDR1, <1> = 0.27 T, 0.27 G, 0.027 {ADEFHIKLMNPQRSVWY} no C <2> = 0.27 D,0.27 N, 0.027 {AEFGHIKLMPQRSTVWY} no C <3> = 0.36 Y,0.0355{ADEFGHIKLMNPQRSTVW} no C                              T   G  <1>  S   S  <2>  V   G------FR1------------------> |-----CDR1--------------------- 16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  Q   S   I   T   I   S   C   T   G   T   S   S   D   V   G|caa|agt|atc|act|att|tct|TGT|ACA|ggt|act|tct|tct|gat|gtt|ggc|                         BsrGI.. a second vg scheme for CDR1 givessegments of length 11: G₂₃<2><4>L<4><4><4><3><4><4> where<4> = equimolar {ADEFGHIKLMNPQRSTVWY} no C <1> <3> <2> <3>  V   S = vgScheme #1, length = 14-----CDR1------------->|--------FR2-------------------------31  32  33  34  35  36  37  38  39  40  41  42  43  44  45 G   Y   N   Y   V   S   W   Y   Q   Q   H   P   G   K   A|ggt|tac|aat|tac|gtt|tct|tgg|tat|caa|caa|caC|CCG|GGc|aaG|GCG|                                           XmaI....    KasI.....                                           AvaI....                        <4> <4> <4> <2>  R   P   S--FR2-----------------> |------CDR2--------------->|-----FR3--46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 P   K   L   M   I   Y   E   V   S   N   R   P   S   G   V|CCg|aag|ttg|atg|atc|tac|gaa|gtt|tcc|aat|cgt|cct|tct|ggt|gtt| KasI....-------FR3---------------------------------------------------- 61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  S   N   R   F   S   G   S   K   S   G   N   T   A   S   L|agc|aat|cgt|ttc|TCC|GGA|tct|aaa|tcc|ggt|aat|acc|gcA|AGC|TTa|                 BspEI..          |                HindIII.                      BsaBI........(blunt)-------FR3--------------------------------------------------->| 76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  T   I   S   G   L   Q   A   E   D   E   A   D   Y   Y   C|act|atc|tct|ggt|CTG|CAG|gct|gaa|gac|gag|gct|gac|tac|tat|tgt|                 PstI... <5> = 0.36 S, 0.0355{ADEFGHIKLMNPQRTVWY} no C <4> <5> <4> <2> <4>  S  <4> <4> <4> <4>  V-----CDR3---------------------------------->|---FR4--------- 91  92  93  94  95  96  97  98  99 100 101 102 103 104 105  S   S   Y   T   S   S   S   T   L   V   V   F   G   G   G|tct|tct|tac|act|tct|tct|agt|acc|ctt|gtt|gtc|ttc|ggc|ggt|GGT|                                                         KpnI...-------FR4-------------->  106 107 108 109 110 111 112 113 114 115 116117 118 119 120  T   K   L   T   V   L   G   Q   P   K   A   A   P   S   V 279|ACC|aaa|ctt|act|gtc|ctc|gGT|CAA|CCT|aAG|Gct|gct|cct|tcc|gtt|KpnI...                      HincII..                                 Bsu36I...  121 122 123 124 125 126 127128 129 130 131 132 133 134 135  T   L   F   P   P   S   S   E   E   L   Q   A   N   K   A 324|act|ctc|ttc|cct|cct|agt|tct|GAA|GAG|Ctt|caa|gct|aac|aag|gct|                             SapI.....  136 137 138 139 140 141 142 143144 145 146 147 148 149 150  T   L   V   C   L   I   S   D   F   Y   P   G   A   V   T 369|act|ctt|gtt|tgc|tTG|ATC|Agt|gac|ttt|tat|cct|ggt|gct|gtt|act|                  BclI....  151 152 153 154 155 156 157 158 159 160 161162 163 164 165  V   A   W   K   A   D   S   S   P   V   K   A   G   V   E 414|gtc|gct|tgg|aaa|gcc|gat|tct|tct|cct|gtt|aaa|gct|ggt|gtt|GAG|                                                         BsmBI...  166167 168 169 170 171 172 173 174 175 176 177 178 179 180  T   T   T   P   S   K   Q   S   N   N   K   Y   A   A   S 459|ACG|acc|act|cct|tct|aaa|caa|tct|aac|aat|aag|tac|gct|gcG|AGC|BsmBI....                                                   SacI.... 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195  S   Y   L   S   L   T   P   E   Q   W   K   S   H   K   S 504|TCt|tat|ctt|tct|ctc|acc|cct|gaa|caa|tgg|aag|tct|cat|aaa|tcc| SacI... 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210  Y   S   C   Q   V   T   H   E   G   S   T   V   E   K   T 549|tat|tcc|tgt|caa|gtt|acT|CAT|GAa|ggt|tct|acc|gtt|gaa|aag|act|                       BspHI...  211 212 213 214 215 216 217 218 219  V   A   P   T   E   C   S   .   . 594|gtt|gcc|cct|act|gag|tgt|tct|tag|tga|GGCGCGCC                                     AscI....                                      BssHII 629 aacgatgttc aag GCGGCCGCaacaggaggag                NotI.... Scab....... Lambda 14-7(A) 2a2::JH2::Clambda AA sequence tested

TABLE 36P Tally of 23 CDR1s of length 11 from human lambda chains TallyA C D E F G H I K L M N P Q R S T V W Y 1 1 6 10 6 x 2 1 1 21 G 3 15 1 7DNx 4 2 1 1 3 7 1 8 X 5 7 16 L 6 11 1 2 8 1 X 7 1 1 1 2 2 1 14 1 X 8 110 1 1 1 2 7 X 9 2 6 15 Yx 10 11 1 11 X 11 3 7 9 2 2 X

TABLE 37P Tally of 80 CDR2s of length 7 from human lambda chains Tally AC D E F G H I K L M N P Q R S T V W Y 1 1 14 32 1 13 3 1 4 5 1 2 3 X 218 2 8 16 2 34 X 3 1 2 1 31 39 4 2 X 4 6 4 1 14 1 41 8 1 1 2 1 DNx 5 1 178 R 6 1 77 2 P 7 2 78 S

TABLE 38P Tally of 27 CDR3s of length 11 from human lambda chains TallyA C D E F G H I K L M N P Q R S T V W Y 1 4 5 6 5 4 3 X 2 3 1 2 14 5 2Sx 3 1 7 13 6 X 4 19 2 1 1 4 DNx 5 1 4 2 2 2 1 13 2 X 6 1 3 1 21 1 S 7 17 12 1 4 2 X 8 2 1 10 1 6 6 1 X 9 3 1 8 10 3 1 1 X 10 1 4 1 1 1 3 1 1 65 3 X 11 2 25 V

TABLE 40P Synthetic Kappa light chain gene with stuffers 1 GAGGACCATtGGGCCCC                ctccgagact Scab...... EcoO109I            ApaI.28 CTCGAG    cgca XhoI.. 38 acgcaatTAA TGTgagttag ctcactcatt aggcaccccaggcTTTACAc tttatgcttc       ..-35..         Plac                    ..-10. 98 cggctcgtatgttgtgtgga attgtgagcg gataacaatt tc 140 acacagga aacagctatgac 160catgatta cgCCAAGCTT TGGagccttt tttttggaga ttttcaac           PflMI.......              Hind3. M13 III signal sequence (AAseq)---------------------------> 1   2   3   4   5   6   7   8   9  10  11  12  13  14  15 M   K   K   L   L   F   A   I   P   L   V   V   P   F   Y 206 gtg aagaag ctc cta ttt gct atc ccg ctt gtc gtt ccg ttt tac--Signal-->  FR1-------------------------------------------> 16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  S   H   S   A   Q   S   V   L   T   Q   S   P   G   T   L 251|agc|cat|aGT|GCA|Caa|tcc|gtc|ctt|act|caa|tct|cct|ggc|act|ctt|          ApaLI... ----- FR1--------------------------------->|-------Stuffer-> 31  32  33  34  35  36  37  38  39  40  41  42  43  S   L   S   P   G   E   R   A   T   L   S   |   | 296|tcG|CTA|AGC|CCG|GGt|gaa|cgt|gct|acC|TTA|AGt|TAG|TAA|gct|ccc|   EspI.....                       AflII...            XmaI.... -------Stuffer for CDR1------------------------->|- FR2 -->                                                    59  60                                                     K   P 341|AGG|CCT|ctt|TGA|tct|                              g|aaA|CCT| StuI...                                               SexAI... -----FR2 ------|-----------Stuffer for CDR2----------------> 61  62  63  64  65  66   G   Q   A   P   R   |   | 363|GGT|caG|GCG|CCg|cgt|TAA|TGA|a AGCGCT aa TGGCCA aca gtg SexAI....KasI....             AfeI..    MscI.. Stuffer-->|--- FR3----------------------------------------------->  <1> 76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  T   G   I   P   D   R   F   S   G   S   G   S   G   T   D 405|act|gGG|ATC|CCG|GAC|CGt|ttc|tct|ggc|tct|ggt|tca|ggt|act|gac|      BamHI...              RsrII..... ------ FR3---------------------STUFFER for CDR3------------------> 91  92  93  94  95  96  97   F   T   L   T   I   S   R   |   | 450|ttt|acc|ctt|act|att|TCT|AGA|TAA|TGA| GTTAAC TAG acc TACGTA acc tag                     XbaI...          HpaI..         SnaBI.-----------------CDR3 stuffer------------------>|-----FR4--->                                                118 119 120                                                  F   G   Q 501                                                |ttc|ggt|caa|-----FR4------------------->| <------- Ckappa ------------ 121 122 123124 125 126 127   128 129 130 131 132 133 134  G   T   K   V   E   I   K     R   T   V   A   A   P   S 510|ggt|aCC|AAG|Gtt|gaa|atc|aag| |CGT|ACG|gtt|gcc|gct|cct|agt|      StyI....                 BsiWI.. (CDR3 installed as XbaI to (StyIor BsiWI) cassette.)  135 136 137 138 139 140 141 142 143 144 145 146147 148 149   V   F   I   F   P   P   S   D   E   Q   L   K   S   G   T552 |gtg|ttt|atc|ttt|cct|cct|tct|gac|gaa|CAA|TTG|aag|tca|ggt|act|                                     MfeI... 866 acgcatctctaa GCGGCCGCaacaggaggag              NotI....               EagI.. A27::JH1 with allCDRs replaced by stuffers. Each stuffer contains at least one stop codonand a restriction site that will be unique within the diversity vector.

TABLE 41P Variegated DNA for kappa chains Kappa chains For CDR1: <1>ADEFGHIKLMNPQRSTVWY equimolar <2> S(0.2) ADEFGHIKLMNPQRTVWY (0.044 each)<3> Y(0.2) ADEFGHIKLMNPQRSTVW (0.044 each) <4> A(0.2) DEFGHIKLMNPQRSTVWY(0.044 each) (Ka1vg600) 5′-gct|acC|TTA|AGt|tgc|cgt|gct|tcc|cag-|<1>|gtt|<2>|<2>|  <3>|ctt|gct|tgg|tat|caa|cag|aaA|CC-3′ (Ka2vg650)5′-caG|GCG|CCg|cgt|tta|ctt|att|tat|<1>|gct|tct|<2>|cgc|<4>|-|<1>|gGG|ATC|CCG|GAC|CGt|ttc|tct|ggt|tctcacc-3′ (Ka3vg670)5′-gac|ttc|gct|gtt|-|tat|tat|tgC|CAa|cag|<3>|<1>|<1>|<1>|cct|<1>|act|ttc|ggt|caa|-|ggt|aCC|AAG|Gtt|g-3′

TABLE 42P Variegated DNA for lambda chains For CDR1, <1> = 0.27 T, 0.27G, 0.027 {ADEFHIKLMNPQRSVWY} no C <2> = 0.27 D, 0.27 N, 0.027{AEFGHIKLMPQRSTVWY} no C <3> = 0.36 Y, 0.0355{ADEFGHIKLMNPQRSTVW} no C<4> = equimolar {ADEFGHIKLMNPQRSTVWY} no C <5> = 0.36 S,0.0355{ADEFGHIKLMNPQRTVWY} no C (Lm1vg710)5′-gt|atc|act|att|tct|TGT|ACA|ggt|<1>|tct|tct|<2>|gtt|ggc|-|<1>|<3>|<2>|<3>|gtt|tct|tgg|tat|caa|caa|caC|CC-3′ (Lm2vg750)5′-G|CCg|aag|ttg|atg|atc|tac|-<4>|<4>|<4>|<2>|cgt|cct|tct|ggt|gtc|agc|aat|c-3′ (Lm3vg817)5′-gac|gag|gct|gac|tac|tat|tgt|-|<4>|<5>|<4>|<2>|<4>|tct|<4>|<4>|<4>|<4>|gtc|ttc|ggc|ggt|GGT|-|ACC|aaa|ctt|ac-3′

TABLE 43P Constant DNA for Synthetic Library CDR3 library components(Ctop25) 5′-gctctggtcaa C|TTA|AGg|gct|gag|g-3′ (CtprmA) 5′-gctctggtcaaC|TTA|AGg|gct|gag|gac-                AflII...|acc|gct|gtc|tac|tac|tgc|gcc-3′ (CBprmB) [RC]5′-|tac|ttc|gat|tac|ttg|ggc|caa|GGT|ACC|ctG|GTC|ACC|tcgctccacc-3′                            BstEII... (CBot25) [RC]5′-|GGT|ACC|ctG|GTC|ACC|tcgctccacc-3′ Kappa chains (Ka1Top610)5′-ggtctcagtt-G|CTA|AGC|CCG|GGt|gaa|cgt|gct|acC|TTA|AGt|tgc|cgt|gct|tcc|cag-3′(Ka1STp615) 5′-ggtctcagtt- G|CTA|AGC|CCG|GGt|g-3′ (Ka1Bot620) [RC]5′-ctt|gct|tgg|tat|caa|cag|aaA|- CCt|GGT|caG|GCG|CC aagtcgtgtc-3′(Ka1SB625) [RC] 5′-cct|GGT|caG|GCG|CC aagtcgtgtc-3′ (Ka2Tshort657)5′-cacgagtcctA|CCT|GGT|- caG|GC-3′ (Ka2Tlong655)5′-cacgagtcctA|CCT|GGT|- caG|GCG|CCg|cgt|tta|ctt|att|tat-3′(Ka2Bshort660) [RC] 5′-|GAC|CGt|ttc|tct|ggt|tctcacc-3′ (Ka3Tlon672)5′-gacgagtcct TCT|AGA|ttg|gaa|cct|gaa|gac|ttc|gct|gtt|-|tat|tat|tgC|CAa|c-3′ (Ka3BotL682) [RC] 5′-act|ttc|ggt|caa|-|ggt|aCC|AAG|Gtt|gaa|atc|aag| |CGT|ACG| tcacaggtgag-3′ (Ka3Bsho694) [RC]5′-gaa|atc|aag| |CGT|ACG| tcacaggtgag-3′ (Lm1TPri75) 5′-gacgagtcctGG|TcA|CCt|GGT|-3′ (Lm1TLo715) 5′-gacgagtcct GG|TcA|CCt|GGT|-caa|agt|atc|act|att|tct|TGT|ACA|ggt-3′ (Lm1BLo724) [RC]5′-gtt|tct|tgg|tat|caa|caa|caC|CCG|GGc|aaG|GCG|- AGA TCT  tcacaggtgag-3′(Lm1BSh737) [RC] 5′-Gc|aaG|GCG|- AGA TCT  tcacaggtgag-3′ (Lm2TSh757)5′-gagcagagga C|CCG|GGc|aaG|GC-3′ (Lm2TLo753) 5′-gagcagaggaC|CCG|GGc|aaG|GCG|CCg|aag|ttg|atg|atc|tac|-3′ (Lm2BLo762) [RC]5′-cgt|cct|tct|ggt|gtc|agc|aat|cgt|ttc|TCC|GGA|tcacaggtgag-3′(Lm2BSh765) [RC] 5′-cgt|ttc|TCC|GGA|tcacaggtgag-3′ (Lm3TSh822)5′-CTG|CAG|gct|gaa|gac|gag|gct|gac-3′ (Lm3TLo819)5′-CTG|CAG|gct|gaa|gac|gag|gct|gac|tac|tat|tgt|-3′ (Lm3BLo825) [RC]5′-gtc|ttc|ggc|ggt|GGT|- |ACC|aaa|ctt|act|gtc|ctc|gGT|CAA|CCT|aAG|Gacacaggtgag-3′ (Lm3BSh832) [RC] 5′-c|gGT|CAA|CCT|aAG|G acacaggtgag-3′

TABLE 48P Synthtic human lambda-chain gene with stuffers in place ofCDRs 1 GAGGACCATt GGGCCCC   ttactccgtgac / Scab...... EcoO109I           ApaI..        -----------FR1-------------------------------------------->         1   2   3   4   5   6   7   8   9  10  11  12  13  14  15 S   A   Q   S   A   L   T   Q   P   A   S   V   S   G   S   P   G 30aGT|GCA|Caa|tcc|gct|ctc|act|cag|cct|GCT|AGC|gtt|tcc|gGG|TcA|CCt|GGT| ApaLI...                           NheI...          BstEII...                                                          SexAI....------FR1------------------> |-----stuffer for CDR1--------- 16  17  18  19  20  21  22  23   Q   S   I   T   I   S   C   T 81|caa|agt|atc|act|att|tct|TGT|ACA|tct TAG TGA ctc                         BsrGI..-----Stuffer--------------------------->--------------------31  32  33  34  35  36  37  38  39  40  41  42  43  44  45 R   S   |   |   P   |                   H   P   G   K   A 117AGA TCT TAA TGA ccg tag                 caC|CCG|GGc|aaG|GCG|BglII                                     XmaI....    KasI.....                                          AvaI....--|-------------Stuffer ------------------------------------->  P 150|CCg|TAA|TGA|atc tCG TAC G                        ct|ggt|gtt|KasI....          BsiWI...-------FR3---------------------------------------------------- 61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  S   N   R   F   S   G   S   K   S   G   N   T   A   S   L 177|agc|aat|cgt|ttc|TCC|GGA|tct|aaa|tcc|ggt|aat|acc|gcA|AGC|TTa|                 BspEI..          |                HindIII.                      BsaBI........(blunt)-------FR3------------->|--Stuffer-------------------------->| 76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  T   I   S   G   L   Q 222 |act|atc|tct|ggt|CTG|CAG|gtt ctg tag ttcCAATTG ctt tag tga ccc                  PstI...                 MfeI..-----Stuffer------------------------------->|---FR4---------                                                  103 104 105                                                  G   G   G 270                                                  |ggc|ggt|GGT|                                                           KpnI...-------FR4-------------->  106 107 108 109 110 111 112 113 114 115 116117 118 119 120  T   K   L   T   V   L   G   Q   P   K   A   A   P   S   V 279|ACC|aaa|ctt|act|gtc|ctc|gGT|CAA|CCT|aAG|Gct|gct|cct|tcc|gtt|KpnI...                      HincII..                                 Bsu36I...  121 122 123 124 125 126 127128 129 130 131 132 133 134 135  T   L   F   P   P   S   S   E   E   L   Q   A   N   K   A 324|act|ctc|ttc|cct|cct|agt|tct|GAA|GAG|Ctt|caa|gct|aac|aag|gct|                             SapI.....  136 137 138 139 140 141 142 143144 145 146 147 148 149 150  T   L   V   C   L   I   S   D   F   Y   P   G   A   V   T 369|act|ctt|gtt|tgc|tTG|ATC|Agt|gac|ttt|tat|cct|ggt|gct|gtt|act|                  BclI.... Lambda 14-7(A) 2a2 ::JH2::Clambda AA sequencetested

TABLE 50P 3-23::CDR3::JH4 Stuffers in place of CDRs                       FR1(DP47/V3-23)---------------           20  21  22  23  24  25  26  27  28  29  30            A   M   A   E   V   Q   L   L   E   S   G ctgtctgaac  CC atggcc gaa|gtt|CAA|TTG|tta|gag|tct|ggt|Scab......  NcoI....          | MfeI  |      --------------FR1--------------------------------------------       31  32  33  34  35  36  37  38  39  40  41  42  43  44  45        G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A      |ggc|ggt|ctt|gtt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct|             ----FR1-------------------->|...CDR1stuffer....|---FR2------       46  47  48  49  50  51  52  53  54  55  56  57  58  59  60        A   S   G   F   T   F   S   S   Y   A   |   |   W   V   R      |gct|TCC|GGA|ttc|act|ttc|tct|tCG|TAC|Gct|TAG|TAA|tgg|gtt|cgC|          | BspEI |                 | BsiWI|                     |BstXI.             -------FR2-------------------------------->|...CDR2stuffer.      61  62  63  64  65  66  67  68  69  70  71  72  73  74  75       Q   A   P   G   K   G   L   E   W   V   S   |   p   r   |      |CAa|gct|ccT|GGt|aaa|ggt|ttg|gag|tgg|gtt|tct|TAA|CCT|AGG|TAG|  ...BstXI        |                                  AvrII..     .....CDR2 stuffer....................................|---FR3---      --------FR3-------------------------------------------------        91  92  93  94  95  96  97  98  99 100 101 102 103 104 105        T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M      |act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|              | XbaI  |             ---FR3-----------..> Stuffer------------->|        106 107 108 109110         N   S   L   R   A       |aac|agC|TTA|AGg|gct|TAG TAA AGG cctTAA              |AflII |              StuI...              |----- FR4---(JH4)-----------------------------------------       Y   F   D   Y   W   G   Q   G   T   L   V   T   V   S   S     |tat|ttc|gat|tat|tgg|ggt|caa|GGT|ACC|ctG|GTC|ACC|gtc|tct|agt|...                                  | KpnI  |  | BstEII |

1.-43. (canceled)
 44. A focused library of vectors or genetic packages,comprising a first set of variegated DNAs each of which comprises anucleotide sequence encoding an antibody heavy chain, which comprises aCDR1 region, a CDR2 region, and a CDR3 region, the first set ofvariegated DNAs collectively comprising the components V::nz::JHn,V::nz::D::ny::JHn, or a mixture thereof, wherein V is a v gene, nz is aseries of bases that are essentially random, D is a D segment, ny is aseries of bases that are essentially random, and JHn is one of the sixJH segments.
 45. The library of claim 44, wherein the JH segment is aJH4 segment.
 46. The library of claim 44, wherein the JHn is one of thesix JH segments having a base or bases edited from the N-terminus. 47.The library of claim 44, wherein the D is a D segment having a base orbases edited from its 5′ end, 3′ end, or both.
 48. The library of claim47, wherein the D segment has nucleotides encoding one, two, three,four, or five N-terminal amino acids removed.
 49. The library of claim47, wherein the D segment has nucleotides encoding one, two, three,four, or five C-terminal amino acids removed.
 50. (canceled)
 51. Thelibrary of claim 44, wherein the JHn encodes an amino acid sequence thatincludes the sequence DYWG, wherein D and Y are part of heavy chain CDR3and W and G are part of the framework 4 region of the heavy chain. 52.The library of claim 44, wherein the antibody heavy chains encoded bythe first set of variegated DNAs include CDR3s ranging from seven tofifteen amino acids in length.
 53. The library of claim 52, wherein theamino acids in the heavy chain CDR3s are the amino acids most commonlyrepresented from naturally occurring antibodies.
 54. The library ofclaim 53, wherein the heavy chain CDR3s are seven to fifteen amino acidsin length and the amino acids at each position is selected from the mostcommonly represented amino acids at that position shown in Table 11P.55. The library of claim 54, wherein the heavy chain CDR3s that areseven amino acids in length contains: an amino acid residue selectedfrom G, D, L, R, W, A and E at position 1; an amino acid residueselected from R, G, N, H, V, F and K at position 2; an amino acidresidue selected from G, S, D, W, Y, P and V at position 3; an aminoacid residue selected from G, Y, S, A, N, R and V at position 4; anamino acid residue selected from F, I, G, L, M, A and R at position 5;an amino acid residue selected from D, V, P, T, H, I and S at position6; and an amino acid residue selected from Y, V, I, N, D, H and S atposition
 7. 56. (canceled)
 57. The library of claim 54, wherein theheavy chain CDR3s that are eight amino acids in length contain: an aminoacid selected from G, D, L, T, V, R and S at position 1; an amino acidselected from G, D, T, N, R, S and V at position 2; an amino acidselected from G, L, S, T, Y, V and D at position 3; an amino acidselected from G, Y, R, A, L, Q and D at position 4; an amino acidselected from A, G, Y, H, L, T and P at position 5; an amino acidselected from F, I, A, L, P, S and V at position 6; amino acid D, A, H,S, E, L and N at position 7; and an amino acid selected from Y, I, S, F,L, V and D at position
 8. 58. (canceled)
 59. The library of claim 54,wherein the heavy chain CDR3s that are nine amino acids in lengthcontain: an amino acid selected from G, D, A, R, N and V and L atposition 1; an amino acid selected from G, P, S, R, L, N and T atposition 2; an amino acid selected from G, T, P, S, Q, N and R atposition 3; an amino acid selected from G, S, D, F, L, A and R atposition 4; an amino acid selected from G, S, Y, A, L, N and D atposition 5; an amino acid selected from Y, A, G, H, N, L and P atposition 6; an amino acid selected from F, L, M, A, P, W and I) atposition 7; an amino acid selected from D, E, G, L, S, A and H atposition 8; and an amino acid selected from Y, V, I, S, F, H and P atposition
 9. 60. (canceled)
 61. The library of claim 54, wherein theheavy chain CDR3s that are nine amino acids in length contain: an aminoacid selected from G, D, A, R, N, V, L, E, Q, T, K, W, H, I, P, S and Yat position 1; an amino acid selected from G, P, S, R, L, N, T, H, E, F,K, Y, D, M, Q and W at position 2; an amino acid selected from G, T, P,S, Q, N, R, V, W, Y, A, D, E, F, L and M at position 3; an amino acidselected from G, S, D, F, L, A, R, I, T, Y, E, N, P, W, H, V, K and Mposition 4; an amino acid selected from G, S, Y, A, L, N, D, F, V, E, R,W, H, M, Q, T and P at position 5; an amino acid selected from Y, A, G,H, N, L, P, S, V, F, T, W, D, I, E, K, M, Q and R at position 6; anamino acid selected from F, L, M, A, P, W, 1, D, G, S, V, K, N, Q, T andY at position 7; an amino acid selected from D, E, G, L, S, A, C, H, N,Q, R and V at position 8; and an amino acid selected from Y, V, I, S, F,H, P, L, N, T, D, G and R at position
 9. 62. (canceled)
 63. The libraryof claim 54, wherein the heavy chain CDR3s that are ten amino acids inlength contain: an amino acid selected from D, G, N, A E, R and T atposition 1; an amino acid selected from L, G, R, D, S, P and V atposition 2; an amino acid selected from G, S, Y, D, A, V and T atposition 3; an amino acid selected from G, S, Y, A, R, D and I atposition 4; an amino acid selected from G, Y, T, E, S, A and N atposition 5; an amino acid selected from G, Y, R, S, W, A and D atposition 6; an amino acid selected from Y, A, S, G, P, R and W atposition 7; an amino acid selected from F, L, I, M, S, G and W atposition 8; an amino acid selected from D, G, A, Q, E, N and I atposition 9; and an amino acid selected from Y, I, P, S, V, F and H atposition
 10. 64. (canceled)
 65. The library of claim 54, wherein theheavy chain CDR3s that are eleven amino acids in length contain: anamino acid selected from a D, E, V, R, A and L at position 1; an aminoacid selected from G, S, R, D, Y, L and P at position 2; an amino acidselected from S, G, T, V, R, L and Y at position 3; an amino acidselected from S, G, A, R, T, W and Y at position 4; an amino acidselected from G, S, V, Y, D, T and N at position 5; an amino acidselected from G, S, Y, W, T, F and A at position 6; an amino acidselected from G, Y, S, N, R, D and W at position 7; an amino acidselected from Y, A, G, W, F, L and D at position 8; an amino acidselected from F, L, M, Y, V, I and T at position 9; an amino acidselected from D, E, G, A, H, L and M at position 10; and an amino acidselected from Y, P, V, I, S, F and L at position
 11. 66. (canceled) 67.The library of claim 54, wherein the heavy chain CDR3s that are twelveamino acids in length contain: an amino acid selected from G, D, R, E,S, V and L at position 1; an amino acid selected from G, S, R, L, P, Dand I at position 2; an amino acid selected from G, R, S, Y, L, A and Tat position 3; an amino acid selected from G, V, S, D, N, A and F atposition 4; an amino acid selected from G, S, A, I, D, Y and L atposition 5; an amino acid selected from G, A, V, D, S, F and Y atposition 6; an amino acid selected from Y, G, S, P, L, R and A atposition 7; an amino acid selected from Y, G, D, S, N, L and T atposition 8; an amino acid selected from G, Y, W, A, R, F and I atposition 9; an amino acid selected from F, M, L, I, P, Y and D atposition 10; an amino acid selected from D, G, Y, A, E, H and S atposition 11; and an amino acid selected from Y, V, P, I, H, F and S atposition
 12. 68. (canceled)
 69. The library of claim 54, wherein theheavy chain CDR3s that are thirteen amino acids in length contain: anamino acid selected from G, D, T, E, S, H and R at position 1; an aminoacid selected from G, R, S, P, A, L and T at position 2; an amino acidselected from G, S, Y, H, Q, T and D at position 3; an amino acidselected from G, S, W, Y, T, I and A at position 4; an amino acidselected from G, L, S, Y, D, A and T at position 5; an amino acidselected from G, Y, S, P, T, D and A at position 6; an amino acidselected from L, G, Y, S, T, D and P at position 7; an amino acidselected from Y, D, S, G, L, A and R at position 8; an amino acidselected from N, G, Y, D, S, W and H at position 9; an amino acidselected from Y, G, A, F, W, H and L at position 10; an amino acidselected from F, M, L, Y, G, I and V at position 11; an amino acidselected from D, G, Y, E, Q, N and H at position 12; and an amino acidselected from Y, V, L, I, P, S and F at position
 13. 70. (canceled) 71.The library of claim 54, wherein the heavy chain CDR3s that are fourteenamino acids in length contain: an amino acid selected from G, D, V, H,E, R and T at position 1; an amino acid selected from G, P, D, R, Y, Sand V at position 2; an amino acid selected from G, V, A, R, Y, L and Sat position 3; an amino acid selected from S, G, V, Y, P, D and E atposition 4; an amino acid selected from G, Y, S, D, T, V and A atposition 5; an amino acid selected from Y, G, S, T, D, R and A atposition 6; an amino acid selected from G, S, V, T, Y, N and A atposition 7; an amino acid selected from G, S, Y, T, W, A and P atposition 8; an amino acid selected from Y, S, G, T, L, V and A atposition 9; an amino acid selected from Y, G, S, D, N, T and Q atposition 10; an amino acid selected from Y, G, W, A, P, V and F atposition 11; an amino acid selected from F, M, L, G, I, P and S atposition 12; an amino acid selected from D, G, E, A, N, Q and H atposition 13; and an amino acid selected from Y, V, P, I, L, H and F atposition
 14. 72. (canceled)
 73. The library of claim 44, wherein theheavy chain CDR3s of the heavy chains encoded by the first set ofvariegated DNAs have the same length distribution as seen in heavy chainCDR3s of natural antibodies.
 74. The library of claim 44, wherein theheavy chains further comprise one or more framework regions of germlinesequences selected from the group consisting of 3-23, 4-34, 3-30,3-30.3, and 4-30.1.
 75. (canceled)
 76. The library of claim 44, whereinthe CDR1s of the heavy chains encoded by the first set of variegatedDNAs are five amino acids in length, seven amino acids in length, and/orfourteen amino acids in length.
 77. The library of claim 76, wherein theheavy chain CDR1s are five amino acids in length and variegated atpositions 1, 3 and 5 and the amino acids at positions 1, 3, and 5 cannot be C.
 78. The library of claim 77, wherein the heavy chain CDR1shave Y at position 2 and M at position
 4. 80. The library of claim 76,wherein the heavy chain CDR1s have the sequence: X-Y-X-M-X, in which Xis any one of amino acids A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S,T, V, W, and Y.
 81. (canceled)
 82. The library of claim 44, wherein theCDR2s of the heavy chains encoded by the first set of variegated DNAsare seventeen amino acids in length, sixteen amino acids in length,and/or nineteen amino acids in length.
 83. The library of claim 82,wherein the heavy chain CDR2s encoded by the first set of variegatedDNAs are seventeen amino acids in length having the sequence:<2>I<2><3>SGG<1>T<1>YADSVKG, in which each <1> independently is selectedfrom the group consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R,S, T, V, W, and Y; each <2> independently is an amino acid selected fromthe group consisting of Y, R, W, V, G and S; and <3> is selected fromthe group consisting of P and S.
 84. (canceled)
 85. The library of claim44, wherein the first set of variegated DNAs collectively encodeantibody heavy chains comprising one or more of the following CDR3regions: xxxYCSSTSCxxx, in which x is any amino acid or is absent;xxxxxxxSGYxxx, in which x is any amino acid or is absent; xxxVVVPAAxxxx,in which x is any amino acid or is absent; xxxYYDSSGYxx, in which x isany amino acid or is absent; xxxTIFGVxxxx, in which x is any amino acidor is absent; xxxYGSGSYYx, in which x is any amino acid or is absent;xxxxYSYGxxx, in which x is any amino acid or is absent; xxxCSGxxCYxx, inwhich x is any amino acid or is absent; xxxxAAAGxxx, in which x is anyamino acid or is absent; xxxSGSYxxx, in which x is any amino acid or isabsent; xxxSSSWxxx, in which x is any amino acid or is absent;xxx(IV)AVAGxx, in which x is any amino acid or is absent; xxLWFGELxx, inwhich x is any amino acid or is absent; xxxxxGExxx, in which x is anyamino acid or is absent; xxxxSGWxx, in which x is any amino acid or isabsent; xxxVRGVxx, in which x is any amino acid or is absent; xxxIAAxxx,in which x is any amino acid or is absent; xxxYGDxx, in which x is anyamino acid or is absent; xxVGATxx, in which x is any amino acid or isabsent; xxxYSSSx, in which x is any amino acid or is absent. 86.(canceled)
 87. The library of claim 44, wherein: (a) nz encodes thesequence <1><1><1>, in which each <1> independently is any amino acidresidue other than C; D encodes the sequence S<2>S<3>, in which <2> is Sor G and <3> is Y or W; ny encodes the sequence <1><1><1>, in which each<1> independently is any amino acid residue other than C; and JHnencodes the sequence YFDY, (b) nz encodes the sequence <1><1><1>, inwhich each <1> independently is any amino acid residue other than C; Dencodes the sequence CSG<1><1>CY, in which each <1> independently is anyamino acid residue other than C; ny encodes the sequence <1>, which isany amino acid residue other than C; and JHn encodes the sequence YFDY,(c) nz encodes the sequence <1><1>S<1>, in which each <1> independentlyis any amino acid residue other than C; D encodes the sequence TIFG; nyencodes the sequence <1><1><1><1><1>, in which each <1> independently isany amino acid residue other than C; and JHn encodes the sequence YFDY,(d) nz encodes the sequence <1><1><1>, in which each <1> independentlyis any amino acid residue other than C; D encodes the sequenceYY<2>S<3><3>YY, in which <2> is D or G, and each <3> independently is Sor G; ny encodes the sequence <1><1><1>, in which each <1> independentlyis any amino acid residue other than C; and JHn encodes the sequenceYFDY, or (e) nz encodes the sequence <1><1><1><1>, in which each <1>independently is any amino acid residue other than C; D encodes thesequence YC<2><2><3><1>CY, in which <1> is any amino acid residue otherthan Cys, each <2> independently is S or G, and <3> is T, D or G; nyencodes the sequence <1><1><1> in which each <1> independently is anyamino acid residue other than C; and JHn encodes YFDY. 88-91. (canceled)92. The library of claim 44, wherein the V::nz::D::ny::JHn componentscollectively encode one or more of the following sequences:YYCA21111YFDYWG, in which each 1 independently is selected from thegroup consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V,W, and Y; and 2 is selected from the group of K and R;YYCA2111111YFDYWG, in which each 1 independently is selected from thegroup consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V,W, and Y; and 2 is selected from the group of K and R;YYCA211111111YFDYWG, in which each 1 independently is selected from thegroup consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V,W, and Y; and 2 is selected from the group of K and R;YYCAR111S2S3111YFDYWG, in which each 1 independently is selected fromthe group consisting of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T,V, W, and Y; 2 is selected from the group of S and G; and 3 is selectedfrom the group consisting of Y and W; YYCA2111CSG11CYFDYWG, in whicheach 1 independently is selected from the group consisting of A, D, E,F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and 2 is selectedfrom the group of K and R; YYCA211S1TIFG11111YFDYWG, in which each 1independently is selected from the group consisting of A, D, E, F, G, H,I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and 2 is selected from thegroup of K and R; YYCAR111YY2S33YY111YFDYWG, in which each 1independently is selected from the group consisting of A, D, E, F, G, H,I, K, L, M, N, P, Q, R, S, T, V, W, and Y; 2 is selected from the groupof D and G; and each 3 independently is selected from the groupconsisting of S and G; and YYCAR1111YC2231CY111YFDYWG, in which each 1independently is selected from the group consisting of A, D, E, F, G, H,I, K, L, M, N, P, Q, R, S, T, V, W, and Y; 2 is selected from the groupof S and G; and 3 is selected from the group consisting of T, D and G.93. (canceled)
 94. The library of claim 44, wherein the D segments inthe first set of variegated DNAs collectively encode one or more of thefollowing sequences: GYCSSTSCYT; GYCSGGSCYS; YYYGSGSYYN; YYYDSSGYYY;DYGDY; GYSSSWY; YSGSYY; GYSYGY; and GYSSGWY.


95. (canceled)
 96. The library of claim 44, wherein the vectors orgenetic packages further comprise a second set of variegated DNAs, eachof which comprises a nucleotide sequence encoding an antibody lightchain, which comprises CDR1, CDR2 and CDR3.
 97. The library of claim 96,wherein the light chain further comprises a framework region of germlinesequence A-27.
 98. The library of claim 97, wherein the light chainfurther comprises a JK1 region or a JK4 region.
 99. (canceled)
 100. Thelibrary of claim 96, wherein the light chain is a kappa light chain.101. (canceled)
 102. The library of claim 101, wherein the second set ofvariegated DNAs collectively encode kappa light chains having CDR1regions that are eleven and/or twelve amino acids in length.
 103. Thelibrary of claim 100, wherein the CDR2 in the kappa light chain is sevenamino acids in length.
 104. (canceled)
 105. The library of claim 100,wherein the second set of variegated DNAs collectively encode kappalight chains having CDR3 regions that are eight, nine, and/or ten aminoacids in length.
 106. The library of claim 100, wherein the kappa lightchain further comprises a framework region of a germline sequenceselected from the group consisting of 2a2, 31, 4b, 1a and 6a. 107.(canceled)
 108. The library of claim 106, wherein the kappa light chainfurther comprises a L2J region, L1J region, a L3J region, or a L7Jregion.
 109. (canceled)
 110. The library of claim 96, wherein the lightchain is a lambda light chain.
 111. (canceled)
 112. The library of claim110, wherein the second set of variegated DNAs collectively encodelambda light chains having CDR1 regions that are eleven and/or fourteenamino acids in length.
 113. The library of claim 110, wherein the CDR2in the lambda light chain is seven amino acids in length. 114.(canceled)
 115. The library of claim 110, wherein the second set ofvariegated DNAs collectively encode lambda light chains having CDR3sthat are ten and/or eleven amino acids in length.
 116. The library ofclaim 44, wherein the genetic packages are cells, spores, or viralparticles.
 117. The library of claim 116, wherein the genetic packagesare phages or yeast cells.
 118. (canceled)
 119. The library of claim117, wherein the genetic packages are yeast cells, which display theantibody heavy chains encoded by the first set of variegated DNAs. 120.The library of claim 44, wherein the vectors are yeast vectors.
 121. Thelibrary of claim 96, wherein the genetic packages are cells, spores, orviral particles.
 122. The library of claim 121, wherein the geneticpackages are phages or yeast cells.
 123. (canceled)
 124. The library ofclaim 122 wherein the genetic packages are yeast cells, which displayantibodies containing the antibody heavy chains encoded by the first setof variegated DNAs and the antibody light chains encoded by the secondset of variegated DNAs.
 125. The library of claim 96, wherein thevectors are yeast vectors.